Probing the active site of anthranilate phosphoribosyltransferase from Mycobacterium tuberculosis to facilitate novel drug development by Cookson, Tammie Violet Marie
  
 
Probing the active site of anthranilate 
phosphoribosyltransferase from Mycobacterium 
tuberculosis to facilitate novel drug development 
 
A thesis 
 submitted in partial fulfilment  
of the requirements for the degree  
of  
Doctor of Philosophy in Chemistry  
at the  
University of Canterbury 
by  
Tammie Violet Marie Cookson 
 
 
 
 
 
November 2013 
  
 
 
 
 
 
 
 
 
 
 
 
 
i 
 
Acknowledgements 
I almost can’t believe I’ve made it to this point. This PhD journey has been full of ups and downs for 
me, with many, ‘Woohoo! I’ve got this done’ moments, ‘Man, this must be the millionth time I’ve 
done this’ moments and the ultimately depressing, ‘What am I even doing here?’ moments. What I 
do believe is that I would not have come this far without the amazing support system I am lucky to 
have around me, and I would like to thank every one of you from the bottom of my heart. 
My first and foremost mention must be to my primary supervisor, Professor Emily Parker, whose 
happy, upbeat and optimistic attitude about this science business is one of the main reasons I 
wanted to work with her in the first place. Mostly though, I would like to thank Emily for her 
constant patience, understanding and reassurances that no, I am not an imposter in the chemistry 
department. 
I would also like to thank all past and present members of the fairly sizeable Parker group. I have 
made some wonderful friends here, and I want you all to know how awesome you are. To Dmitri 
Joseph – what started out as a decidedly rocky first year working together has transformed into a 
relationship I could not do without. Thank you for all your help in the lab, and for the many happy 
memories you have helped me create during my time here. To my office neighbour, Sarah Wilson-
Coutts, you are absolutely one of the nicest, warmest, friendliest and most willing to help people 
that I have ever met. I shall miss our dance parties in the lab/hallway/office, and I hope you keep 
these up in my absence!! Frances Huisman – conversing with you about all things television, movies, 
award-show fashion and a huge range of other random stuff helped to keep me sane and smiling. 
Michael Hunter – a good friend with the uncanny ability to make you laugh as he insults you – thank 
you for taking the time to help me out with problems in my research. As the only one studying my 
enzyme within the Parker group, it meant a lot to have someone to nut things out with. To my other 
friends - Nicky Blackmore, David Tran, Wanting Jiao, Eric Lang, Richard Hutton and all the rest of you 
in the Parker Group – you are all people I am glad to have met. 
I would also like to acknowledge and thank the lovely people I have worked and collaborated with at 
the University of Auckland – Dr Shaun Lott, Dr Esther Bulloch, Dr Genevieve Evans and Dr Alina 
Castell. Thank you for your continued help and friendship during the course of this project, and for 
taking me in as an earthquake refugee for a few weeks! A special thank you must go to Dr Genevieve 
Evans, who has spent many hours helping me in the lab and with crystallography techniques. 
ii 
 
Many hours have been spent in the lab over the past few years, and I wish to particularly thank Dr 
Tim Allison for introducing me to the Parker lab and showing me how everything works, Dr Richard 
Hutton for his invaluable help with my variant proteins, Dr Marie Squire for running many, many, 
many samples through the Mass Spectrometer for me, and lastly Dr Meike Holzenkaempfer, Dr Matt 
Polson and Alistair Duff for general technical assistance. Thank you also to Dr Wanting Jiao and Dr 
Sebastian Reichau for helping me with crystallography, and to the various people who collected data 
on my behalf at the Australian Synchrotron. 
The Maurice-Wilkins Centre has generously provided me with funding for this research, as well as for 
several excursions to and from Auckland, which was very gratefully received. I wish to especially 
acknowledge Rochelle Ramsay, a research manager within the centre, who always took the time to 
make us Christchurch lot feel welcome and to chat with us about our research. I was also provided 
with a travel scholarship by the New Zealand Federation of Graduate Women, which greatly assisted 
with my expenses for travel to the Pacifichem 2010 conference, held in Hawaii, USA.  
My family has been my rock during this PhD saga, and I am so thankful for the unwavering support 
and encouragement they continue to give me every day. Thank you also for telling everyone that I 
am curing tuberculosis and making me sound awesome! 
 
 
 
 
 
iii 
 
Abstract 
Tuberculosis (TB) is a highly infectious disease that claims the lives of millions of people per year in 
numerous countries around the world. The bacterium responsible for this disease, Mycobacterium 
tuberculosis (Mtu), is becoming resistant to many of the current anti-TB drugs currenly available, 
making the discovery of novel anti-TB drugs crucial. The enzyme anthranilate phosphoribosyl 
transferase (AnPRT) from Mtu catalyses the Mg2+-dependent reaction between α-5’-phosphoribosyl 
1’-pyrophosphate (PRPP) and anthranilate to form N-(5’-phosphoribosyl)anthranilate (PRA), which is 
the second committed step of the tryptophan biosynthetic pathway in Mtu. The presence of AnPRT 
within Mtu has been shown to be absolutely necessary for the bacteria’s virulence, making it a viable 
drug target. 
Crystal structures of apo wild-type Mtu-AnPRT and wild-type Mtu-AnPRT with PRPP and Mg2+ bound 
have been solved prior to this study, and have elucidated the binding sites for these ligands as well 
as the conformational changes triggered upon ligand binding. Kinetic parameters for Mtu-AnPRT 
have also been previously obtained using a fluorimetric assay. Conversely, the anthranilate binding 
site/s within Mtu-AnPRT have not been well characterised, and the reaction mechanism is unknown.  
This thesis describes the functional and structural studies of the active site of Mtu-AnPRT, with the 
end goal of increasing Mtu-AnPRT knowledge to improve future drug design. 
Chapter 2 of this thesis describes the physical and kinetic characterisation of wild-type Mtu-AnPRT, 
and the inhibition of this enzyme using a range of anthranilate-like compounds. A novel enzyme-
coupled UV-based assay was developed to kinetically characterise Mtu-AnPRT, which yielded 
apparent KM values for each substrate and a turnover number of 2 s
-1. The potencies of several 
inhibitors were characterised against Mtu-AnPRT, and demonstrated that a ‘bi-anthranilate’-like 
compound was the strongest inhibitor. Crystal structures of Mtu-AnPRT with these inhibitor 
compounds bound identified several common inhibitor-binding residues, as well as a third potential 
binding site for anthranilate (previously only two anthranilate sites were predicted). 
In Chapter 3, the substrate specificity of Mtu-AnPRT is explored using a range of fluoro-, methyl- and 
methoxy-substituted anthranilate analogues. These analogues were characterised as substrates of 
Mtu-AnPRT using a commercially available pyrophosphate assay. The methoxy-substituted 
compounds did not act as Mtu-AnPRT substrates, whereas all fluoro-substituted compounds were 
readily accepted. The methyl-substituted compounds were also accepted, but had considerably 
weaker binding affinities for the enzyme and lower turnover numbers. 1H NMR spectroscopy 
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confirmed the turnover of these compounds by Mtu-AnPRT, and the formation of α and β PRA 
anomers that interconvert via an imine intermediate. Crystal structures of the fluoro- and methyl-
substituted anthranilate analogues bound to Mtu-AnPRT provided further insight into the reaction 
mechanism of the enzyme, and highlighted the presence of several anthranilate binding sites. 
The effects of mutating six key residues individually in the Mtu-AnPRT active site are outlined in 
Chapter 4, including physical, kinetic and structural characterisation. The variant proteins Mtu-
G107P, Mtu-N183A, Mtu-P180A, Mtu-R193A, Mtu-R193L and Mtu-R194A were all successfully 
expressed and purified, and displayed similar physical attributes to the wild-type Mtu-AnPRT 
enzyme. Kinetic characterisation of the variants emphasised the importance of the conserved R193 
residue for both substrate binding and catalysis, and the crucial role of G107 for enzyme function. 
Structures of these variants were obtained in the presence of various ligands, with Mtu-R194A and 
Mtu-R193A capturing anthranilate in three different binding sites between them. 
Chapter 5 involves the kinetic and structural characterisation of Mtu-N138A, Mtu-P180A and Mtu-
R194A in the presence of two inhibitors: an anthranilate-like inhibitor with two additional methyl 
groups on the C3 and C5 positions (ACS142), and a ‘bi-anthranilate’-like inhibitor (ACS172). No 
significant differences were observed between the variant and wild-type enzymes for ACS172, 
however, several considerable changes in inhibitor potency and Mtu-AnPRT binding were observed 
for ACS142. 
Finally, Chapter 6 discusses and interprets all aspects of the thesis and the applications of the 
research with respect to novel drug design. 
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Introduction 
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1.1 Tuberculosis 
Tuberculosis (TB) is a highly infectious, pestilent disease that stretches back centuries into mankind’s 
history,1 and yet still we are unable to completely eradicate it. Infection is spread via inhalation of 
the TB bacteria into the lungs, where they are then engulfed by alveolar macrophages as part of the 
immune response.2 Within these macrophages, the bacteria are able to survive and proliferate.3 
Lesions (or granulomas/tubercles) form within the lungs as the body attempts to eliminate these 
infected macrophages, within which caseous necrosis occurs.4 The necrosis can erode the 
surrounding tissue, including blood vessels, leading to distribution of the bacteria throughout the 
body via the bloodstream.5 Fatalities usually arise from internal bleeding, respiratory failure as 
granulomas spread throughout the lungs or suffocation due to excess phlegm/blood in the lungs.6 
Before the rise of modern chemotherapy, treatments for TB tended to vary from extreme measures, 
such as surgical removal of infected lung tissue,1 to less invasive remedies such as fresh air and bed 
rest in sanatoria.1, 7 The discovery of the organism responsible for this disease, Mycobacterium 
tuberculosis (M. tuberculosis, Mtu), was made by Robert Koch in 1882, and his finding paved the way 
towards more effective chemotherapeutic treatment with antibiotics.8 
As treatments of TB with first-line antibiotics such as isoniazid (ISZ), rifampin (RIF) and pyrazinamide 
as well as second-line antibiotics such as ethionamide, cycloserine and the quinolones were 
introduced,  the incidences of mortality dramatically decreased from approximately 75% to 20% 
from the 1960s onward.9 However, the emergence of Multi-Drug Resistant TB (MDR-TB) and 
Extensively Drug Resistant TB (XDR-TB) is seriously undermining the efforts made to control this 
disease.10 MDR-TB is defined by resistance of Mtu to the two first-line drugs ISZ and RIF, and XDR-TB 
is defined by resistance to ISZ and RIF, as well as any fluoroquinoline and at least one of the three 
injectable second-line drugs, capreomycin, amikacin or kanamycin,10 making treatment of patients 
with these resistant strains difficult. Additionally, patients who are co-infected with both HIV and TB 
suffer from the added complication of detrimental interactions between the drugs used for treating 
each of these diseases. For example, it has been observed that RIF activates the enzyme cytochrome 
P450, which causes some HIV protease inhibitors to be metabolised too quickly.11 
In 2011, TB caused a total of 1.4 million deaths, with an estimated 8.7 million new cases of the 
disease reported.12 With treatment options becoming more limited due to MDR-TB, XDR-TB and HIV, 
further understanding of the Mtu cell biology is necessary in order to locate novel drug targets 
and/or antibiotics. 
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1.2 Mycobacterium tuberculosis 
The majority of TB infections are caused by the pathogen Mtu, however, other closely related 
organisms such as Mycobacterium bovis (Mbo), Mycobacterium africanum (Maf) and 
Mycobacterium canetti (Mca) can also cause the disease.13 Mbo can infect both cattle and humans, 
though its prevalence in humans was drastically lowered once the pasteurisation of milk was 
introduced.1 Maf and Mca are almost exclusively human pathogens, with both organisms found 
primarily in Sub-Saharan Africa.14  
Mycobacteria are rod-shaped bacilli that are non-motile and do not form spores.15 Their complex cell 
envelope is structurally distinct from those of other bacteria, with four main layers extending 
outwards from the plasma membrane. These layers are made up of peptidoglycan, arabinogalactan 
sugars and mycolic acids respectively, with a ‘capsule layer’ nearest to the surface (Figure 1.1).9, 16 
Upon exposure of Mtu to Gram stain, the bacteria resist decolourisation even in the presence of 
acidic alcohol, and are thus classified as ‘acid-fast’.17 
Upon phagocytosis of Mtu into an alveolar macrophage, the bacteria are faced with a hostile 
environment that is nitrosative, oxidative, acidic and nutrient-deficient.18 In order to survive, Mtu 
must synthesise essential sugars and amino acids that cannot be ingested from its surroundings. 
There are many biosynthetic pathways within Mtu that are not present in mammalian organisms, 
which generate necessary cell wall components, amino acids and sugars.19 These pathways provide 
an important focus for the synthesis of antibiotics, which will ideally target the bacteria while leaving 
the host unharmed. 
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Figure 1.1 The cell wall of Mycobacterium tuberculosis. Figure extracted from Rom & Garay.
9
 Abbreviations are 
as follows: PM – plasma membrane, PG – peptidoglycan, AG – arabinogalactan, MA – mycolic acids, PL – 
phospholipids, CL – capsule layer, AM – arabinomannan, LAM - lipoarabinomannan, GLU - glucan, LM – 
lipomannan.  
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1.3 Aromatic Amino Acid Biosynthesis 
The amino acids tryptophan, phenylalanine and tyrosine share a similar aromatic structure, and as 
such Mtu and other bacteria utilise the same metabolic pathway to synthesise the precursors for 
these amino acids. This pathway, named the shikimate pathway, is present in bacteria, fungi, plants 
and parasites but is absent in mammals,20 and has been a focal point for novel drug synthesis and 
herbicides.21  
The shikimate pathway contains seven enzyme-catalysed reactions leading to the formation of 
chorismate, which acts as a branch-point for the formation of several important compounds 
including folic acid and vitamins E and K.22 With respect to aromatic amino acid synthesis, the 
pathway splits in two directions after the synthesis of chorismate, where one branch leads to the 
formation of prephenate, the precursor for phenylalanine and tyrosine, and the other branch leads 
to anthranilate, from which tryptophan is made (Figure 1.2). 
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1.4 Tryptophan Biosynthesis 
The biosynthesis of the amino acid tryptophan from chorismate by Mtu is an example of a bacterial 
metabolic pathway that can be exploited as a potential drug target. Auxotrophic mutants of Mtu 
containing gene knockouts within the tryptophan pathway have been shown to be unable to 
replicate in cultured murine macrophages, while also showing an attenuation of virulence in mice.23 
These results indicate that tryptophan is not bio-available within the murine macrophage. The 
inability to infect mice was especially apparent in the TrpD knockout strain, which was found to be 
essentially avirulent in immune-deficient mice,23 suggesting that removal of the TrpD gene leaves 
the bacteria with no alternate means to acquire tryptophan.  
The tryptophan pathway is a series of six enzyme-catalysed reactions, which has been identified and 
characterised in several organisms.24 The full reaction pathway is outlined in Figure 1.3. The pathway 
begins with the conversion of chorismate and glutamine into anthranilate by anthranilate synthase 
(AS), which also releases pyruvate and glutamate as byproducts. AS is a heterodimeric enzyme 
containing a synthase component and a glutamine amidotransferase component, coded for by the 
genes TrpE and TrpG respectively.25 Anthranilate and 5’-phosphoribosyl 1’-pyrophosphate (PRPP) are 
then converted to N-(5’-phosphoribosyl)anthranilate (PRA) by anthranilate phosphoribosyl 
transferase (AnPRT) in a magnesium dependent reaction. PRA is then isomerised to 1-(o-
carboxyphenylamino)-1’-deoxyribulose-5’-phosphate (CDRP). In some organisms, the isomerisation 
is performed by a dedicated PRA isomerase (PRAI), which is encoded for by TrpF. However, a 
homologue of TrpF has not been found anywhere in the Mtu genome, and the conversion of PRA to 
CDRP is thought to instead be catalysed by the ProFAR isomerase protein encoded by the gene HisA, 
which acts as part of the histidine biosynthesis pathway.26 
The conversion of CDRP to indole-3-glycerol phosphate is carried out by indole-3-glycerol phosphate 
synthase (InGPS) (encoded by TrpC), with CO2 and H2O released in the process. The final two steps in 
this pathway are catalysed by tryptophan synthase (TS); a heterodimeric protein made up of an α 
subunit (encoded by TrpA) and a β subunit (encoded by TrpB). First, the α subunit catalyses the 
cleavage of glyceraldehyde-3-phosphate from the indole moiety, then the β subunit catalyses the 
reaction of the indole with L-serine to form L-tryptophan.  
In some organisms, the genes encoding for proteins that catalyse consecutive reactions are fused 
into a single open reading frame (ORF). Examples of this phenomenon are found in E. coli where 
TrpD and TrpG are fused as well as TrpF and TrpC,27 and in Thermotoga maritima where TrpD and 
TrpG are fused.28  
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1.5 Phosphoribosyltransferases 
All phosphoribosyltransferase (PRT) enzymes are characterised by their usage of PRPP, whereby the 
phosphoribosyl group of PRPP is transferred to a nitrogenous and generally aromatic base.29 The 
glycosidic bond between the C1 carbon of the ribose ring and the oxygen of the pyrophosphate (PPi) 
moiety of PRPP is cleaved in this process.30 The reactions proceed with inversion of stereochemistry 
at the anomeric carbon, and require Mg2+ for catalysis.31 
Mtu-AnPRT is encoded by the gene TrpD, which has previously been shown to be essential for the 
virulence of Mtu in mice.23 This enzyme belongs to the phosphoribosyltranferase superfamily, which 
is divided into four sub-categories: type I, type II, type III and type IV.   
The type I PRTs are a homologous group of enzymes that are part of the nucleotide synthesis and 
salvage pathways.31c They are defined by a common protein fold comprised of a central five-
stranded β sheet surrounded by α helices, and also by a 13-residue sequence motif which 
corresponds to a PRPP binding loop.32 Some type I PRTs are subject to allosteric regulation, such as 
glutamine PRPP amidotransferase which catalyses the first step of purine biosynthesis and is 
inhibited by the end-products of the pathway.33 Many of these dimeric proteins require a 
conformational change to facilitate catalysis, which was first demonstrated in crystal structures of 
glutamine PRPP amidotransferase where the occlusion of the active site via the movement of a 
flexible loop could be observed.34 Further examples of type I PRTs include orotate PRT (pyrimidine 
biosynthesis) (Figure 1.4A),35 hypoxanthine-guanine PRT (purine biosynthesis)36 and uracil PRT (uracil 
salvage).37 
Some examples of type II PRTs include quinolinic acid PRT (NAD biosynthesis)38 and nicotinic acid 
PRT (NAD salvage).39 The type II PRTs do not display the protein fold and 13-residue sequence 
characteristic of type I PRTs, and instead exhibit an irregular seven-stranded α/β barrel and an N-
terminal open-faced β-sandwich domain. The oligomeric structures of these proteins can vary, with 
some existing as hexamers (Homo sapiens quinolinic acid PRT),40 domain-swapped dimers 
(Salmonella typhimurium quinolinic acid PRT)38 or monomers (Saccharomyces cerevisiae (Sce) 
nicotinic acid PRT).39 Structures of Mtu quinolinic acid PRTs (Figure 1.4B) showed little gross 
conformational change upon substrate binding, in contrast to what has been observed for type I 
PRTs.31a 
AnPRTs are mostly considered to represent the type III category, with a few exceptions labelling 
them as type IV.41 The type III AnPRT enzymes catalyse the reaction between anthranilate and PRPP 
to form PRA as part of the tryptophan biosynthesis pathway. Structures of AnPRTs from different 
10 
 
organisms such as Sulfolobus solfataricus (Sso),42 Pectobacterium carotovorum (Pca)43 and Mtu41a, 44 
(Figure 1.4C) have identified a novel protein fold distinct from the type I, type II and type IV 
enzymes. The AnPRT monomers are made up of a smaller N-terminal α helical domain and a larger 
C-terminal α/β domain, which are joined by a hinge region. This fold has a similar architecture to 
some pyrimidine nucleoside phosphorylases (PyNPs), which catalyse the near reverse reaction of 
AnPRTs to yield ribose-1-phosphate and a free nitrogenous base. AnPRTs and PyNPs also share a 
similar quaternary structure, consisting of a head-to-head homodimer, and it has been suggested 
that AnPRTs and thymidine NPs (a type of PyNP) have evolved from a common ancestor.43, 45 
Type IV PRTs are solely represented by the adenosine triphosphate PRTs (ATP PRTs), which catalyse 
the formation of PR-ATP from PRPP and ATP as the first step of the histidine biosynthetic pathway. 
These enzymes are highly regulated by the end product of the pathway – histidine. There are two 
sub-families within these type IV enzymes, which are decidedly different in their quaternary 
structure. The first sub-family are the hexameric ATP PRTs, which contain six HisGL subunits 
composed of two domains that comprise an α/β bi-lobal catalytic domain, and a third domain for 
allosteric histidine binding (Figure 1.4D).46 The second sub-family are hetero-octamer ATP PRTs, 
which are made up of four HisGS catalytic subunits and four regulatory HisZ subunits, with both 
subunits required for a functional complex (Figure 1.4E).47  
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Figure 1.4 Representatives of the different types and sub-families of PRTs. Different protein chains are 
coloured separately unless specified. A) Type I S. typhimurium orotate PRT (PDB ID: 1LH0) with PRPP (orange), 
orotic acid (magenta) and Mg
2+
 (red spheres) bound. B) Type II Mtu quinolinic acid PRT (PDB ID: 1QPR) with 
5’phosphoribosyl 1’-(β-methylene)-pyrophosphate (orange), phthalic acid (blue) and Mn
2+
 (red spheres) 
bound. C) Type III Mtu AnPRT (PDB ID: 1ZVW) with PRPP (orange) and Mg
2+
 (red spheres) bound). D) Type IV 
Escherichia coli ATP PRT hexamer (PDB ID: 1Q1K) with PR-ATP (orange) and tartaric acid (pink) bound. E) Type 
IV Lactococcus lactis ATP PRT hetero-octamer (PDB ID: 1Z7N) with PRPP (magenta) bound. The four HisGS 
subunits are coloured cyan, with the four HisZ subunits coloured green. 
C. D. 
A. B. 
E. 
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1.6 Anthranilate Phosphoribosyltransferases 
The anthranilate phosphoribosyltransferases (AnPRTs) specifically catalyse the Mg2+ dependent 
reaction between anthranilate and PRPP to form PRA and PPi (Figure 1.5), which constitutes the 
third committed step of the tryptophan biosynthetic pathway. This section will detail what is 
currently known about these enzymes, and draw comparisons of orthologues to Mtu-AnPRT where 
appropriate. 
 
 
 
 
Figure 1.5 The reaction catalysed by AnPRT. 
 
1.6.1 Sequence Alignment 
A structure-based sequence alignment of AnPRT enzymes from Mtu, Sso, Pca and Thermus 
thermophilus (Tth) was performed and used to create a multiple sequence alignment from a diverse 
range of bacteria including Clostridium acetobutylicum (Cac), Staphylococcus aureus (Sau), Brucella 
melitensis (Bme) and Agrobacterium tumefaciens (Atu).44 This sequence alignment is recreated in 
Figure 1.6. The alignment demonstrated the existence of several conserved sequence motifs, with 
some pertaining to the dimer interface and to the PRPP, Mg2+ and anthranilate binding sites. 
Conserved residues with respect to ligand binding include an absolutely conserved GTGGD motif 
from residues 107-111 (numbered for the Mtu enzyme), which is located on the β1-α5 loop and is 
involved in PRPP binding. Two residues, D251 and E252, are absolutely conserved and pertain to 
Mg2+ binding. A ψψKHGN motif from residues 133-138 (where ψ stands for a hydrophobic amino 
acid) is located on the β2-α6 loop and is involved in both anthranilate and PRPP binding. A conserved 
R193 residue located on the α8 helix is also associated with anthranilate binding. There is also a 
conserved A179 residue which appears to be conserved for structural reasons. A conserved 
TψψNψψGPLxNP sequence from residues 200-211 is located on the α9 helix which makes up part of 
the hinge region between the two domains of the AnPRT monomer. 
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Figure 1.6 A sequence alignment of AnPRTs from Mtu, Sso, Pca, Tth, Cac, Sau, Bme and Atu, recreated from 
Lee et al.
44
 using TCOFFEE: Advance.
48
 The figure was created using Jalview.
49
 Dots indicate residues involved 
with the hinge region (red), PRPP binding (blue), anthranilate binding (green) and Mg
2+
 binding (purple). Black 
dots indicate residues that appear to be conserved for structural reasons.
44
 Blue solid lines indicate α helices, 
green solid lines indicate β strands and red solid lines indicate loop regions. 
 
1.6.2 Crystal Structures 
Structures of the enzymes from the organisms Pca,43 Sso,42, 50 Tth (PDB ID: 1V8G), Acinetobacter 
baylyi (Aba) (PDB ID: 4GTN), Xanthomonas campestris (Xca) (PDB ID: 4HKM) and Mtu41a, 44, 51 have 
been obtained with various ligands bound. All structures are head-to-head homodimers, with the 
monomers interacting via the smaller N-terminal domain, which is composed of six α-helices. The N-
α1 α2 α3 α4 
α4 α5 α6 β1 β2 
α7 α8’ α8 α9 α10 β3 β4 
α12 α13 α14 
α11’ α11’’ α11 β5 β6 β7 
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terminal domain is joined to the larger α/β domain via a hinge region. The α/β domain is folded 
around a central seven-stranded β-sheet, with a number of α-helices packed on either side of it 
(Figure 1.7).  
The dimer interface of the AnPRTs has no salt bridge interactions, few hydrogen bonds and appears 
to be mostly hydrophobic, with some conservation of hydrophobic residues in this region.44 The 
purpose of the dimeric structure of the AnPRTs is likely to maximise the stability of the enzyme, 
which was discovered when monomeric variants of Sso-AnPRT displayed similar kinetic activity to 
the wild-type dimer, but showed a decrease of 10 °C in their denaturation temperatures.52  
 
 
 
 
 
 
 
Figure 1.7 The Mtu-AnPRT dimer. Mtu-AnPRT with PRPP (orange) and Mg
2+
 (red spheres) bound (PDB ID: 
1ZVW) showing chain A coloured in cyan, with chain B coloured by domain, with the smaller N-terminal helix 
bundle coloured magenta, and the larger C-terminal α/β domain coloured green. The hinge region is indicated 
by an arrow. 
 
1.6.2.1 AnPRT Apoenzyme Structures 
Structures of apo AnPRTs show a very similar protein fold, with the RMSD values of various apo 
structures as compared to apo Mtu-AnPRT outlined in Table 1.1. Some obvious differences include a 
C-terminal helix extension for Sso-AnPRT, an extended α12 – α13 loop and helix formation within 
the β2-α6 loop for Mtu-AnPRT, and an extended α11 – α12 loop for Aba-AnPRT (Figure 1.8). There is 
also a Mtu-AnPRT 25-residue N-terminal extension, which can be observed in the sequence 
alignment in Figure 1.6, however, this extension remains disordered in all known structures of Mtu-
AnPRT. 
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AnPRT organism PDB ID RMSD value (Å) 
(monomer)* 
RMSD value (Å) 
(dimer) 
Sulfolobus solfataricus 1O17 1.794 4.331 
Pectobacterium carotovorum 1KHD 1.764 5.481 
Thermus thermophilus 1VG8 1.698 4.489 
Acinetobacter baylyi 4GTN 1.989 3.983 
Xanthomonas campestris 4HKM 1.419 4.600 
 
Table 1.1 RMSD values of apo AnPRTs as compared to apo Mtu-AnPRT (PDB ID: 2BPQ) when superimposed 
using PyMOL software.
53
 *Chain A from each organism is superimposed onto chain A from Mtu-AnPRT. 
 
 
 
 
 
 
 
 
 
Figure 1.8 Superimposition of apo AnPRT structures. Mtu-AnPRT is shown in green, Sso-AnPRT is shown in 
magenta, Pca-AnPRT is shown in blue, Tth-AnPRT is shown in yellow, Aba-AnPRT is shown in grey and Xca-
AnPRT is shown in purple. 
 
1.6.2.2 AnPRT PRPP Binding 
The active site of the AnPRTs is located in the cleft between the N-terminus α-helical domain and the 
larger α/β domain. Structures of Pca-AnPRT (PDB ID: 1KGZ), Sso-AnPRT (PDB ID: 1ZXY) and Mtu-
Sso-AnPRT 
C-terminal 
helix 
α11-α12 
loop 
α12-α13 
loop 
β2-α6 
loop 
16 
 
AnPRT (PDB ID: 1ZVW) have been solved with PRPP and Mg2+ bound in the active site, though the 
Sso-AnPRT structures place PRPP in a significantly different orientation compared to Pca and Mtu. 
Equivalent residue numbers between the different organisms mentioned are outlined in Table 1.2. 
The Pca and Mtu-AnPRT structures place PRPP between the β1-α5 and β2-α6 loops, with the PPi 
group buried the most deeply within the protein and the phosphate group facing out towards the 
solvent (Figure 1.9A and B). The PRPP molecule bound to chain A of the Pca-AnPRT structure makes 
hydrogen bond contacts to G94 via its phosphate group, and to G91, N101, S103, T104, S132 
(numbered for Pca enzyme) and a Mn2+ (referred to as Mn1) ion via its PPi group. The ribose ring 
does not make any hydrogen bonds with the protein, which is likely due to the disordered nature of 
the β2-α6 loop (Figure 1.9C). Chain B of Pca-AnPRTmakes slightly different contacts to the PRPP 
molecule, with contacts to G91, G94, S103 and T104 as before, but with extra hydrogen bonds to 
K119 via the PPi group and S132 via the ribose ring. The PRPP molecules in each chain also make 
hydrogen bonds to several water molecules. Mn1 is octahedrally co-ordinated to two PPi oxygen 
atoms, two water molecules and the side chains of S103 and E237, with a second Mn2+ ion (Mn2) 
octahedrally co-ordinated to four water molecules and the side chains of D236 and E237. 
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Figure 1.9 PRPP binding in Pca-AnPRT. A) An overlay of chain A of Pca-AnPRT (cyan) with PRPP (magenta) and 
Mn
2+
 (purple spheres) bound with chain A of Mtu-AnPRT (green) with PRPP (yellow) and Mg
2+
 (red spheres) 
bound. B) A closer view of the active site of Pca-AnPRT overlaid with Mtu-AnPRT. C) Stereo diagram of the Pca-
AnPRT active site with PRPP (magenta) and Mn
2+
 (purple spheres) bound. The equivalent positions of the Mtu-
AnPRT PRPP molecule (yellow) and Mg
2+
 ions (red spheres) are also shown. Yellow dashes indicate Pca-AnPRT 
polar contacts. Black dashes indicated Mn
2+
 contacts. Residues are numbered for the Pca-AnPRT enzyme. 
 
 
 
 
 
 
A. B. 
C. 
G94 
G91 
D236 E237 
S132 
T104 
S103 
N101 
G94 
G91 
D236 E237 
S132 
T104 
S103 
N101 
β2-α6 loop 
β1-α5 loop 
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PRPP/metal ion binding residues 
Mtu-AnPRT residues Equivalent Sso-AnPRT residue Equivalent Pca-AnPRT residue 
V105 T77 I89 
G107 G79 G91 
G110 G82 G94 
D111 D83 D95 
T115 T87 S99 
N117 N89 N101 
S119 S91 S103 
T120 T92 T104 
K135 K106 K119 
G147 S118 S132 
D251 D223 D236 
E252 E224 E237 
 
Table 1.2 Equivalent PRPP/metal binding residues in Mtu-AnPRT, Sso-AnPRT and Pca-AnPRT. 
 
The Sso-AnPRT structure (PDB ID: 1ZXY) has the PPi group of the PRPP molecule in the same position 
as the Mtu-AnPRT and Pca-AnPRT structures. The PRPP molecule bound to chain A of Sso-AnPRT 
makes hydrogen bonds to G79, N89, S91, T92, K106 and a Mg2+ ion (Mg1) via the PPi moiety. The 
ribose ring and phosphate group, however, extend out from the PPi site in a completely different 
direction. The ribose ring makes hydrogen bonds to S91, D223, E224, a water molecule and Mg1, 
with the phosphate moiety hydrogen bonded to D83, T87 and a second Mg2+ ion (Mg2). Mg1 makes 
contacts to T77, S91, a water molecule, the two hydroxyls on the PRPP ribose ring and an oxygen 
from the PRPP PPi group in a distorted octahedral co-ordination. Mg2 makes only three contacts to 
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D223, E224 and the PRPP phosphate group (Figure 1.9). Chains B, C and D of the Sso-AnPRT structure 
make similar hydrogen bond contacts to the PRPP and Mg2+ ligands.  
An inspection of the electron density maps corresponding to 1ZXY, however, reveals that the binding 
mode of PRPP described is very unlikely. In the 1ZXY structure, the entire PRPP molecule and two 
Mg2+ ions are modelled into density which cannot feasibly accommodate them. Figure 1.10D depicts 
the 2Fo-Fc map surrounding the PRPP and Mg
2+ ligands in 1ZXY, and shows the sterically 
unfavourable positioning of the Mg2+ ions relative to the PRPP molecule. In Figure 1.10E, the 2Fo-Fc 
map from the 1ZXY ligands is overlaid with the Mtu-AnPRT structure 1ZVW with PRPP and Mg2+ 
bound. An inspection of the density in this context illustrates that the electron density assigned to 
PRPP and Mg2+ in 1ZXY is likely to be incorrect, and in fact indicates the occupancy of a PPi group and 
two Mg2+ ions only. Furthermore, in Figure 1.10E the phosphate moiety of PRPP from 1ZVW is 
positioned over electron density that accommodates a water molecule in the 1ZXY structure, which 
may suggest that incorrect ligand placement has introduced some model bias in the SSo 1ZXY 
structure.  
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Figure 1.10 PRPP binding in Sso-AnPRT (PDB ID: 1ZXY). A) An overlay of chain A of Sso-AnPRT (magenta) with 
PRPP (cyan) and Mg
2+
 (blue spheres) bound with chain A of Mtu-AnPRT (green) with PRPP (yellow) and Mg
2+
 
(red spheres) bound. B) A closer view of the active site of Sso-AnPRT overlaid with Mtu-AnPRT. C) Stereo 
diagram of the Sso-AnPRT active site with PRPP and Mg
2+
 bound. The equivalent positions of the Mtu-AnPRT 
PRPP molecule and Mg
2+
 ions are also shown. Yellow dashes indicate Sso-AnPRT polar contacts. Black dashes 
indicate Mg
2+
 contacts. Residues are numbered for the Sso-AnPRT enzyme. D) PRPP/Mg
2+
 binding in Sso-
AnPRT, with the 2Fo-Fc map for both ligands shown as blue mesh, contoured at 1.0 σ. E) 2Fo-Fc map for Sso-
AnPRT ligands overlaid with Mtu-AnPRT with PRPP/Mg
2+
 bound.  
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The Sso-AnPRT structure with PRPP, Mg2+ and anthranilate bound (PDB ID: 1ZYK) also shows PRPP in 
this dubious orientation. Figure 1.11A shows the 2Fo-Fc map within the active site loops of 1ZYK, 
which is again suggestive of incorrect modelling of the PRPP substrate. When the map for the 1ZYK 
ligands is overlaid with the Mtu-AnPRT 1ZVW structure with PRPP and Mg2+ bound (Figure 1.11B), it 
can be seen that the density which houses PRPP in 1ZYK better accommodates the PPi moiety of 
PRPP and the two Mg2+ ions only. Figures 1.11A and B also reveal that the phosphate of the 1ZVW 
PRPP molecule fits into suitable density that is not utilised by the PRPP from 1ZYK, which instead 
contains three water molecules. Instead the PRPP in 1ZYK is in a conformation that would be 
sterically unfavourable due to the proximity of the modelled Mg2+ ions (similar to the 
aforementioned 1ZYK structure).  
The structure of a double mutant (D83G/F149S) of Sso-AnPRT with PRPP and Mn2+ bound (PDB ID: 
3GBR) shows a further unique orientation (Figure 1.11C), with supporting electron density. The 
position of the PRPP molecule within the Sso-AnPRT D83G/F149S variant places the PPi moiety in the 
same position observed for all other AnPRT structures, but with the ribose ring approximately 
perpendicular to the Mtu-AnPRT PRPP molecule from the 1ZVW structure. This mutant was 
generated via DNA shuffling,50 a method similar to error-prone PCR,54 with D83 located on the β1-α5 
loop adjacent to the PRPP binding site, and F149 located on the β3-α8’ loop. An overlay of chain A of 
the Sso-AnPRT D83G/F149S variant with chain A of the Sso-AnPRT 1ZXY structure gives an RMSD 
value of 0.461 Å. 
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Figure 1.11 PRPP and metal ion binding in Sso-AnPRT and Mtu-AnPRT structures. A) Sso-AnPRT (magenta) (PDB 
ID: 1ZYK) with PRPP (blue) and Mg
2+
 (purple spheres) bound. The 2Fo-Fc map for the Sso-AnPRT active site 
ligands is shown as blue mesh, contoured at 1.0 σ. B) The 2Fo-Fc map for the Sso-AnPRT active site ligands is 
overlaid with Mtu-AnPRT (green) (PDB ID: 1ZVW) with PRPP (yellow) and Mg
2+
 (red spheres) bound. C) PRPP 
and Mg
2+
 ligands overlaid from different AnPRT structures. Sso-AnPRT (PDB ID: 1ZYK) PRPP is shown in blue, 
with Mg
2+
 as purple spheres. Sso-AnPRT (PDB ID: 1ZXY) PRPP is shown in cyan, with Mg
2+
 as blue spheres. Sso-
AnPRT D83G/F149S (PDB ID: 3GBR) PRPP is shown in purple, with Mn
2+
 as green spheres. Mtu-AnPRT (PDB ID: 
1ZVW) PRPP is shown in yellow, with Mg
2+
 as red spheres. 
 
1.6.2.3 AnPRT Anthranilate Binding 
The structures of Sso-AnPRT with PRPP, Mg2+ and anthranilate bound (PDB ID: 1ZYK) and with only 
anthranilate bound (PDB ID: 2GVQ) have also been solved.42 The 1ZYK structure has four monomers 
present in the asymmetric unit associated as two dimers, with a total of four PRPP molecules (one 
per monomer), eight Mg2+ ions bound (two per monomer) and eight anthranilate molecules bound 
(two per monomer). Each PRPP and Mg2+ ligand is bound as described for the Sso-AnPRT 1ZXY 
structure (Section 1.5.2.2). The anthranilate molecules are bound in a channel that leads from the 
A. B. 
C. 
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solvent to the PRPP binding site (Figure 1.12D). The Sso-AnPRT 1ZYK structure has one anthranilate 
molecule positioned close to the PRPP molecule, making hydrogen bonds to G79 via its amino group, 
and to N109 via its carboxylate group. Other Sso-AnPRT residues such as A78, H107, G108, G177 and 
P178 are involved chiefly in hydrophobic interactions (Figure 1.12C). This anthranilate binding site 
will be referred to as the ‘inner site’ for the remainder of this study. 
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Figure 1.12 The active site of Sso-AnPRT. A) An overlay of chain A of Sso-AnPRT (magenta) with PRPP (blue), 
Mg
2+
 (purple spheres) and anthranilate (white) bound (PDB ID: 1ZYK) with chain B of Sso-AnPRT (cyan) with 
anthranilate (orange) bound (PDB ID: 2GVQ) and with chain A of Mtu-AnPRT (green) with PRPP (yellow) and 
Mg
2+
 (red spheres) bound (PDB ID: 1ZVW). B) A closer view of the active site of the Sso-AnPRTs overlaid with 
Mtu-AnPRT. C) Stereo diagram of the Sso-AnPRT (magenta) active site with PRPP (blue), Mg
2+
 (purple spheres) 
and anthranilate (white) bound overlaid with the active site of Sso-AnPRT (cyan) with anthranilate (orange) 
bound. The equivalent positions of the Mtu-AnPRT PRPP molecule (yellow) and Mg
2+
 ions (red spheres) are 
also shown. Yellow dashes indicate 1ZYK anthranilate polar contacts. Black dashes indicate 2GVQ anthranilate 
polar contacts. Residues are numbered for the Sso-AnPRT enzyme. D) Surface representation of the Sso-AnPRT 
1ZYK structure with PRPP (blue), Mg
2+
 (not shown) and anthranilate (white) bound. 
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A second anthranilate molecule is positioned closer to the entrance of the anthranilate channel, and 
will be referred to as the ‘middle site’ for the remainder of this study. This middle site anthranilate 
makes contacts to N109 and R164 via its carboxylate group, with hydrophobic interactions to A150 
and H154. All of the monomers within the asymmetric unit of the Sso-AnPRT 1ZYK structure 
demonstrate anthranilate bound both in the inner site and the middle site. Equivalent residue 
numbers between the different organisms mentioned are outlined in Table 1.3. 
The Sso-AnPRT 2GVQ structure with only anthranilate bound also has two anthranilate molecules 
bound per monomer, with the exception of chain A which has only one anthranilate molecule bound 
in the middle site. For the monomers with two anthranilate molecules bound, there is one 
positioned in the inner site and one positioned in the middle site, as described for the Sso-AnPRT 
1ZYK structure (Figure 1.11A, B and C). This structure also reveals that anthranilate can bind 
independently to Sso-AnPRT without prior PRPP binding, potentially pointing to a random sequential 
mechanism. 
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Anthranilate binding site residues 
Mtu-AnPRT residues Equivalent Sso-AnPRT residues 
V106 A78 
G107 G79 
T108 T80 
H136 H107 
G137 G108 
N138 N109 
A179 A150 
H183 H154 
R193 R164 
G206 G177 
P207 P178 
 
Table 1.3 Equivalent anthranilate binding residues in Sso-AnPRT and Mtu-AnPRT. 
 
1.6.2.4 Conformational Changes 
A comparison of the different apo and ligand-bound structures of Sso-AnPRT showed little overall 
conformational change. An overlay of chain A of the apo Sso-AnPRT structure with either 2GVQ 
(anthranilate), 1ZYK (PRPP/Mg2+/anthranilate) or 1ZXY (PRPP/Mg2+) gave RMSD values of 0.224 Å, 
0.292 Å and 0.283 Å respectively. A closer inspection of the active site showed an occlusion of the 
β2-α6 loop around the PRPP binding site upon the binding of PRPP/Mg2+, which was not observed 
when anthranilate binding preceded PRPP/Mg2+ binding (Figure 1.13). This loop contains the 
conserved KHGN motif described in Section 1.5.1. Mtu-AnPRT also demonstrates this β2-α6 loop 
movement, and this will be discussed in Section 1.6. An overlay of the Pca-AnPRT apo structure with 
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the Pca-AnPRT PRPP/Mn2+ bound structure gives an RMSD value of 0.534 Å, however, both 
structures show the β2-α6 loop as disordered, unfortunately precluding a comparison of this region.  
 
 
 
 
 
 
Figure 1.13 β2-α6 loop movement in Sso-AnPRT. Sso-AnPRT apo structure (PDB ID: 1O17) – magenta, Sso-
AnPRT with PRPP and Mg
2+
 bound (PDB ID: 1ZXY) – green, Sso-AnPRT with anthranilate bound (PDB ID: 2GVQ) 
– cyan, Sso-AnPRT with PRPP, Mg
2+
 and anthranilate bound (PDB ID – 1ZYK) – yellow. The PRPP (blue) and Mg
2+
 
ions (black spheres) from 1ZYK are also shown. 
 
1.6.3 Sso-AnPRT Variant Kinetics 
Several mutations have been performed on the Sso-AnPRT enzyme to probe the catalytic relevance 
of certain conserved residues involved with substrate binding, namely K106, H107, D223, E224, 
R164, H154 and P178.42 It was concluded that residue R164 was crucial for anthranilate binding, as 
the variant Sso-R164A caused an increase in the anthranilate KM value by a factor of 7000 (Section 
1.6.2.3). However, the effect of the R164A mutation on the turnover number was not as marked, 
with a 7-fold decrease in the kcat value.  
A R164A/H154A double mutation had little additional effect on the Sso-AnPRT enzyme, with similar 
kinetic parameters as recorded for the Sso-R164A variant, though it is possible the R164A mutation 
has masked any H154A effects. The proximity of H154 to the anthranilate binding site coupled with 
its conservation within the AnPRT family suggests an important role for this residue, and it is 
unfortunate that Marino et al.42 did not synthesise a Sso-H154A variant for comparison. 
The variants Sso-K106Q, Sso-D223N and Sso-E224Q were synthesised to investigate whether 
differences in side-chain lengths and/or functionality in conserved residues proximal to the 
PRPP/Mg2+ binding site would have any effect on binding/catalysis. None of these mutations 
appeared to have any significant influence on substrate binding, with KM values similar to those 
β2-α6 loop 
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observed for wild-type Sso-AnPRT. However, a 9-fold decrease in the kcat value was recorded for the 
Sso-K106Q variant, and it was therefore suggested that K106 plays some role in catalysis. These 
mutants also showed no evidence of Mg2+ inhibition, as was observed in wild-type Sso-AnPRT. 
The substitution of a histidine for an alanine at position 107 (H107A) had no significant effect on the 
Sso-AnPRT kinetic parameters, as with H154. A H107A/P178A double mutation caused a 300-fold 
increase in the anthranilate KM value, but had little effect on the kcat value, indicating that the 
presence of P178 appears necessary for binding, but not for catalysis. It is possible that H107 may 
also have played some role in reducing the binding affinity of anthranilate in the Sso-AnPRT 
H107A/P178A variant, however, the Sso-P178A variant was not synthesised for comparison. The 
active site co-ordination of nitrogenated bases via hydrogen bonding with the imidazole groups of 
histidines is a common structural theme among nucleotide/nucleoside-processing enzymes, 
including PRTs, nucleoside phosphorylases and nucleoside hydrolases.31a, 38, 55 It is therefore 
surprising that the conserved H107 and H154 residues in Sso-AnPRT do not play a more central role 
in binding and/or catalysis. As AnPRTs have been suggested to have evolved from PyNPs, it is 
possible that the active site histidines in AnPRT are merely unnecessary evolutionary remnants. 
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1.7 M. tuberculosis Anthranilate Phosphoribosyltransferase  
As has been stated in the previous section, structures of Mtu-AnPRT show that it exists as a head-to-
head homodimer. The two monomers interact via the smaller N-terminal domain composed of four 
α-helices, and are joined to the larger α/β domain via a hinge region. The α/β domain is composed 
of a central seven-stranded β-sheet, consisting of six parallel and one anti-parallel β strands, with a 
number of α-helices packed on either side of it. 
1.7.1 Crystal Structures 
The Mtu-AnPRT apo structure (PDB ID: 2BPQ) and the structure of Mtu-AnPRT with PRPP and Mg2+ 
bound (PDB ID: 1ZVW) have previously been solved by Lee et al.44 Both structures were obtained in 
the presence of the additive benzamidine, which was required for crystal formation.  
 
 
 
 
 
 
 
 
 
 
Figure 1.14 Stereo diagram of PRPP and Mg
2+ 
bound to Mtu-AnPRT (PDB ID: 1ZVW). Mtu-AnPRT residues are 
shown in cyan, with PRPP in yellow and Mg
2+
 as red spheres. 
 
The 1ZVW structure shows PRPP and Mg2+ bound to Mtu-AnPRT as shown in Figure 1.14, with the PPi 
of PRPP forming contacts with the backbone nitrogens of residues G107, S119, T120, the side-chains 
of N117, S119 and K135, various water molecules and a Mg2+ ion (Mg1). The ribose ring of PRPP 
forms hydrogen bonds with N138 via the backbone and side-chain oxygens, with the phosphate 
group interacting with the backbone nitrogens of A141, S142, and G110 and the side-chain hydroxyl 
of S143. Both Mg2+ ions are octahedrally co-ordinated, with Mg1 forming contacts to the side-chain 
hydroxyls of S119 and E252, two water molecules and two PRPP PPi oxygens. The second Mg
2+ ion 
(Mg2) does not interact with the PRPP molecule, and forms contacts to the side-chain hydroxyls of 
D251 and E252, as well as four water molecules.  
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An overlay of chain A from both the Mtu-AnPRT apo and PRPP/Mg2+ bound structures gives an RMSD 
value of 0.200 Å, which is similar to the RMSD values of 0.224 – 0.292 Å recorded between overlaid 
Sso-AnPRT apo and ligand-bound structures. The position of the β2-α6 loop is significantly different 
between both Mtu-AnPRT structures, implying a high degree of flexibility. The β2-α6 loop in the apo 
structure shows some α helix formation, and projects into the PRPP binding site (Figure 1.15), while 
the PRPP/Mg2+ structure shows the β2-α6 loop has moved to enclose the PRPP molecule bound in 
the active site. This loop movement is also observed for Sso-AnPRT, and has been discussed in 
Section 1.5.2.4. Some differences between the Mtu-AnPRT structures can also be observed in the 
β1-α5 loop, which surrounds the Mg1/2 binding sites. This β1-α5 loop is extended slightly in the 
PRPP/Mg2+ structure due to uncoiling of the α5 helix N-terminus.  
 
 
 
 
 
Figure 1.15 β2-α6 loop movement in Mtu-AnPRT. Mtu-AnPRT apo structure (PDB ID: 2BPQ) – green, Mtu-
AnPRT with PRPP (yellow) and Mg
2+
 (red spheres) bound (PDB ID: 1ZVW) – cyan. 
 
By superimposing the Sso-AnPRT structure with anthranilate bound with the Mtu-AnPRT structure 
with PRPP and Mg2+ bound, it is possible to predict the Mtu-AnPRT residues involved in anthranilate 
binding (Figure 1.16). Assuming that anthranilate binds to Mtu-AnPRT in equivalent positions to 
those observed for Sso-AnPRT, it is reasonable to suggest that residues G107, T108 and N138 are 
involved with anthranilate binding at the inner site. N138 could also form a hydrogen bond to an 
anthranilate molecule bound in the middle site, based on the hypothetical bond length of 3.5 Å 
between the side-chain nitrogen of residue N138 from Mtu-AnPRT and the carboxylate group of the 
middle site anthranilate molecule bound to Sso-AnPRT. As depicted in Figure 1.15, residue R193 
from the overlaid Mtu-AnPRT structure is not suitably positioned to form a hydrogen bond to the 
anthranilate molecule bound in the middle site of the Sso-AnPRT structure. However, it is entirely 
β2-α6 loop 
β1-α5 loop 
α5 
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possible that residue R193 could be repositioned closer to the middle site through Mtu-AnPRT 
conformational changes.  
 
It is likely that Mtu-AnPRT utilises the same anthranilate binding sites as Sso-AnPRT, given the 
similarities in their protein structures. It should also be noted that the binding mode of the PRPP 
molecule bound to the Mtu-AnPRT structure places the C1 carbon in an appropriate position for 
nucleophilic attack from an anthranilate molecule bound in the inner site (Figure 1.16). 
 
 
 
 
Figure 1.16 Stereo diagram of Sso-AnPRT and Mtu-AnPRT active sites. Mtu-AnPRT (cyan) with PRPP (yellow) 
and Mg
2+
 (red spheres) bound (PDB ID: 1ZVW) overlaid with Sso-AnPRT (magenta) with PRPP, Mg
2+
 (not 
shown) and anthranilate (white) bound (PDB ID: 1ZXY). Predicted hydrogen bonds between the Sso-AnPRT 
anthranilate molecules and the Mtu-AnPRT enzyme are displayed as yellow dashes, with bond distances (Å) 
shown. Residue labels pertain to the Mtu-AnPRT structure. 
 
1.7.2 Kinetics 
The activity of Mtu-AnPRT has previously been characterised by Dr Clare Lee using a fluorescence-
based assay, with measurements taken using a 96-well plate spectrofluorimeter.56 This assay 
incorporated two enzymes from the tryptophan biosynthetic pathway: Mtu-AnPRT, in order to 
convert anthranilate and PRPP into PRA, and Eco-PRAI:InGPS, which is a single protein in E. coli due 
to the TrpF and TrpC gene fusion,27 in order to convert PRA into the stable InGP product (Figure 
1.16). The presence of Eco-PRAI:InGPS was necessary to remove the build-up of the unstable Mtu-
AnPRT reaction product PRA,57 as the break-down of this compound into ribose-5-phosphate and 
anthranilate would alter the known concentrations of anthranilate in the wells. Removal of PRA also 
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avoided potential product-inhibition of Mtu-AnPRT.56, 58 Eco-PRAI:InGPS was present in excess of 
Mtu-AnPRT in the wells, to ensure that the latter enzyme was rate-limiting. 
The excitation and emission wavelengths were fixed at 313 nm and 390 nm respectively, and the 
disappearance of anthranilate was measured continuously for 1 hour.  Reaction solutions were 
incubated at 25 °C, at a pH of 8.0. Using this method, the KM values for anthranilate and PRPP were 
recorded as 3.3 ± 0.2 µM and 1.3 ± 0.2 µM respectively, with a turnover number (kcat) of 1.1 ± 0.02 s
-
1. A comparison of these values to those obtained in this study and in other orthologues is outlined 
in Section 2.5.1. 
 
 
 
 
 
 
Figure 1.17 The enzymatic reactions utilised in the fluorescence assay used by Lee et al.
56
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1.8 Research Objectives 
The overall aim of this project is to further understand how the Mtu-AnPRT active site facilitates the 
reaction between PRPP and anthranilate, in order to aid future tuberculosis drug development 
which will effectively target and inhibit this enzyme. The specific research objectives can be divided 
into four sections: 
 Characterisation of the wild-type Mtu-AnPRT enzyme and subsequent development of a 
novel enzyme-coupled UV absorbance-based assay, with the aim of kinetically characterising 
previously identified potential inhibitor compounds. 
 Investigation of the ability of Mtu-AnPRT to tolerate different anthranilate-like compounds 
as alternate substrates to anthranilate, including kinetic analysis and product 
characterisation.  
 Synthesis and characterisation of variant Mtu-AnPRT enzymes with postulated key active site 
residues substituted, in order to determine their necessity for binding and/or catalysis. 
 A comparison of the potency of previously identified inhibitor compounds against both wild-
type and variant Mtu-AnPRT enzymes, with the aim of pinpointing any key inhibitor-protein 
interactions for future exploitation.     
Previous characterisation of Mtu-AnPRT has been completed by Dr Clare Lee at the University of 
Auckland.56 This research project follows on from her work, and is supervised jointly by Professor 
Emily Parker (University of Canterbury) and Dr Shaun Lott (University of Auckland).  
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Chapter 2 
 
Characterisation and 
Inhibition of Wild-type Mtu-
AnPRT  
 
 
2.1 Overview 
The first aim of this study was to purify and subsequently characterise wild type Mtu-AnPRT. It was 
also necessary to purify Eco-PRAI:InGPS, as it was required both for enzyme-coupled kinetic assays 
and mass spectrometry experiments.  Physical characterisation of Mtu-AnPRT involved investigation 
into secondary structure, molecular mass and thermal stability of the protein.  
Kinetic characterisation of Mtu-AnPRT was achieved via an enzyme-coupled assay developed in this 
study. Michaelis-Menten kinetic constants were obtained for the natural substrates PRPP and 
anthranilate, and the effects of anthranilate and Mg2+ at high concentrations were evaluated. A 
range of compounds that inhibited the enzyme were kinetically characterised.  
The final part of this chapter describes structural studies of Mtu-AnPRT co-crystallised with several 
inhibitors, as carried out at the University of Auckland.  
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2.2 Introduction 
Prior to this study, the crystal structures of apo Mtu-AnPRT (PDB ID: 2BPQ) and Mtu-AnPRT in the 
presence of PRPP and Mg2+ (PDB ID: 1ZVW) had been solved by Lee et al.44 to resolutions of 1.9 Å 
and 2.3 Å respectively. These structures confirmed the classification of Mtu-AnPRT as a type III 
phosphoribosyltransferase,41b showing a similar structure to the previously described AnPRT 
structures from S. solfataricus42 (PDB ID: 1GXB) and P. carotovorum43 (PDB ID: 1KGZ). 
A comparison of these two Mtu-AnPRT structures showed little differences (RMSD = 0.2 Å) apart 
from the β1-α5 and β2-α6 loops surrounding the PRPP binding site. Upon PRPP and Mg2+ binding, 
these loops rearrange to a position closer to the PRPP molecule (Figure 2.1), simultaneously 
providing some stability for the PRPP phosphate group via contacts to G110, A141, S142 and S143 
and shielding the reactive PRPP from exposure to unproductive nucleophilic attack by water.  
 
 
 
 
 
 
 
Figure 2.1 β1-α5 and β2-α6 loop movement in Mtu-AnPRT. Apo Mtu-AnPRT (green) overlaid with Mtu-AnPRT 
(cyan) with PRPP (yellow) and Mg
2+ 
(magenta spheres) bound. 
 
The structures of Sso-AnPRT co-crystallised with PRPP, Mg2+ and anthranilate (PDB ID: 1ZYK) and 
with anthranilate only (PDB ID: 2GVQ) had also been solved42, 50 and both showed two anthranilate 
molecules present in the anthranilate channel (Figure 1.12).  
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2.3 Protein Isolation 
2.3.1 Transformation  
The Mtu-TrpD gene had previously been cloned into the expression vector pET-23a(+) (Novagen), 
with  the Eco-TrpFC gene also previously cloned into the expression vector pProEX-HTb 
(Invitrogen™).44 These plasmids were provided for use in this study courtesy of the University of 
Auckland. 
Each plasmid was transformed as outlined in Section 7.1.7 into E. coli BL21 (DE3) cells and left to 
grow on LB/agar media containing ampicillin overnight. Successful colony growth was observed for 
cells containing each plasmid, and glycerol stocks of these colonies were made as outlined in Section 
7.1.8.  
Subsequent protein expression trials of Mtu-AnPRT and Eco-PRAI:InGPS in E. coli BL21 (DE3) cells 
showed a large portion of the proteins still present in the insoluble cell debris. Plasmids containing 
the Mtu-TrpD and Eco-TrpFC genes were thus transformed into E. coli BL21 (DE3) pBB528/pBB541 
(chaperone 3 cells), which co-express chaperonins Gro-ES and Gro-EL to aid protein folding and 
solubility. This cell line produced a greater yield of soluble protein for both enzymes, as analysed by 
SDS-PAGE. 
2.3.2 Protein Expression and Purification 
Proteins were expressed and purified as detailed in Sections 7.1.11-17. Cell pellets from scaled up 
cell growths were lysed either by sonication or cell disruption, and the resulting lysate clarified by 
centrifugation to separate out the insoluble cell matter. The soluble protein was then filtered and 
applied to an immobilised metal-affinity column (IMAC) column for purification. Proteins were 
eluted from the column as a result of an increasing imidazole concentration gradient. The fractions 
of interest were then pooled and desalted to either remove or lower the concentration of imidazole 
present. The desalted protein was then concentrated, flash frozen and stored at -80 °C. Samples of 
each of these purification steps were analysed via SDS-PAGE, as can be seen in Figure 2.2 for Mtu-
AnPRT and Figure 2.3 for Eco-PRAI:InGPS. 
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Figure 2.2 SDS-PAGE gel of the Mtu-AnPRT purification. Lane 1 contains the protein ladder, with molecular 
weights defined to the left. Lane 3 – proteins present after cell lysis. Lane 4 – insoluble proteins present in the 
cell debris. Lane 5 – soluble proteins present in the supernatant. Lane 6 – proteins present in the flowthrough 
liquid after purification via a HisTrap™ HP column. Lane 7 – purified Mtu-AnPRT at 39 kDa. Lane 2 is empty. 
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Figure 2.3 SDS-PAGE gel of the Eco-PRAI:InGPS purification. Lane 1 contains the protein ladder, with molecular 
weights defined to the left. Lane 3 – proteins present after cell lysis. Lane 4 – insoluble proteins present in the 
cell debris. Lane 5 – soluble proteins present in the supernatant. Lane 6 – proteins present in the flowthrough 
liquid after purification via a HisTrap™ HP column. Lane 7 – purified Eco-PRAI:InGPS at 53 kDa. Lane 2 is empty. 
 
 
 
 
 
 
 
53 kDa 
160 kDa 
50 kDa 
60 kDa 
40 kDa 
30 kDa 
80 kDa 
110 kDa 
20 kDa 
1 2 3 4 5 6 7 
39 
 
2.4 Physical Characterisation 
2.4.1 Secondary Structure 
Analysis of the secondary structure of both Mtu-AnPRT and Eco-PRAI:InGPS was carried out by 
circular dichroism (CD) to determine whether the proteins were folded correctly (Figure 2.4). 
 
 
 
 
 
 
Figure 2.4 CD spectra of Mtu-AnPRT and Eco-PRAI:InGPS. Solutions contained 0.03 mg/mL enzyme made up to 
3 mL with 20 mM sodium phosphate buffer (pH 8.0). 
 
This data was analysed by the K2D3 secondary structure server,59 which calculated that the ratio of 
α-helices to β-sheets in Mtu-AnPRT was 1.56, which does not match well with the expected value of 
2.43 determined from the crystal structure. If the 4 smaller α-helices 6, 8’, 11’ and 11’’ are ignored, a 
much more comparable value of 1.86 is obtained, though the discrepancy observed is more likely 
due to the inconstant nature of secondary structure determination.60 The expected value of 1.13 for 
Eco PRAI:InGPS, as determined from the crystal structure,61 matched the K2D3 calculated value of 
1.13 exactly. 
2.4.2 Molecular Mass 
The molecular masses of Mtu-AnPRT and Eco-PRAI:InGPS were obtained via mass spectrometry. The 
predicted masses of these enzymes, including their His-tags, were 38804.9 Da and 52732.7 Da 
respectively, as calculated by their amino acid sequences on the ProtParam website.62 The measured 
masses of Mtu-AnPRT and Eco-PRAI:InGPS were found to be 38672.2 Da and 52731.7 Da 
respectively, the latter of which correlates well to the expected value. The value obtained for Mtu-
AnPRT is similar to the calculated value of 38673.7 Da, corresponding to the mass of the protein 
minus the start methionine. The eradication of this amino acid is fairly common in E. coli cells and is 
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likely caused by the presence of methionine aminopeptidase, which cleaves the start methionine 
when it precedes certain amino acids including alanine, such as with Mtu-AnPRT.63  
2.4.3 Thermal Stability 
Differential scanning fluorimetry (DSF) was used to determine the temperatures of denaturation for 
Eco-PRAI:InGPS and Mtu-AnPRT (Figure 2.5), and was carried out as described in Section 7.1.28.64 
This technique employs the use of a dye which fluoresces more strongly when it is bound to 
hydrophobic protein residues. As a protein denatures, the number of previously internalised 
hydrophobic residues available for binding by this dye increases. By steadily raising the temperature 
of a protein’s environment and monitoring the fluorescence, the denaturation temperature can be 
measured as the point of greatest increase in fluorescence. Mtu-AnPRT was also measured in the 
presence of different combinations of its natural ligands at varying concentrations. Raw data from 
the DSF scans can be observed in Appendix 1. 
 
 
 
 
 
 
 
 
Figure 2.5 DSF denaturation temperatures for Mtu-AnPRT and Eco-PRAI:InGPS. When present, the final 
concentrations of ligands were 1 mM Mg
2+
, 0.6 mM PRPP and either 15 µM, 100 µM, 1 mM or 5 mM 
anthranilate. Enzymes were analysed in Tris.HCl buffer (pH 8.0), at concentrations of 1 mg/mL. 
 
The denaturation temperatures of Mtu-AnPRT and Eco-PRAI:InGPS were found to be 54.1 ± 0.3 °C 
and 43.1 ± 0.8 °C respectively.  The presence of natural ligands with Mtu-AnPRT had no significant 
effect on the denaturation temperature, except for when both PRPP and Mg2+ were bound. This 
combination of ligands increased the denaturation temperature to 62.4 ± 0.7 °C, which could infer 
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that the stabilisation of the β1-α5/β2-α6 loops upon PRPP/Mg2+ binding (Figure 2.1) also elicits a 
global increase in stability.  
 
  
 
 
 
 
 
 
Table 2.1 Mtu-AnPRT denaturation temperatures (Tm) in the presence of natural ligands.  
 
 
 
 
 
 
 
 
 
Ligand(s) bound to Mtu-AnPRT Tm (°C) 
No ligand 54.1 ± 0.3 
1 mM Mg2+ 54.7 ± 0.1 
0.6 mM PRPP 54.6 ± 0.8 
1 mM Mg2+ + 0.6 mM PRPP 62.4 ± 0.7 
15 µM anthranilate 54.4 ± 0.2 
100 µM anthranilate 54.5 ± 0.2 
1 mM anthranilate 55.4 ± 1 
5 mM anthranilate 53.3 ± 0.1 
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2.5 Kinetic Characterisation 
An enzyme-coupled absorbance-based UV assay was developed in order to determine the kinetic 
parameters of Mtu-AnPRT. This assay was necessary as further experiments into potential inhibitors 
and alternate substrates of this enzyme cannot be analysed using the previously developed 
fluorescence assay (Section 1.6.2),56 due to potential quenching of the fluorescent signal by 
anthranilate-like compounds. 
The conversion of PRA into InGP, catalysed by PRAI-InGPS, can be monitored spectrophotometrically 
at 270 nm,65 which was confirmed by a wavelength scan performed from 230-320 nm (Figure 2.6). 
The absorbance increase at 270 nm was not observed when Eco-PRAI:InGPS was absent from the 
assay. An assay was therefore developed where Eco-PRAI:InGPS was added in excess of Mtu-AnPRT 
to ensure the AnPRT-catalysed reaction is the rate-limiting step, and the reaction was monitored at 
270 nm to detect the formation of the InGP product. The presence of excess Eco-PRAI:InGPS also 
prevents any PRA breakdown57 as it is immediately removed from solution. Using known 
concentrations of anthranilate, the extinction coefficient for InGP production from anthranilate and 
PRPP was determined to be 7500 L mol-1 cm-1 at 270 nm. The assay was monitored at 25 °C in order 
to compare results with previous studies (Table 2.2). 
 
 
 
 
 
 
Figure 2.6 Wavelength scan of the Mtu-AnPRT reaction using the enzyme-coupled assay (t = time). The 
absorbance can be seen to increase in the 260-290 nm range, and decrease in the 230-255 nm and 295-320 
nm ranges. Solutions contained 1 mM MgCl2, 0.1 µM Mtu-AnPRT, 1.7 µM Eco-PRAI:InGPS, 0.6 mM PRPP and 
100 µM anthranilate made up to 1 mL with buffer (50 mM Tris.HCl, 200 mM NaCl, pH 8.0). Reactions were 
scanned from 320-230 nm for 30 min with a cycle length time of 2.5 min. Solutions were thermally 
equilibrated for 5 min prior to initiation with anthranilate and allowed to go to completion. 
 
t = 0 min 
t = 30 min 
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2.5.1 Michaelis-Menten Kinetics 
The turnover number (kcat) and apparent KM values were determined for Mtu-AnPRT (Figure 2.7) 
using the enzyme-coupled assay as outlined in Section 7.1.24/7.2.1. The apparent KM value of 2.0 ± 
0.2 µM for anthranilate is comparable to those obtained for enzymes isolated from other organisms 
(Table 2.2). The turnover number of 1.9 ± 0.1 s-1 also correlates well with other enzymes. The 
substrate PRPP has an apparent KM value of 48 ± 2 µM, and falls within the range of 1.3 – 180 µM 
recorded for other enzymes. The discrepancies observed between the kinetic parameters of the 
AnPRT homologues listed in Table 2.2 can likely be attributed to differing experimental conditions. 
For example, fluorimetric assays were used to determine the kinetic parameters of Sso, Sce and 
previous Mtu-AnPRTs, with the latter utilising a fluorimetric plate-reader as opposed to cuvettes. An 
inspection of the experimental conditions also highlights variations in the buffer components, pH 
levels and incubation temperatures, all of which could potentially play some role in altering the 
kinetic parameters.56, 58, 66 
 
      
 
 
 
 
 
 
Figure 2.7 Plots of kinetic data for Mtu-AnPRT substrates. Insets: Lineweaver-Burk plots. A) The Michaelis-
Menten plot for anthranilate, with PRPP held at a concentration of 0.6 mM. B) The Michaelis-Menten plot for 
PRPP, with anthranilate held at a concentration of 15 µM. All data was collected with reaction solutions at 25 
°C, pH 8.0. Raw data was fitted to the Michaelis-Menten equation using Grafit 5 software.
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Organism Temp 
(°C) 
KM(anth) (µM) KM(PRPP) (µM) kcat (s
-1) kcat/KM(anth) 
(µM-1s-1) 
kcat/KM(PRPP) 
(µM-1s-1) 
M. tuberculosis 
(this study) 
25 2.0 ± 0.2 48 ± 2 1.9 ± 0.06 0.95 ± 0.13 0.04 ± 
0.003 
M. tuberculosis56 25 3.3 ± 0.2 1.3 ± 0.2 1.1 ± 0.02 0.3 ± 0.03 0.8 ± 0.1 
S. solfataricus52 37 0.085 180 0.41 ± 0.04 4.8 2.3 x 10-3 
S. cerevisiae66a 25 1.6 ± 0.5 22.4 ± 2.6 2.9 ± 0.5 1.8 ± 0.9 0.13 ± 0.04 
*E. coli66b  25 0.28 50 4.4 15.7 0.088 
 
Table 2.2 Kinetic data of AnPRT from different organisms. * indicates the enzyme is covalently linked to 
anthranilate synthase. 
 
2.5.2 Anthranilate Inhibition 
At higher concentrations of the substrate anthranilate, a significant drop in Mtu-AnPRT activity was 
observed. The substrate inhibition of Mtu-AnPRT by anthranilate was therefore examined (Figure 
2.8), using the enzyme-coupled assay as described in Section 7.1.24/7.2.1, by increasing anthranilate 
concentrations from 0-100 µM. Results clearly demonstrate that the enzyme is subject to significant 
substrate inhibition, with a Ki value of 47 ± 7 µM. This observed inhibition is possibly a result of 
simultaneous occupancy of the anthranilate binding sites outlined in Section 1.6.2.3. Anthranilate 
inhibition has previously been reported for Salmonella typhimurium AnPRT only, which is covalently 
linked to the glutamine amidotransferase subunit of the previous tryptophan biosynthesis pathway 
enzyme anthranilate synthase due to the fusion of the TrpG and TrpD genes. However, this substrate 
inhibition was only observed in the presence of tryptophan.68  
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Figure 2.8 Mtu-AnPRT kinetic data for anthranilate inhibition, with PRPP held at a concentration of 0.6 mM. 
Solutions were monitored at 25 °C at pH 8.0, and raw data was fitted to the substrate inhibition equation using 
Grafit 5 software.
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2.5.3 Mg2+ Inhibition 
The concentration of MgCl2 used in the enzyme-coupled assay in this study is set at 1 mM based on 
previous work,56 however, it has been observed during analysis of the Sso-AnPRT enzyme that there 
is a decrease in activity at concentrations of MgCl2 greater than 0.1 mM.
42, 50 The inhibition of Mtu-
AnPRT by MgCl2 was therefore investigated, but contrary to the findings for Sso-AnPRT, no significant 
inhibition up to 10 mM MgCl2 was observed (Figure 2.9). 
 
 
 
 
 
 
 
Figure 2.9 The effect of increasing concentrations of Mg
2+ 
on Mtu-AnPRT activity. The concentrations of PRPP 
and anthranilate were held at 0.6 mM and 15 µM respectively, with solutions held at 25 °C, pH 8.0. Graph 
generated using Grafit 5 software.
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2.5.4 Mechanism 
To determine the kinetic mechanism of Mtu-AnPRT, initial rate measurements were taken at varying 
concentrations of both substrates, as described in Section 7.1.24/7.2.1. This data was then fitted to 
the ternary mechanism equation (Figure 2.10), which clearly shows this enzyme has a sequential 
mechanism. In the crystal structures of Mtu-AnPRT,44 it has been observed that residues from the 
flexible loops β1-α5 and β2-α6 that close over the bound PRPP molecule form contacts for 
anthranilate binding in the inner site. This observation, coupled with our findings of a sequential 
mechanism, could indicate that anthranilate can only bind in the inner site after PRPP has bound. 
 
 
 
 
 
 
 
 
Figure 2.10 Mtu-AnPRT kinetic data as fitted to the ternary mechanism equation using Grafit 5 software
67
 and 
presented as a double reciprocal plot. From this data the KM values for anthranilate and PRPP were 
determined to be 0.9 ± 0.6 µM and 12 ± 4 µM respectively. Anthranilate concentrations were varied from 0 – 
12 µM, with PRPP concentrations varied from 0 - 62.5 µM. Reaction solutions were monitored at 25 °C at pH 
8.0. 
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2.6 Inhibition of Mtu-AnPRT 
Previous work into potential inhibitors of Mtu-AnPRT involved the screening of 165 compounds from 
the Auckland Cancer Society Research Centre (ACSRC) using a fluorescence assay which monitored 
the consumption of anthranilate.41a These compounds were chosen based on their similarities to the 
natural substrate anthranilate, and were ranked based on the percentage decrease in Mtu-AnPRT 
activity observed in the presence of 0.3 mM PRPP, 100 µM inhibitor and 75 µM anthranilate. The top 
compounds from this screen all had aromatic rings with a carboxylate group, and most had 
functional groups present on C2. Some of these compounds acted as substrates for Mtu-AnPRT, and 
these will be discussed in Chapter 3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11 The top 12 hits from the fluorescence assay inhibitor screen. Figure extracted from Castell et al. 
Supplementary Material.
41a
 
 
 
 
Anthranilate 
48 
 
2.6.1 Inhibition Kinetics  
Several compounds from Figure 2.11 were quantitatively examined using the UV enzyme-coupled 
assay developed in this study. The nine compounds chosen for further testing were ACS172, ACS145, 
ACS10, ACS179, ACS142, ACS126, ACS4, ACS165 and ACS174 (Table 2.3). Additional compounds 
tested were 3-aminobenzoic acid and ribose-5-phosphate (R5P). 3-Aminobenzoic acid was tested as 
it was readily available and to fully analyse the inhibitory effect caused by the position of the amino 
group on the anthranilate aromatic ring (C2 (anthranilate) and C4 (ACS4) were already under 
investigation). Ribose-5-phosphate (R5P) (Figure 2.13A) was tested as a potential PRPP-like inhibitor 
which, if successful at binding, could later be used in conjunction with anthranilate to elucidate 
different aspects of Mtu-AnPRT mechanics, by obtaining crystal structures with both compounds 
bound or dissociation constants. 
Inhibitor compounds predicted to compete with anthranilate were tested using the enzyme coupled 
assay with anthranilate concentrations below 15 µM to avoid substrate inhibition. Results were 
fitted to each of four inhibition equations (competitive, pure non-competitive, uncompetitive and 
mixed inhibition) and the χ2 values compared to determine which fit best described the data. 
Inhibition was observed for all compounds tested with the exception of ACS4 and 3-aminobenzoic 
acid. Ki values of anthranilate-like inhibitors ranged from 5.5 – 129 µM (Table 2.3, Figure 2.12), and 
all compounds demonstrated competitive inhibition, with the exception of ACS172 which showed 
pure non-competitive inhibition. The pure non-competitive inhibition displayed by ACS172 indicates 
that the binding affinity of this compound for the enzyme both with and without anthranilate bound 
is equal, allowing both ACS172 and anthranilate to be bound simultaneously. ACS172 had the lowest 
Ki value of 5.5 ± 0.3 µM and is bi-anthranilate-like in character, having no additional functional 
groups on the aromatic rings. The absence of extra groups likely allows this compound to bind to 
Mtu-AnPRT in a manner most similar to the natural substrate anthranilate, and has been observed to 
bind at different stages along the anthranilate channel (PDB ID: 3QQS, discussed in Section 2.7). 
These multiple binding modes support the pure-noncompetitive inhibition behaviour observed for 
ACS172, indicating that anthranilate and ACS172 could bind simultaneously.  
Complementary structural information of ACS172, ACS142 (PDB ID: 3UU1), ACS174 (PDB ID: 3QS8), 
ACS145 (PDB ID: 3R88), ACS179 (PDB ID: 3R6C) and ACS10 (PDB ID: 3TWP) bound to Mtu-AnPRT 
(discussed further in Section 2.7) show the majority of inhibitors binding primarily at the entrance to 
the anthranilate channel. ACS172, ACS174 and ACS142 were the only inhibitors observed to bind in 
multiple sites within the channel, with all three having Ki values under 10 µM. This observation 
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indicates that stronger inhibition is obtained when multiple anthranilate sites are occupied by 
inhibitor compounds.  
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Table 2.3 Chemical structures, Ki values and types of inhibition displayed for anthranilate-like inhibitors tested 
against Mtu-AnPRT. 
 
 
ACS 
number 
Structure Ki value (µM) Type of 
inhibition 
174 
 
6.1 ± 0.5 Competitive 
172 
 
5.5 ± 0.3 
Pure non-
Competitive 
142 
 
8.5 ± 0.7 Competitive 
179 
 
5.7 ± 0.5 Competitive 
145 
 
129 ± 14 Competitive 
10 
 
30 ± 3 Competitive 
126 
 
103 ± 10 Competitive 
165 
 
70 ± 8 Competitive 
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Figure 2.12 Mtu-AnPRT inhibition graphs for determination of inhibitor Ki values, as calculated by the graphing 
software Grafit 5.
67
 Solutions contained PRPP held at a concentration of 0.6 mM, at a temperature of 25 °C, pH 
8.0. ACS compound numbers and concentrations used are indicated in the blue boxes.   
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The compound R5P was tested as a PRPP-like inhibitor using the enzyme-coupled assay with 
anthranilate held at a concentration of 15 µM to avoid anthranilate inhibition. This compound 
demonstrated competitive inhibition but gave a high Ki value of 1 ± 0.1 mM. This is unsurprising as 
crystal structures of Mtu-AnPRT with PRPP and Mg2+ bound (PDB ID: 1ZVW) show that the PPi group 
of PRPP, missing in R5P, is stabilised by numerous hydrogen bonds to Mtu-AnPRT, Mg2+ and several 
water molecules, implying a high degree of molecular recognition (Figure 2.13C).44 It is possible that 
the inhibition of R5P would improve upon the addition of PPi to the assay, though this was not 
tested. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13 Inhibition of Mtu-AnPRT by R5P. A) The chemical structure of R5P. B) The Mtu-AnPRT Michaelis-
Menten inhibition graph for determination of the Ki value of R5P. Anthranilate is held at a concentration of 15 
µM, with reaction solutions monitored at 25 °C at pH 8.0. C) Wild-type Mtu-AnPRT (cyan) co-ordinated to PRPP 
(yellow) and Mg
2+
 (magenta spheres), with the PRPP PPi group and Mg
2+
 polar contacts displayed as yellow 
dashes. Water molecules are shown as red spheres. 
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2.7 Crystal Structures of Anthranilate-Like Inhibitors Bound To Mtu-
AnPRT 
Crystal structures of ACS172 (PDB ID: 3QQS), ACS174 (PDB ID: 3QS8), ACS142 (PDB ID: 3UU1), 
ACS145 (PDB ID: 3R88), ACS179 (PDB ID: 3R6C) and ACS10 (PDB ID: 3TWP) bound to Mtu-AnPRT in 
the presence of PRPP and Mg2+ were obtained by Dr Alina Castell and Dr Genevieve Evans at the 
School of Biological Sciences, University of Auckland. These structures complement the information 
found via enzymology in this study and are discussed and interpreted in this section.  
Mtu-AnPRT co-crystallised with ACS172, PRPP and Mg2+ showed the inhibitor bound to Mtu-AnPRT 
in three different binding modes (Figure 2.14). The first orientation, designated Mode 1, can be 
observed in chains A and B of the structure (PDB ID: 3QQS), where the innermost aromatic ring of 
ACS172 can be seen to overlap with the middle anthranilate binding site observed in Sso-AnPRT 
structures (Figure 2.14A).42, 50 The carboxylate group on the innermost aromatic ring of ACS172 
forms a salt bridge with R193 as well as a hydrogen bond to a water molecule, while the carboxylate 
group on the outermost ring forms hydrogen bonds to N138, R194 (both chains) and a water 
molecule (chain B only). This outermost ring is also oriented parallel to the P180 imidazole ring, 
suggestive of C-H...π interactions.69 
Chains C and D show ACS172 bound (occupancy = 0.6) in a position where the innermost aromatic 
ring of the inhibitor overlaps with the Sso-AnPRT inner binding site (Figure 2.14B), and is designated 
Mode 2. In this mode, the carboxylate group of the innermost aromatic ring of ACS172 makes 
hydrogen bonds to R193 and either one (chain C) or two (chain D) water molecules, while the 
carboxylate group on the outermost aromatic ring hydrogen bonds to N138 (both chains) and a 
water molecule (chain C only). Chains C and D also show a second ACS172 molecule bound, in a 
position designated Mode 3. In this mode the carboxylate group on the inner-most ring of ACS172 
makes hydrogen bonds to R194 (both chains), N138 (chain C only) and a water molecule (both 
chains) and is oriented parallel to P180, however, the outer ring carboxylate group makes no 
contacts to the relevant protein chains. It is entirely possible that this binding mode arises due to 
crystal packing, though the innermost ring of ACS172 in this mode creates similar contacts to the 
outermost ring as it is bound in Mode 1. 
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Figure 2.14 Wild-type Mtu-AnPRT with ACS172 bound. A) Stereo diagram of Mtu-AnPRT (purple) co-
crystallised with ACS172, PRPP (yellow) and Mg
2+
 (red spheres) (PDB ID: 3QQS), with anthranilate (pink) 
overlaid from Sso-AnPRT (PDB ID: 1ZYK). Mode 1 of ACS172 (green) is shown, which overlaps with the middle 
site anthranilate molecule of Sso-AnPRT. B) Stereo diagram of Mode 2 of ACS172 (cyan) showing overlap with 
both inner site and middle site anthranilate molecules of Sso-AnPRT. Mode 3 of ACS172 (white) is also shown. 
C) Surface representation of Mtu-AnPRT showing Mode 1 of ACS172. D) Surface representation of Mtu-AnPRT 
showing Modes 2 and 3 of ACS172. 
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ACS174, PRPP and Mg2+ co-crystallised with Mtu-AnPRT shows ACS174 bound in two orientations. 
Interestingly, the orientation seen in all four chains shows ACS174 bound in a pose similar to Mode 2 
for ACS172, where the outer aromatic ring of ACS174 overlaps with the middle anthranilate site 
observed in Sso-AnPRT. This is contrary to what is observed for the other inhibitors, the majority of 
which are bound near the entrance to the anthranilate channel. In this Mode 2 site, the carboxylate 
group of ACS174 makes hydrogen bonds with R193, Y186 and a water molecule. An additional 
ACS174 molecule is observed in chains A and D, where the carboxylate group is bound to R194 and 
two water molecules (Figure 2.15). 
 
 
 
 
 
 
 
Figure 2.15 Stereo diagram of wild-type Mtu-AnPRT with ACS174 bound. Mtu-AnPRT (green) (PDB ID: 3QS8) 
co-crystallised with PRPP (yellow), Mg
2+
 (red spheres) and ACS174 (Mode 2 shown in cyan, and the other 
binding mode shown in white) with anthranilate (pink) overlaid from Sso-AnPRT (PDB ID: 1ZYK).  
 
The Mtu-AnPRT structure co-crystallised with ACS142, PRPP and Mg2+ shows the inhibitor bound in 
two orientations. The orientation observed in all four chains shows ACS142 bound in the entrance to 
the anthranilate channel, making contacts via its carboxylate group to R194, N138, and one (chains 
A, C and D) or two (chain B) water molecules, and in chain B via its amino group to a water molecule. 
This binding site will be referred to as the ‘outer site’ for the remainder of this study. Chains B and C 
also show a second ACS142 (Figure 2.16) molecule bound in a site that overlaps with the inner 
anthranilate site observed for Sso-AnPRT. In this site ACS142 forms hydrogen bonds with R193 and 
two water molecules via its carboxylate group, and to two water molecules via its amino group. 
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Figure 2.16 Stereo diagram of wild-type Mtu-AnPRT with ACS142 bound. Mtu-AnPRT (magenta) (PDB ID: 
3UU1) co-crystallised with PRPP (yellow), Mg
2+
 (red spheres) and ACS142 (inner site shown in cyan, and the 
outer site shown in green) with anthranilate (white) overlaid from Sso-AnPRT (PDB ID: 1ZYK). 
 
The remaining inhibitors ACS145, ACS179 and ACS10 bound solely in the entrance to the 
anthranilate channel, with their ring structures oriented parallel to P180. The binding modes of 
these inhibitors, and of ACS142, ACS172 and ACS174, bound in the anthranilate channel entrance 
can be compared in Figure 2.17.  
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Figure 2.17 Inhibitors of Mtu-AnPRT as bound at the anthranilate channel entrance, with bond lengths 
indicated. A) Mode 1 of ACS172 (PDB ID: 3QQS, purple). B) ACS142 (PDB ID: 3UU1, magenta).  C) ACS174 (PDB 
ID: 3QS8, green). D) ACS145 (PDB ID: 3R88, orange). E) ACS179 (PDB ID: 3R6C, cyan). F) ACS10 (PDB ID: 3TWP, 
grey). 
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During this crystallisation process, a new structure was also elucidated for apo Mtu-AnPRT (PDB ID: 
3QR9) without the need for the additive benzamidine, previously required to obtain diffraction-
quality crystals. This new apo structure illuminated differences in the positions of several helices 
compared to the previously solved apo structure, including the α8 and α9 helices and the β2-α6 
loop, thought to be caused by rearrangement of these secondary structures to accommodate 
benzamidine (Figure 2.18).41a A comparison of the β2-α6 loop between the new apo structure and 
the Mtu-AnPRT structure with PRPP and Mg2+ bound still demonstrates the loop rearrangement 
discussed earlier in Section 2.2, however, the PRPP and Mg2+ bound structure also contains the 
benzamidine additive. Ideally, a better comparison would be between the new apo structure and a 
PRPP/Mg2+ bound structure without benzamidine present. Several attempts to obtain structures of 
the latter were undertaken during this study, however, none of the crystals sent for analysis were of 
diffraction quality (Figure 2.19). 
 
 
 
 
 
 
 
 
 
Figure 2.18 An overlay of the old and new Mtu-AnPRT apo structures. The old apo Mtu-AnPRT structure (PDB 
ID: 2BPQ) is shown in orange with benzamidine (blue) bound, with the new apo Mtu-AnPRT structure (PDB ID: 
3QR9) shown in green. 
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Figure 2.19 Crystals of wild-type Mtu-AnPRT co-crystallised with PRPP and Mg
2+
, with the crystal solution 
containing 0.2 M imidazole malate (pH 7.0), 13% PEG-4000 (w/v). 
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2.8 Summary 
Both Mtu-AnPRT and Eco-PRAI:InGPS plasmids were successfully transformed into BL21 (DE3) cell 
lines containing plasmids pBB528 and pBB541 for co-expression of the chaperonins Gro-ES and Gro-
EL. These proteins were successfully purified, with masses of the expected size as determined via 
mass spectrometry. CD spectra were obtained indicating the proteins were properly folded, and DSF 
results showed melting temperatures of 54 ± 0.3 °C and 43 ± 0.8 °C for Mtu-AnPRT and Eco-
PRAI:InGPS respectively. When PRPP and Mg2+ are included, the melting temperature of Mtu-AnPRT 
increased to 62 ± 0.7 °C. 
Kinetic characterisation of Mtu-AnPRT was carried out using the UV enzyme-coupled assay 
developed in this study, with Eco-PRAI:InGPS as the coupling enzyme. The apparent KM values for the 
natural substrates PRPP and anthranilate were 48 ± 2 µM and 2.0 ± 0.2 µM respectively, with a kcat 
value of 1.9 ± 0.1 s-1. Anthranilate inhibition was observed for Mtu-AnPRT, with a Ki value of 47 ± 7 
µM, while Mg2+ inhibition, which has been observed for Sso-AnPRT, was not apparent. The kinetic 
profile of Mtu-AnPRT is consistent with that of a sequential mechanism, possibly indicating that 
PRPP binds first before anthranilate can bind in the catalytically relevant site. 
A series of anthranilate-like inhibitors were tested against Mtu-AnPRT using the enzyme-coupled 
assay, with Ki values ranging from 5.5 – 129 µM. The most potent of these inhibitors was ACS172 
with a pure non-competitive Ki value of 5.5 ± 0.3 µM, the only compound not to display competitive 
inhibition. R5P was the only compound to be tested as a possible PRPP-like inhibitor, but had a high 
Ki value of 1 ± 0.1 mM. 
In conjunction with the inhibition enzymology studies, structures of Mtu-AnPRT co-crystallised with 
PRPP, Mg2+ and various anthranilate-like inhibitors were obtained by Dr Alina Castell and Dr 
Genevieve Evans. These structures showed the inhibitors bound in the anthranilate channel, with 
ACS172, ACS174 and ACS142 displaying multiple binding modes within the asymmetric unit. All 
inhibitors showed at least one binding mode at the entrance to the anthranilate channel; a position 
previously undefined by crystal structures or modelling as an anthranilate binding site. These 
structures point to the possibility of a third outer binding site for anthranilate within Mtu-AnPRT. 
 
 
61 
 
 
Chapter 3  
 
Alternative Substrates of 
Wild-type Mtu-AnPRT  
 
 
3.1 Overview 
This chapter outlines the characterisation of Mtu-AnPRT-catalysed reactions utilising various 
alternate substrates to anthranilate. Initial kinetic characterisation was achieved via a commercially 
available PPi assay to monitor Mtu-AnPRT turnover alone without relying on additional Eco-
PRAI:InGPS turnover. 
Physical characterisation of the PRA-substituted products arising from alternate substrate catalysis 
was achieved using techniques including NMR and mass spectrometry. The appearance of PRA 
anomers was observed, with interconversion via an imine intermediate. The ability of Eco-
PRAI:InGPS to catalyse the PRA-substituted products was investigated using the enzyme-coupled 
assay developed in Chapter 2, and physical characterisation of any Eco-PRAI:InGPS reaction products 
were carried out using mass spectrometry.  
The final part of this chapter describes structural studies of Mtu-AnPRT co-crystallised with several 
anthranilate-like substrates, as carried out by Dr Alina Castell at the University of Auckland.  
 
62 
 
3.2 Introduction 
Mtu-AnPRT catalyses the displacement of PPi of PRPP by anthranilate with inversion of 
stereochemistry at C1 of PRPP, creating β-PRA from α-PRPP. However, it is unknown whether this 
reaction proceeds via an SN1 mechanism, whereby the PPi moiety of PRPP is completely cleaved 
prior to nucleophilic attack of the anthranilate amine (creating a fully-formed oxocarbenium ion 
intermediate), or via an SN2 mechanism where these two events occur in the same reaction step.  
 
 
 
 
 
 
 
 
 
Figure 3.1 The reaction catalysed by Mtu-AnPRT, showing both possible mechanisms. 
Kinetic isotope effect experiments with the type I orotate and hypoxanthine – guanine PRTs 
provided results which support an SN1 mechanism, with evidence of a fully-formed carbocation 
transition state.31b, 70 Structures of other type I PRT enzymes co-crystallised with substrates or 
transition state analogues demonstrate the C1 of PRPP in several different positions between the PPi 
and nitrogenous base.31b, 41b, 71 These results are indicative of a relatively mobile oxocarbenium ion 
characteristic of an SN1 mechanism, as opposed to a stationary carbon held in place by an SN2 
mechanism. Kinetic isotope experiments have not been carried out on type II PRTs thus far, 
however, it has been suggested that the type II human nicotinamide PRT enzyme utilises an SN2 
transition state based on an inspection of the crystal structure with nicotinamide and PRPP bound.72  
During the screening process of potential anthranilate-like inhibitors for Mtu-AnPRT (Section 2.6), 
several compounds were discovered that acted as alternate anthranilate substrates for this enzyme 
(e.g. ACS125 and ACS130). Based on this finding, a series of compounds were selected to investigate 
δ+ 
δ- 
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the tolerance of Mtu-AnPRT to substitutions at various positions on the aromatic ring of 
anthranilate. These compounds included methyl-, methoxy- or fluoro- substitutions at positions C3-
C6, substitution of the carboxylate group for a sulfonyl group, and repositioning of the amine group 
at C3 or C4. Investigation into the behaviour of these compounds with Mtu-AnPRT may elucidate key 
features of the kinetic mechanism of this enzyme that will further aid the development of potential 
inhibitors. 
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3.3 Kinetic Characterisation 
As it was not known whether the PRA-like products produced by the reaction of the anthranilate 
analogues with PRPP would be turned over by Eco-PRAI:InGPS, the enzyme-coupled assay utilised in 
the previous chapter could not be used to monitor the formation of InGP. Instead, the commercially 
available EnzChek® Pyrophosphate Assay Kit (Invitrogen™) was used to monitor amount of inorganic 
pyrophosphate (PPi) produced by the Mtu-AnPRT reaction. 
Mtu-AnPRT produces PPi in a 1:1 stoichiometric ratio with anthranilate. Using the EnzChek® 
Pyrophosphate Assay Kit (Invitrogen™), inorganic pyrophosphatase then converts the PPi produced 
by the Mtu-AnPRT reaction into inorganic phosphate (Pi) with a 1:2 stoichiometry. The Pi is then 
reacted with the substrate 2-amino-6-mercapto-7-methylpurine ribonucleoside (MESG) by purine 
nucleoside phosphorylase (PNP) in a 1:1 ratio to form ribose-1-phosphate and 2-amino-6-mercapto-
7-methylpurine, the latter of which can be monitored spectrophotometrically at 360 nm. Excess Eco-
PRAI:InGPS was also included in this assay in an attempt to stem the breakdown of any PRA-
substituted products. The reactions involved in this assay are summarised in Figure 3.2. 
Inorganic pyrophosphatase and PNP were added in excess to ensure that the Mtu-AnPRT catalysed 
reaction was the rate-limiting step. The extinction coefficient for 2-amino-6-mercapto-7-
methylpurine production from anthranilate and PRPP was determined to be 26200 L mol-1cm-1 using 
known concentrations of anthranilate under the assay conditions outlined in Section 7.1.26/7.3.1.  
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3.3.1 Michaelis-Menten Kinetics 
The apparent KM value of 1.7 ± 0.1 µM for anthranilate using the PPi assay is comparable to the value 
of 2.0 ± 0.2 µM obtained using the enzyme-coupled assay. The Mtu-AnPRT turnover numbers 1.9 ± 
0.1 s-1 and 2.0 ± 0.1 s-1, obtained using the enzyme-coupled assay and PPi assay respectively, are 
identical within experimental error. The similarity of the kinetic parameters obtained between these 
two assays indicates that the PPi assay is a valid alternative to investigate anthranilate analogue 
turnover.  
The Mtu-AnPRT apparent KM and kcat values were found for all anthranilate analogues (Table 3.1, 
Figure 3.3) with the exceptions of ACS142, ACS145, ACS10, ACS4 and 3-aminobenzoic acid. The 
compounds which are not classified as substrates did not induce detectable Mtu-AnPRT activity 
greater than 0.001 s-1, in the presence of ≤ 200 mM analogue. The apparent KM values for the fluoro-
substituted analogues ranged from 1.4 – 31 µM and are highly dependent on the site of substitution, 
with fluoro-substitution on C4 and C6 having little effect on binding, whereas fluoro-substitution on 
C3 and C5 showed an 18- and 6- fold increase in KM, respectively. None of the fluoro-substituted 
analogues had a significant effect on the kcat of Mtu-AnPRT, showing similar results to the natural 
substrate anthranilate. 
Methyl-substitution around the aromatic ring of anthranilate had a substantially detrimental effect 
on both the KM and kcat values. The apparent KM values for these analogues ranged from 290 – 800 
µM, showing an increase of at least 17-fold compared to anthranilate, while kcat values showed a 
minimum 3-fold decrease. These results demonstrate a lower tolerance for methyl-substitutions 
compared to fluoro-substitutions around the anthranilate ring, likely due to increased steric bulk of 
the methyl group creating unfavourable steric interactions within the anthranilate channel of Mtu-
AnPRT. 
Orthanilate showed a 76-fold increase in KM value, showing a binding affinity significantly worse than 
the fluoro-analogues, though still better than the methyl-analogues. However, orthanilate had the 
slowest turnover rate of all the analogues tested with a kcat value of 0.1 ± 0.004 s
-1, and highlights the 
importance of the anthranilate carboxylate group for efficient catalysis.  
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Substrate Structure KM value 
(µM) 
kcat value (s
-1) kcat/KM (s
-1 µM-1) 
Anthranilate 
 
1.7 ± 0.1 2.0 ± 0.1 1.2 ± 0.1 
3-fluoroanthranilate 
(3FA) 
 
31 ± 3 1.4 ± 0.03 0.05 ± 0.006 
4-fluoroanthranilate 
(4FA) 
 
2.1 ± 0.2 1.2 ± 0.1 0.6 ± 0.1 
5-fluoroanthranilate 
(5FA) 
 
10 ± 1 1.3 ± 0.1 0.13 ± 0.01 
6-fluoroanthranilate 
(6FA) 
 
1.4 ± 0.1 1.3 ± 0.1 0.9 ± 0.1 
3-methylanthranilate 
(3MA) 
 
290 ± 20 0.63 ± 0.03 0.002 ± 0.0002 
4-methylanthranilate 
(4MA) 
 
490 ± 130 0.15 ± 0.02 0.0003 ± 0.0001 
5-methylanthranilate 
(5MA) (ACS125) 
 
570 ± 120 0.62 ± 0.07 0.0011 ± 0.0004 
6-methylanthranilate 
(6MA) 
 
800 ±120 0.62 ± 0.07 0.0009 ± 0.0002 
Orthanilate 
(ACS130) 
 
130 ± 11 0.1 ± 0.004 0.0008 ± 0.0001 
 
Table 3.1 Chemical structures, KM values, kcat values and kcat/KM values for anthranilate analogues tested as 
substrates for Mtu-AnPRT. 
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Figure 3.3 The Michaelis-Menten plots for determination of the anthranilate-analogue kinetic parameters. 
Insets: Lineweaver-Burk plots. Data was obtained using the EnzChek® Pyrophosphate Assay Kit (Invitrogen™) 
with PRPP held at a concentration of 120 µM. Reactions were initiated with the addition of 
anthranilate/analogue. All data points were fitted using the graphing software Grafit 5.
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3.3.2 Anthranilate-Analogue Inhibition 
Due to the observation of anthranilate inhibition discussed in Section 2.5.2, the fluoro-substituted 
anthranilate analogues were further tested at higher concentrations to investigate whether this 
phenomenon still occurred. The fluoro-analogues were selected due to the similarity of their kinetic 
parameters to anthranilate.  
Substrate inhibition of anthranilate and the fluoro-substituted analogues was examined using the PPi 
assay as outlined in Section 7.1.26/7.3.1, with analogue concentration increased up to a 800 µM 
maximum (Table 3.2, Figure 3.4). Inhibition of the natural substrate anthranilate gave a similar Ki 
value of 45 ± 6 µM to that obtained using the enzyme-coupled assay (47 ± 7 µM). Substrate 
inhibition was observed for all fluoro-analogues tested, and again showed dependence on the site of 
fluoro-substitution, though with a different trend to that observed for the KM values in Section 3.3.1. 
Fluoro-substitutions at the C3 and C4 positions showed the most significant influence on the Ki 
values, with a 24- and 8- fold increase respectively. Substitution at the C5 and C6 positions, however, 
had less of an effect, with these analogues displaying similar Ki values to anthranilate. Combined 
with the results in Section 3.3.1, it can be seen that 6FA possesses kinetic parameters that are most 
similar to those of anthranilate. 
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Substrate Structure Ki value 
(µM) 
Anthranilate 
 
45 ± 6 
3-fluoroanthranilate 
(3FA) 
 
1090 ± 330 
4-fluoroanthranilate 
(4FA) 
 
380 ± 100 
5-fluoroanthranilate 
(5FA) 
 
60 ± 11 
6-fluoroanthranilate 
(6FA) 
 
34 ± 5 
 
Table 3.2 Chemical structures and Ki values for the fluoro-analogues as substrate inhibitors of Mtu-AnPRT.  
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Figure 3.4 Substrate inhibition plots for fluoro-/anthranilate. Data was obtained using the EnzChek® 
Pyrophosphate Assay Kit (Invitrogen™) with PRPP held at a concentration of 120 µM. Reactions were initiated 
with the addition of fluoro-/anthranilate. All data points are fitted to the substrate inhibition equation using 
Grafit 5 software.
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3.4 Product Characterisation 
3.4.1 NMR 
As the PPi assay described in Section 3.3 monitors PPi production only, it was necessary to confirm 
the presence of substituted PRA products produced by the reactions between PRPP and the 
anthranilate analogues. Thus, 1H NMR spectroscopy was carried out by Dr Esther Bulloch at the 
University of Auckland to follow the Mtu-AnPRT-catalysed reaction of each of these analogues with 
PRPP. 
An excess of Mtu-AnPRT and both natural substrates were incubated and the 1H spectra recorded at 
100 – 300 s intervals, with results showing an obvious loss of both substrates coupled with the 
appearance of peaks corresponding to PRA (Figure 3.5). However, the emergence of two anomeric 
proton peaks (at 5.70 and 5.31 ppm) and two sets of aromatic proton peaks corresponding to PRA 
indicated that both α and β anomers of this product were present. Due to spectral peak overlap, the 
PRA aromatic protons and the ribose protons could not be uniquely assigned. 
This 1H NMR method was used to follow all the Mtu-AnPRT-catalysed reactions of PRPP with the 
fluoro- and methyl-substituted anthranilate analogues and orthanilate. Peaks corresponding to the 
analogues and PRPP were observed to disappear concurrently with the formation of PRA analogues, 
with the exception of 3MA (Appendix 2).51 As with PRA, the PRA analogues all existed as a mixture of 
α and β anomers of which the anomeric protons could all be uniquely assigned, despite the 
significant overlap of peaks corresponding to other structural features. It is surprising that the PRA 
product resulting from PRPP and 3MA is not detected using this technique, as the kcat value was 
observed to be similar to both 5MA and 6MA (Table 3.1). It is possible that this product has a 
relatively short half life, and thus is conducive to break-down before detection, or that substrate 
inhibition for this compound is triggered at lower concentrations.  
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Figure 3.5 Monitoring the reaction catalysed by Mtu-AnPRT using 
1
H NMR spectroscopy. A) Spectrum of assay 
solution containing -PRPP (2.5 mM) and anthranilate (1 mM) at pH 8 before incubation with Mtu-AnPRT. 
Note that the commercially obtained -PRPP also contains -PRPP as an impurity, which is not a substrate for 
Mtu-AnPRT. B) Spectrum of assay solution following incubation with Mtu-AnPRT (0.8 M) at 25 °C for 10 min. 
The substrates PRPP and anthranilate are consumed, and both -PRA and -PRA are present in approximately 
a 7:3 molar ratio. Chemical shifts are given relative to TSP ( 0 ppm). Figure extracted from Cookson et al.
51
 
 
3.4.2 Mechanism of Anomerisation 
It is likely that the Mtu-AnPRT reaction proceeds with inversion of stereochemistry at the C1 position 
of the ribose ring of PRPP, as has been observed with other PRT enzymes.31a, 73 Crystal structures of 
AnPRT orthologues support this prediction,42, 44, 74 as anthranilate can only approach PRPP from the β 
position, thereby only forming β-PRA. α-PRA could therefore be formed post-reaction via the rapid 
anomerisation of β-PRA in solution, a phenomenon that has been identified in other PRA-like 
compounds such as phosphoribosyl amine.75 Anomerisation is likely to occur via intramolecular 
rearrangement through an imine intermediate (Figure 3.6).  
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Figure 3.6 The anomerisation of the Mtu-AnPRT product PRA via an imine intermediate and its reduction to 
the open chain form. 
 
To investigate this hypothesis, Mtu-AnPRT was incubated with PRPP and anthranilate with an excess 
of the reducing agent NaCNBH3, as outlined in Section 7.3.2, with the intent of trapping the iminium 
ion intermediate in its amine open-chain form. NaCNBH3 was chosen based on its ability as a mild 
reducing agent, widely used for converting imines to amines. After 5 mins reaction time, samples 
were collected and analysed via mass spectrometry. Evidence for the reduced amine open-chain 
product was observed with m/z peaks present at 352.0782 and 374.0603 amu corresponding to the 
masses of the expected product and its sodium salt. These values compare well with the calculated 
values of 352.0792 and 374.0611 amu for the reduced amine open-chain product and its sodium salt 
respectively. 
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3.5 Eco-PRAI:InGPS Turnover 
As it had been confirmed that all the anthranilate analogues could be turned over by Mtu-AnPRT, 
with all observed to form the corresponding PRA-substituted product (excluding 3MA), the ability of 
the PRA-substituted products to be turned over by Eco-PRAI:InGPS was then investigated. 
 
Initially these compounds were tested for Eco-PRAI:InGPS turnover using the enzyme-coupled assay, 
also used to obtain the natural substrate KM values in Section 2.5.1. For each fluoro-analogue (except 
3FA), a significant increase in absorbance at 270 nm consistent with the formation of an indole ring 
was observed, indicating successful Eco-PRAI:InGPS turnover of fluoro-PRA. Control assays of the 
fluoro-analogues showed that when the concentration of Eco-PRAI:InGPS alone was increased, an 
increase in the rate of InGP formation was also observed (Figure 3.7). This demonstrated that Eco-
PRAI:InGPS was limiting the formation of product even with a minimum 10-fold excess compared to 
Mtu-AnPRT. This observation indicates that Eco-PRAI:InGPS is less tolerant of fluoro-PRA than of 
regular PRA, and validates the use of the PPi assay for determination of anthranilate-analogue kinetic 
parameters.  
 
The methyl-analogues and 3FA had minimal kinetic rates difficult to distinguish from the 
experimental baseline, with no concrete evidence of turnover. The product of orthanilate and PRPP, 
sulfonyl-PRA, could theoretically undergo the rearrangement catalysed by PRAI to yield CdRP but not 
the decarboxylation catalysed by InGPS to form InGP as the stability of the sulfonyl moiety makes it a 
bad leaving group (Figure 3.8). Correspondingly, there was not a significant increase in absorbance at 
270 nm on incubation of sulfonyl-PRA with Eco-PRAI:InGPS.  
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Figure 3.7 Apparent activity of Mtu-AnPRT when utilising anthranilate analogues as substrates, as monitored 
by the enzyme-coupled assay. Solutions contained 0.3 µM Mtu-AnPRT, 1 mM MgCl2, 0.6 mM PRPP and (3 x KM) 
µM fluoro/anthranilate analogues or 0.5 mM methyl analogues with varying concentrations of Eco-PRAI:InGPS. 
 
 
 
 
 
 
 
 
Figure 3.8 The InGPS-catalysed reaction resulting in formation of InGP. A) The reaction of the natural substrate 
CdRP. B) The reaction of sulfonyl-substituted CDRP cannot from the InGP product. Red curly arrows indicate 
electron movement that cannot take place. 
 
 
 
A. 
B. 
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3.5.1 Wavelength Scans 
The enzyme-coupled assay was used in conjunction with continuous wavelength scanning to 
qualitatively ascertain successful turnover of substituted PRA by Eco-PRAI:InGPS, as described in 
Section 7.3.3. These wavelength scans (from 200 - 380 nm) were also used to determine whether 
substituted InGP shifts the wavelength at which the absorbance maximum is observed. 
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Figure 3.9 Wavelength scans of the Mtu-AnPRT/Eco-PRAI:InGPS reaction using anthranilate/analogues, with 
the initial scan marked by t = 0. The absorbance can be seen to increase in the range 260 – 290 nm for each 
substrate, indicating the formation of InGP product. Solutions for analysis of fluoro-/anthranilate contained 1 
mM MgCl2, 0.1 µM Mtu-AnPRT, 1.7 µM Eco-PRAI:InGPS, 0.6 mM PRPP and 100 µM fluoro-/anthranilate. 
Solutions for analysis of methyl-anthranilate contained 1 mM MgCl2, 30 µM Mtu-AnPRT, 150 µM Eco-
PRAI:InGPS, 0.6 mM PRPP and 0.5 mM methyl-anthranilate. Reactions were scanned from 360-220 nm with a 
cycle length time of 2.5 min. Solutions were thermally equilibrated for 5 min prior to initiation with alternate 
substrate and either allowed to go to completion or to a maximum of 50 cycles. 
 
During incubation of each of the fluoro-substituted analogues with both enzymes a considerable 
increase in absorption from 265 - 275 nm could be observed (Figure 3.9). This is consistent with 
formation of the expected fluoro-InGP analogues. 6MA and 5MA also showed a significant increase 
in absorption in this range, though at a much slower rate. No definitive evidence of a new 
substituted InGP product could be detected for 3MA or 4MA using this method, as the total 
absorbance change observed did not exceed that of the respective blanks (containing all assay 
constituents minus the anthranilate analogue). However, the reactions for 3MA and 4MA with all 
assay constituents present did show individual scans in increasing order of reaction time, as shown 
by the progression from darker colours (early scans) to lighter colours (later scans) in Figure 3.10. 
The experiment blanks for 3MA and 4MA, however, did not show such a progression, which could 
t = 0 
t = 0 
t = 125 min 
t = 125 min 
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indicate that 3MA and 4MA are indeed turned over, though with an exceedingly slow reaction rate. 
Nonetheless, these results indicate Eco-PRAI:InGPS is less tolerant of methyl substitutions of the 
aromatic moiety of PRA, especially at the C3 and C4 positions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
t = 0 
t = 0 
t = 0 
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Figure 3.10 Wavelength scans of the Mtu-AnPRT/Eco-PRAI:InGPS reaction for 3MA and 4MA, with the initial 
scan marked as t = 0. The colours of the individual scans indicate how much time has passed, with earlier scans 
represented by darker colours, and later scans indicated by lighter colours. Solutions contained 1 mM MgCl2, 
30 µM Mtu-AnPRT, 150 µM Eco-PRAI:InGPS, 0.6 mM PRPP and 0.5 mM methyl-anthranilate. Blanks contained 
all constituents minus the methyl-anthranilate. Reactions were scanned from 360-220 nm for 50 cycles, with a 
cycle length time of 2.5 min. Solutions were thermally equilibrated for 5 min prior to initiation with alternate 
substrate.  
  
3.5.2 Mass Spectrometry 
To complement the findings in Section 3.5.1, mass spectrometry was utilised to detect substituted 
InGP formation. Using the experimental conditions described in Section 7.3.4, analysis of the 
alternate substrates in solution with PRPP, Mg2+, Mtu-AnPRT and Eco-PRAI:InGPS confirmed the 
presence of all fluoro- and methyl-InGP products as sodium salts with the exclusion of 3MA (Table 
3.3). The catalysis of 3-methyl-PRA by Eco-PRAI:InGPS is therefore either too low for detection using 
this method, or it does not occur. Orthanilate was not tested using this method as the sulfonyl-CdRP 
product has the same expected mass as its sulfonyl-PRA precursor.  
 
 
 
 
 
t = 0 
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Substrate Formula of InGP 
Product 
Expected Mass of 
Product (g/mol) 
Observed Mass of 
Product (g/mol) 
Anthranilate C11H14NO6PNa 310.0451 310.0441 
6FA C11H13FNO6PNa 328.0357 328.0348 
5FA C11H13FNO6PNa 328.0357 328.0349 
4FA C11H13FNO6PNa 328.0357 328.0347 
3FA C11H13FNO6PNa 328.0357 328.0350 
6MA C12H16NO6PNa 324.0607 324.0597 
5MA C12H16NO6PNa 324.0607 324.0600 
4MA C12H16NO6PNa 324.0607 324.0605 
3MA C12H16NO6PNa 324.0607 - 
 
Table 3.3 Masses of the substituted InGP products resulting from analogue turnover using the enzyme-coupled 
assay. Solutions contained 1.2 mM PRPP, 0.6 µM Mtu-AnPRT, 6 µM Eco-PRAI:InGPS, 2 mM MgCl2, and either 
400 µM fluoro-/anthranilate or 2 mM methyl-anthranilate. (-) indicates that the expected product could not be 
observed.  
 
3.5.3 NMR 
To further characterise and confirm the substituted InGP products arising from Mtu-AnPRT/Eco-
PRAI:InGPS catalysis of PRPP and anthranilate, 4FA or orthanilate, 1H NMR spectroscopy was again 
used to follow the reactions, and was carried out by Dr Esther Bulloch at the University of Auckland. 
Initially, Mtu-AnPRT was incubated with PRPP, Mg2+ and anthranilate, and upon observed PRA 
formation Eco-PRAI:InGPS was then added. Immediately after Eco-PRAI:InGPS addition, the complete 
loss of both PRA anomers (Section 3.4.1) was observed with concurrent formation of peaks 
corresponding to the expected InGP product (Figure 3.11). With a rate similar to PRA, 4F-PRA was 
also turned over by Eco-PRAI:InGPS, with the appearance of peaks consistent with those expected 
for 4F-InGP. 
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As expected, in experiments with sulfonyl-PRA, the PRAI:InGPS-catalysed reaction did not proceed to 
form an indole-containing compound. However, a small decrease in the intensity of the sulfonyl-PRA 
peaks was observed (Figure 3.12D) as well as the appearance of new peaks in the aromatic and 
ribose regions of the spectra, though the latter were highly overlapped. These new peaks may 
correspond to the formation of sulfonyl-CDRP from sulfonyl-PRA, however, no further analysis was 
performed to confirm this. 
 
 
 
 
 
 
 
 
Figure 3.11 
1
H NMR spectrum of InGP. PRA was formed by the incubation of anthranilate (1 mM) and PRPP 
(2.5 mM) with Mtu-AnPRT (0.8 µM). Addition of Eco-PRAI:InGPS (2.5 µM) and incubation at 25 °C for 
approximately 10 min resulted in complete conversion to InGP.  7.83 (d, 8 Hz, H6), 7.54 (d, 8.2 Hz, H3), 7.46 
(s, H1’), 7.27 (dd, 7.6 Hz, H4), 7.19 (dd, 7.5 Hz, H5), 5.10 (d, 8.2 Hz, H3’). Figure extracted from Cookson et al. 
Supplementary Material.
51
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Figure 3.12 1H NMR spectra for the Eco-PRAI:InGPS-catalysed reaction of 4-fluoro-PRA (4F-PRA) and sulfonyl-PRA. A) 4F-
PRA was formed by the incubation of 4FA (1 mM) and PRPP (2.5 mM) with Mtu-AnPRT (0.8 µM). B) Addition of 
Eco-PRAI:InGPS (2.5 μM) to this 4F-PRA sample resulted in complete conversion to 4F-InGP.  7.76 (dd, 5.5, 8.8 
Hz, H6), 7.42 (s, H1’), 7.25 (dd, 10.1, 2.2 Hz, H3), 6.98 (ddd, 2.2, 9.4 Hz, H5), 5.06 (d, 8.2 Hz, H3’) C) Sulfonyl-
PRA was formed by the incubation of orthanilate (0.5 mM) and PRPP (2.5 mM) with Mtu-AnPRT (0.8 µM). D) 
Addition of Eco-PRAI:InGPS (2.5 μM) to this sulfonyl-PRA sample resulted in the production of a new set of 
minor resonances as indicates by the dashed arrows ( 7.70, 7.42, 6.84 and 6.74 ppm), possibly corresponding 
to the CdRP analogue, 1-(o-sulfonylphenylamino)-1-deoxyribulose 5-phosphate. Samples were incubated at 25 
°C for approximately 10 min following the addition of each enzyme. Peaks marked by an asterisk result from an 
imidazole impurity present in the PRAI:InGPS preparation used for these experiments. Figure extracted from 
Cookson et al. Supplementary Material.
51
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3.6 Crystal Structures of Alternate Anthranilate-like Substrates 
Bound to Mtu-AnPRT 
Structures of Mtu-AnPRT with PRPP, Mg2+ and either the fluoro- or methyl-anthranilates bound were 
obtained by Dr Alina Castell at the School of Biological Sciences, University of Auckland. These 
structures provide further insight into both the ligand binding order and potential catalytic 
mechanism of Mtu-AnPRT, and are discussed and interpreted in this section. Unfortunately, not all 
of these structures were completely refined at the time of writing this thesis, and as such only 
complete structures will be discussed. 
Crystals of Mtu-AnPRT were formed in the presence of PRPP and Mg2+, and prior to structure 
collection were soaked in solutions of fluoro-/methyl-anthranilate for various lengths of time. Two 
structures were obtained from crystals soaked in 4FA, with one exposed to a 6 s soak time, and the 
other exposed to a 6 min soak time.  
The 4FA 6 min structure (PDB ID: 4N5V) shows two 4FA molecules bound to each monomer, with 
one bound in the inner site and the other bound in the outer site (Figure 3.13A). This outer site has 
previously been identified by inhibitor binding (Section 2.7), but has not been observed in structures 
of Sso-AnPRT. 42, 50 The inner site 4FA molecule makes hydrogen bonds via its amino group to G107 
and the PRPP C2 hydroxyl, with the carboxylate group hydrogen bonded to N138, R193 and four 
water molecules (Figure 3.13B and C). The binding mode of the inner site 4FA molecule places its 
amino group 4.2 Å from the C1 atom of PRPP, in a favourable orientation for nucleophilic attack on 
PRPP from the β position. The 4FA molecule bound in the outer site makes hydrogen bonds to R194 
and three water molecules with its carboxylate group, with the amino group hydrogen bonded to 
H183 (Figure 3.13B and D). The aromatic ring of the outer site 4FA is also stacked parallel with the 
proline ring of P180, forming likely C-H...π interactions.  
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Figure 3.13 Chain A of the 4FA 6 min Mtu-AnPRT structure showing the 4FA binding sites. Analogous binding is 
observed for chain B. A) An overlay of Sso-AnPRT with PRPP, Mg
2+
 and anthranilate (yellow) bound with Mtu-
AnPRT chain A (green) with PRPP (magenta), Mg
2+
 (blue spheres) and 4FA (cyan) bound. B) Mtu-AnPRT chain A 
(green) with PRPP (magenta), Mg
2+
 (blue spheres) and 4FA (cyan) bound. Polar contacts of 4FA are shown as 
yellow dashes. C) Stereo diagram of 4FA bound to the inner site. D) Stereo diagram of 4FA bound to the outer 
site.  
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A comparison of the 4FA molecules bound at each site highlights the positioning of the amino group; 
in order for the 4FA compound bound at the outer site to progress to the inner site and emulate the 
same binding mode, the aromatic ring of 4FA would have to flip 180°. However, the position of the 
fluorine group on 4FA could be forcing the amino group to point towards H183 in order to minimise 
steric clashes with the surrounding protein. 
The structure of Mtu-AnPRT with PRPP, Mg2+ and 6MA bound (PDB ID: 4N93), obtained from a 30 
min soak of 6MA, shows two 6MA molecules bound to each monomer (Figure 3.14). The 6MA 
molecule bound in the inner site makes hydrogen bond contacts to R193, N138 and three water 
molecules via its carboxylate group, with the amino group hydrogen bonded to G107 only, showing a 
similar binding mode to 4FA. The 6MA molecule bound in the outer site is hydrogen bonded to R194, 
H183 and a water molecule. Inspection of the Fo-Fc map of the 6MA structure reveals a potential 
third binding site between the inner and outer sites, which would be analogous to the middle site 
observed for the Sso-AnPRT structures (Figure 3.14B).42, 50 This density indicates a possible mode of 
passage of 6MA through the anthranilate channel, from the outer site through the middle site to the 
inner site.  
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Figure 3.14 Chain B of the 6MA 30 min Mtu-AnPRT structure showing the 6MA binding sites. Analogous 
binding is observed for chain A. A) Mtu-AnPRT chain B (orange) with PRPP (magenta), Mg
2+
 (blue spheres) and 
6MA (cyan) bound. Polar contacts of 6MA are shown as yellow dashes. B) Mtu-AnPRT chain B (orange) with 
PRPP (magenta), Mg
2+
 and 6MA (cyan) bound. The 2Fo-Fc map for both 6MA ligands are shown as blue mesh, 
contoured at 1.0 σ. The Fo-Fc map is shown as green mesh, contoured at 3.0 σ. 
 
The 4FA 6 s structure (PDB ID: 4N8Q) shows only one 4FA molecule bound to each monomer, 
without PRPP or Mg2+ bound. The analogue is bound in the outer site, and makes similar contacts to 
N138, H183 and R194 as described for the 4FA 6 min soak (Figure 3.15A). The β2-α6 loop, which has 
previously been observed to close over the PRPP binding site once PRPP has bound,44 is folded into 
the anthranilate channel (Figure 3.15B), which perhaps prevents the 4FA molecule from advancing 
further along the channel. This structure raises the possibility that PRPP is not the first ligand to bind 
to the Mtu-AnPRT enzyme, and that anthranilate binding at the outer site could precede PRPP and 
Mg2+ binding.  
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Figure 3.15 Chain B of the 4FA 6 s Mtu-AnPRT structure. Analogous binding and structural features are 
observed for chain A. A) Mtu-AnPRT (magenta) with 4FA (green) bound in the outer site. B) An overlay of Mtu-
AnPRT with 4FA bound (magenta), Mtu-AnPRT with PRPP (green) and Mg
2+
 (red spheres) bound (yellow) and 
apo Mtu-AnPRT (cyan) depicting the differing β2-α6 loop positions. 
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3.7 Summary 
Kinetic characterisation of Mtu-AnPRT with alternate anthranilate substrates was carried out using a 
commercially available PPi assay. The apparent KM value and kcat values for the natural substrate 
anthranilate were determined as 1.7 ± 0.1 µM and 2.0 ± 0.1 s-1 respectively, comparing well to the 
values obtained in Chapter 2 (Section 2.5.1). Alternate substrates employing fluoro- or methyl- 
substitutions to the anthranilate aromatic ring were accepted as substrates for Mtu-AnPRT, as well 
as ACS130 which substituted the carboxylate group for a sulfonyl group. Compounds involving 
methoxy-substitutions or repositioning of the anthranilate amine group to C3 or C4 did not act as 
substrates for Mtu-AnPRT. 
Fluoro-substitution around the aromatic ring of anthranilate had the least effect on the reaction 
kinetics of Mtu-AnPRT, with apparent KM values ranging from 1.4 – 31 µM and kcat values ranging 
from 1.2 – 1.4 s-1. These results contrast significantly with those obtained for the methyl-substituted 
substrates, with higher KM values ranging from 290 – 800 µM and lower kcat values ranging from 0.15 
– 0.63 s-1 demonstrating a dramatic decrease in Mtu-AnPRT tolerance for the sterically larger methyl 
moiety. ACS130 displayed an increased binding affinity (KM = 130 ± 11 µM) compared to the methyl-
substituted analogues, but had the lowest overall kcat value of 0.1 ± 0.004 s
-1, highlighting the 
importance of the anthranilate carboxylate group for Mtu-AnPRT catalysis. High concentrations of 
the fluoro-substituted analogues caused Mtu-AnPRT inhibition similar to that observed for 
anthranilate, with Ki values ranging from 34 – 1090 µM.  
Characterisation of PRA-substituted products resulting from successful Mtu-AnPRT catalysis of the 
anthranilate analogues was performed using mass spectrometry and NMR, and showed the 
appearance of both α and β PRA anomers in solution. Selective reduction of the suspected PRA 
imine species formed during anomer interconversion and subsequent mass spectrometry analysis 
confirmed this anomerisation mechanism. 
The ability of Eco-PRAI:InGPS to catalyse the PRA-substituted products arising from Mtu-AnPRT 
catalysis of anthranilate analogues was investigated using the enzyme-coupled assay, mass 
spectrometry and NMR. Clear evidence of catalysis was observed for all substrates tested with the 
exception of 3MA and ACS130. 
Structures of Mtu-AnPRT co-crystallised with PRPP, Mg2+ and various anthranilate analogues were 
obtained by Dr Alina Castell. 4FA and 6MA were seen to bind in both the inner and outer sites, with 
binding in the inner site replicating the previously predicted binding mode for anthranilate in Mtu-
AnPRT44 and which had been directly observed in Sso-AnPRT.42, 50 
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Chapter 4 
 
Variants of Mtu-AnPRT 
 
 
4.1 Overview 
The first part of this chapter describes the generation of Mtu-AnPRT variant proteins containing 
point mutations of identified key residues. Mutated plasmids were synthesised using PCR, confirmed 
via sequencing, and successfully transformed into E. coli cells. Subsequent purification of the variant 
proteins was achieved, and physical characterisation utilising mass spectrometry, CD and DSF 
revealed that all variants displayed similar physical attributes to the wild-type Mtu-AnPRT.  
Kinetic characterisation of the variants was carried out using the enzyme-coupled assay described in 
Chapter 2. Anthranilate inhibition was also investigated. 
Finally, crystal structures of the variants in the presence of various combinations of the natural 
ligands PRPP, Mg2+ and anthranilate are described in detail. 
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4.2 Introduction 
Prior to this study, a structure-based sequence alignment of AnPRT enzymes from M. tuberculosis, S. 
solfataricus, P. carotovorum and T. thermophilus was performed and used to create a multiple 
sequence alignment from a diverse range of bacteria - Clostridium acetobutylicum, Staphylococcus 
aureus, Brucella melitensis and Agrobacterium tumefaciens.44 This alignment demonstrated the 
existence of several conserved sequence motifs that have since been shown to be involved in the 
binding of one or both substrates: including a GTGGD sequence (residues 107-111 – numbered for 
Mtu enzyme) located on the β1-α5 loop involved in PRPP binding, a ψψKHGN anthranilate binding 
motif (residues 133-138, where ψ stands for a hydrophobic amino acid) located on the β2-α6 loop, a 
conserved A179 residue located on the α8’ helix and a conserved R193 residue located on the α8 
helix associated with anthranilate binding.  
 
 
 
 
 
 
 
 
Figure 4.1 A partial sequence alignment of AnPRT enzymes from M. tuberculosis (Mtu), S. solfataricus (Sso), P. 
carotovorum (Pca), T. thermophilus (Tth), C. acetobutylicum (Cac), S. aureus (Sau), B. melitensis (Bme) and A. 
tumefaciens (Atu) recreated from Lee et al.
44
 using TCOFFEE:Advance.
48
 The diagram was made using Jalview.
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Dots indicate residues involved with PRPP binding (blue), anthranilate binding (green) and Mg
2+
 binding 
(purple). Black dots indicate residues that appear to be conserved for structural reasons. Blue solid lines 
denote α helices, green solid lines indicate β strands and red solid lines indicate loop regions. 
 
The crystal structure of Sso-AnPRT in the presence of PRPP, Mg2+ and anthranilate (PDB ID: 1ZYK) 
gave further insight into the roles of the aforementioned conserved residues in substrate binding. In 
α5 α6 
α6 α7 α8’ α8 
β2 
β3 
β1 
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particular, the presence of two anthranilate molecules bound in the active site was surprising, as this 
had not been shown in a crystal structure of AnPRT previously. 
In the Sso-AnPRT structure, the anthranilate molecules are associated with the N-terminal helical 
domain, with one ligand bound in an inner site and another bound in a ‘middle’ site, located 
between the inner site and the outer site discussed in Sections 2.7 and 3.6 (Figure 4.2).  The 
anthranilate bound in the inner site creates hydrogen bonds with G79, N109, and several water 
molecules (numbered for the Sso enzyme). The carboxylate group of this anthranilate interacts with 
N109, with its amino group pointing towards the bound PRPP molecule and held in place by the 
backbone carbonyl of G79. The carboxylate group of the anthranilate bound in the middle site 
interacts with the protein residues R164 and N109, while the amino group interacts with a water 
molecule.  
Several variants of the Sso-AnPRT enzyme were synthesised prior to this study to probe the catalytic 
relevance of certain conserved residues involved with substrate binding, namely K106, H107, D223, 
E224, R164, H154 and P178 (all mutated to alanine residues).42 Conclusions drawn from studies of 
these variants state the importance of R164 alone for anthranilate binding, with R164A and K106A 
slightly influencing the rate of catalysis.  
 
 
 
 
 
 
 
 
94 
 
4.3 Residues Mutated 
The residues selected for mutagenesis in Mtu-AnPRT were based on the sequence and structural 
information as well as mutations characterised from the Sso-AnPRT enzyme (Section 4.2). The 
discovery of a third potential binding site for anthranilate (Sections 2.7 and 3.6) highlighted some 
additional key binding residues which were also taken into consideration.  
The residue G107 was chosen for its involvement in the binding of both the PPi group of PRPP and 
the amino moiety of the inner catalytic anthranilate site, with the latter seen in the Sso-AnPRT 
structure42 as the equivalent residue G79. It is also part of the conserved GTGGD motif located in the 
flexible β1-α5 loop which closes over the PRPP molecule after it has bound. The mutation chosen for 
this study is G107P, to investigate the effect on substrate binding after the flexibility of that loop has 
been decreased.  
N138 forms part of the conserved KHGN motif on the β2-α6 loop and is another residue that binds 
both substrates in Mtu-AnPRT – the carboxylate group of anthranilate (bound in the inner site) via its 
side-chain nitrogen, and the PRPP C3 hydroxyl via its backbone oxygen. The equivalent residue in 
Sso-AnPRT is N109. The mutation chosen is N138A, where complete removal of the side-chain will 
determine if it is necessary for binding and/or catalysis.  
P180 is adjacent to the conserved residue A179 as part of the α8’ helix, which is located at the 
entrance to the anthranilate channel. The equivalent residue from the Sso-AnPRT enzyme is Q151. 
Structures of Mtu-AnPRT co-crystallised with inhibitors (Section 2.7) and anthranilate analogues 
(Section 3.6) implicate this residue in anthranilate binding at the entrance of the anthranilate 
channel (outer site). The mutation P180A was chosen to investigate whether removing the rigidity of 
the α8’ helix would have any effect on the protein’s structure, and will also determine the necessity 
of this non-conserved residue for anthranilate recruitment. 
R194 is also located at the entrance to the anthranilate channel and is adjacent to the conserved 
R193 residue on the α8 helix. Like P180, this residue has also been implicated in anthranilate binding 
at the outer site and likely binds the anthranilate carboxylate group. Sso-AnPRT has a lysine residue 
(K165) present at this position. Mutating this non-conserved arginine to an alanine (R194A) will 
determine how crucial this residue is for anthranilate recruitment, with the additional effect of 
altering the overall charge of the outer site environment.  
The final residue chosen for mutation is R193, a conserved residue highly involved in anthranilate 
binding in both the inner site and the middle site.  Studies on the Sso-AnPRT variant R164A 
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(equivalent to R193 in Mtu-AnPRT), have previously shown this residue to be important for both 
anthranilate binding and reaction catalysis,42 and structures of wild-type Sso-AnPRT with PRPP and 
anthranilate bound show the formation of a salt bridge between the R164 guanidinium moiety and 
the inner site anthranilate carboxylate group in some protein chains.42 Two mutations have been 
chosen for this residue: R193A and R193L. R193A was selected in order to investigate the effect of 
completely removing the side-chain, and additionally altering the overall charge of the environment. 
R193L, however, will retain most of the structure of the side-chain with the functionality removed, 
again altering the overall charge of the environment.  
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Figure 4.2 Potential Mtu-AnPRT anthranilate binding sites. A) Sso-AnPRT chain C (orange) with PRPP (purple), 
Mg
2+
 (blue spheres) and anthranilate (green) bound. Polar contacts for anthranilate are shown as yellow 
dashes, with black text indicating Sso-AnPRT residues. B) An overlay of Mtu-AnPRT (yellow) with PRPP (cyan), 
4FA (purple) and Mg
2+
 (magenta spheres) bound with Sso-AnPRT (not shown) with PRPP (not shown), Mg
2+
 
(not shown) and anthranilate (green) bound. Anthranilate binding sites are indicated by red text. Polar 
contacts between Mtu-AnPRT and the 4FA molecules are indicated by yellow dashes. C) Stereo diagram of Sso-
AnPRT chain C (orange) with PRPP (not shown), Mg
2+
 (not shown) and anthranilate (green) bound overlaid with 
Mtu-AnPRT with PRPP (cyan) Mg
2+
 (magenta spheres) and 4FA (purple) bound. Polar contacts for anthranilate 
are shown as black dashes, with polar contacts for 4FA shown as yellow dashes. Water molecules from Sso-
AnPRT are shown as red spheres, with Mtu-AnPRT water molecules as blue spheres. Black text indicates Mtu-
AnPRT residue numbers. 
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4.4 Protein Isolation 
4.4.1 Preparation of Mutant Plasmids 
In order to form TrpD plasmids containing the required mutations, PCR reactions were carried out 
using the conditions outlined in Section 7.4.2. Mutant plasmids formed as a result of the PCR 
reaction were visualised using agarose gels (Figure 4.3). 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Agarose gel of TrpD mutant PCR products. Lane 1 contains the DNA ladder, with base pair sizes 
defined to the left. Lane 3 – R194A. Lane 4 – R193A. Lane 5 – R193L. Lane 6 – P180A. Lane 7 – N138A. Lane 8 – 
G107P. Lane 2 is empty. 
 
4.4.2 Transformation 
Each mutant plasmid was transformed as outlined in Section 7.1.7 into both One Shot® Top10 
chemically competent E. coli cells and E. coli BL21 (DE3) pBB528/pBB541 cells. The transformed cells 
were then left to grow on LB/agar media overnight. Successful colony growth was observed for all six 
Mtu-AnPRT mutants, and 5 mL LB media cultures containing ampicillin were inoculated and left to 
grow overnight at 37 °C in a shaking incubator. Glycerol stocks of each mutant in both cell lines were 
made and snap frozen with liquid N2 for storage at -80 °C. 
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4.4.3 Protein Expression and Purification 
After verification of successful gene mutations via sequencing, the variant proteins were expressed 
and purified exactly as described for wild-type Mtu-AnPRT. Samples of each pure Mtu-AnPRT variant 
were analysed via an SDS-PAGE gel, as depicted in Figure 4.4. These variant proteins will be referred 
to by their mutation: Mtu-N138A, Mtu-P180A, Mtu-G107P, Mtu-R194A, Mtu-R193A and Mtu-R193L. 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 SDS-PAGE gel of purified wild-type/variant Mtu-AnPRTs. Lane 1 contains the protein ladder, with 
molecular weights defined to the left. Lane 3 – wild-type Mtu-AnPRT. Lane 4 – Mtu-R194A. Lane 5 – Mtu-
R193A. Lane 6 – Mtu-R193L. Lane 7 – Mtu-P180A. Lane 8 – Mtu-N138A. Lane 9 – Mtu-G107P. Lane 2 is empty.  
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4.5 Physical Characterisation 
4.5.1 Secondary Structure 
To determine whether the Mtu-AnPRT variant proteins had folded correctly, a CD spectrum was 
obtained for each variant and compared to the wild-type Mtu-AnPRT spectrum (Figure 4.5).  
 
 
 
 
 
 
 
Figure 4.5 CD spectra of wild-type/variant Mtu-AnPRTs. Solutions contained 0.03 mg/mL enzyme in 20 mM 
sodium phosphate buffer (pH 8.0). 
 
An inspection of the CD spectra for both wild-type and variant Mtu-AnPRTs illustrates a clear 
similarity between the proteins, and thus that the mutations to Mtu-AnPRT have not introduced 
significant changes to the secondary structure.  
4.5.2 Molecular Mass 
The masses of the Mtu-AnPRT variant proteins were obtained via mass spectrometry under the 
same conditions as wild-type Mtu-AnPRT (Table 4.1). All masses obtained were similar to the values 
predicted by the website tool ProtParam.62  
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Mtu-AnPRT variant Expected Mass (Da) Observed Mass (Da) 
R193A 38588.6 38587.5 
R193L 38630.7 38628.9 
R194A 38588.6 38587.5 
P180A 38647.7 38646.6 
N138A 38630.7 38629.5 
G107P 38713.8 38712.9 
 
Table 4.1 Masses of Mtu-AnPRT variants as obtained via mass spectrometry. 
 
4.5.3 Thermal Stability 
The temperature of denaturation for the Mtu-AnPRT variants was determined via DSF using the 
same protocol outlined for wild-type Mtu-AnPRT (Figure 4.6, Table 4.2). Raw data from DSF scans 
can be observed in Appendix 1. Mtu-N138A and Mtu-R194A had denaturation temperatures most 
similar to that of wild-type enzyme, demonstrating that while these residues may be important for 
substrate capture (Section 3.6) they have no impact on the thermal stability of the protein. 
Mutations to the residue R193, however, show a surprising increase in the denaturation 
temperature of approximately 10 °C. Mtu-P180A and Mtu-G107P show a decrease in the 
denaturation temperature of 4 °C and 9 °C respectively. For Mtu-P180A, this decrease is perhaps 
unsurprising given the substitution of the conformationally restricted proline ring for the relatively 
unrestricted methyl moiety of alanine, although this reasoning does not explain why the 
introduction of a proline group in Mtu-G107P should also cause a decrease in the denaturation 
temperature. 
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Figure 4.6 DSF denaturation temperatures of wild-type/variant Mtu-AnPRTs. Enzymes were analysed in 
Tris.HCl buffer (pH 8.0), at concentrations of 1 mg/mL. 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2 DSF denaturation temperatures of wild-type/variant Mtu-AnPRTs. 
 
Mtu-AnPRT 
Temperature of 
Denaturation (°C) 
Wild-type 54.1 ± 0.3 
R193L 66.5 ± 0.6 
N138A 53.8 ± 0.2 
R194A 54.7 ± 0.5 
R193A 64.9 ± 0.6 
P180A 50 ± 2 
G107P 45 ± 1 
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4.6 Kinetic Characterisation 
4.6.1 Michaelis-Menten Kinetics 
Using the enzyme-coupled assay as outlined in Section 7.1.24/7.4.4, the turnover number and 
apparent KM values were found for all variants of Mtu-AnPRT (Figure 4.7, Table 4.3) with the 
exception of Mtu-G107P, which was catalytically inactive. The apparent KM values for PRPP for the 
variants are comparable to the wild-type value of 48 ± 2 µM, with the exception of Mtu-N138A, 
which has an increased KM value of 160 ± 20 µM. As N138 is observed to hydrogen bond to the C3 
hydroxyl of PRPP via its backbone oxygen,44 it is possible that the introduction of alanine causes 
increased flexibility of this region, located at the C-terminal end of the β2 sheet. Mtu-N138A also 
displays a 5-fold increase in the apparent KM of anthranilate and a 50% decrease in the kcat value, 
indicating a role for this residue in both anthranilate binding and catalysis.  
Mutations to the residue R193 have the greatest impact on the apparent KM of anthranilate, with a 
240- and 150-fold increase observed for Mtu-R193A and Mtu-R193L respectively. Mtu-R193A and 
Mtu-R193L also have the largest effect on the turnover number, with a 25- and 54-fold decrease 
observed respectively, indicating that residue R193 is not only crucial for anthranilate binding but 
also for catalysis between anthranilate and PRPP. Similar results have been observed for the 
equivalent Mtu-R193A variant in Sso-AnPRT (Sso-R164A), with a 7000-fold increase in the apparent 
KM value of anthranilate, and a 7-fold decrease in the turnover number.
42 
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Table 4.3 Kinetic data for wild-type/variant Mtu-AnPRTs. (-) indicates that activity could not be detected above 
0.001 s
-1
. 
 
 
 
 
 
 
 
 
 
 
Mtu-AnPRT 
variant 
KM Anth (µM) KM PRPP (µM) kcat (s
-1) 
kcat/KM Anth 
(µM-1 s-1) 
kcat/KM PRPP 
(µM-1 s-1) 
Wild-type 2.0 ± 0.2 48 ± 2 1.9 ± 0.06 0.95 ± 0.13 0.04 ± 0.003 
N138A 8.0 ± 0.6 160 ± 20 1.0 ± 0.02 0.13 ± 0.01 0.006 ± 0.0007 
R193A 480 ± 24 40 ± 4 0.075 ± 0.002 
0.0002 ± 
0.00002 
0.002 ± 0.0003 
R193L 300 ± 18 48 ± 5 0.035 ± 0.001 
0.0001 ± 
0.000009 
0.0007 ± 
0.00009 
P180A 4.0 ± 0.3 68 ± 5 1.7 ± 0.05 0.43 ± 0.045 0.025 ± 0.003 
R194A 5.8 ± 0.4 46 ± 3 1.9 ± 0.05 0.33 ± 0.031 0.041 ± 0.0038 
G107P - - - - - 
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Figure 4.7 Michaelis-Menten plots for Mtu-AnPRT variants. Insets: Lineweaver-Burk plots. Solutions for 
analysis of the kinetic parameters of anthranilate contained PRPP held at a concentration of 0.6 mM, with all 
solutions incubated at 25 °C at pH 8.0. A) Mtu-N138A. Solutions for analysis of the kinetic parameters of PRPP 
contained anthranilate held at a concentration of 200 µM. B) Mtu-R193A. Solutions for analysis of the kinetic 
parameters of PRPP contained anthranilate held at a concentration of 200 µM. C) Mtu-R193L. Solutions for 
analysis of the kinetic parameters of PRPP contained anthranilate held at a concentration of 200 µM. D) Mtu-
P180A. Solutions for analysis of the kinetic parameters of PRPP contained anthranilate held at a concentration 
of 25 µM. E) Mtu-R194A. Solutions for analysis of the kinetic parameters of PRPP contained anthranilate held 
at a concentration of 25 µM.  
 
4.6.2 Anthranilate Inhibition 
To investigate whether any of the residues mutated were involved in the mechanism of anthranilate 
inhibition, Mtu-N138A, Mtu-P180A and Mtu-R194A were tested with higher concentrations of 
anthranilate (0 – 220 µM) using the enzyme-coupled assay (Table 4.4, Figure 4.8). Mtu-R193A and 
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Mtu-R193L were not tested as their higher KM values (Table 4.3) suggested that significantly higher 
concentrations of anthranilate would be required, thereby causing high absorbance readings that 
would impair accurate rate measurements. Mtu-P180A and Mtu-R194A both still demonstrated a 
capacity for anthranilate inhibition, though both showed a marked increase in Ki value of 9- and 2-
fold respectively. Interestingly, Mtu-N138A showed no signs of inhibition up to 220 µM of 
anthranilate, indicating a clear role for the conserved N138 residue in Mtu-AnPRT anthranilate 
inhibition. All three variants tested showed weaker anthranilate inhibition, and N138, P180 and R194 
have also been identified in Section 3.6 as residues involved with the binding of anthranilate 
analogues in the outer site. Thus it is highly likely that anthranilate binding at this outer site is 
instrumental for successful anthranilate inhibition.  
 
 
 
 
 
 
 
 
 
 
 
Table 4.4 Ki values for wild-type/variant Mtu-AnPRTs. (-) indicates that the variant was not subject to 
anthranilate inhibition. 
 
 
 
 
 
 
 
 
 
 
 
Mtu-AnPRT variant Ki value (µM) 
Wild-type 47 ± 7 
N138A - 
P180A 440 ± 110 
R194A 89 ± 11 
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Figure 4.8 Anthranilate inhibition plots for Mtu-AnPRT variants. All solutions contained PRPP held at a 
concentration of 0.6 mM, and were incubated at 25 °C at pH 8.0. A) Mtu-N138A as fitted to the Michaelis-
Menten equation. B) Mtu-P180A as fitted to the substrate inhibition equation. C) Mtu-R194A as fitted to the 
substrate inhibition equation. All graphs fitted using Grafit 5 software.
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4.7 Structural Characterisation 
Crystals were obtained for all Mtu-AnPRT variants with the exception of Mtu-G107P, which could not 
be concentrated enough to facilitate crystal growth due to protein precipitation. Attempts were 
made to grow crystals at low Mtu-G107P concentrations of approximately 13 µM, however, no 
crystal formation was observed. Variants were co-crystallised in the presence of 10 mM PRPP and 10 
mM MgCl2, with some exposed to 10 mM anthranilate soaks for various lengths of time. All crystals 
grew within 24 hours, and showed the same diamond morphology seen for wild-type Mtu-AnPRT 
crystals (Figure 4.9). All data processing and refinement data for each structure can be found in 
Appendix 3, while all omit maps for ligands present in structures can be observed in Appendix 4.  
 
 
 
 
 
 
 
Figure 4.9 Crystals of Mtu-R194A co-crystallised with 10 mM PRPP and 10 mM MgCl2 in the presence of 0.2 M 
imidazole malate (pH 7.0) and 7% PEG-4000 (w/v). 
 
In all structures obtained during this project, both apo and ligand bound, the positions of the α8 and 
α9 helices overlaid almost exactly with the positions observed in the wild-type Mtu-AnPRT apo 
structure without benzamidine (PDB ID: 3QR9), not the positions observed in the wild-type Mtu-
AnPRT PRPP/Mg2+ bound structure with benzamidine (PDB ID: 1ZVW) (Figure 4.10). It is therefore 
likely that the presence of the crystal additive benzamidine does cause the rearrangement of these 
helices, as has been suggested by Castell et al.41a 
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Figure 4.10 Structures of PRPP/Mg
2+ 
bound Mtu-AnPRT variants overlaid with wild-type apo and 
PRPP/Mg
2+
/benzamidine bound structures. Wild-type apo Mtu-AnPRT is shown in green, wild-type Mtu-AnPRT 
with PRPP/Mg
2+
/benzamidine bound is shown in cyan, Mtu-N138A is shown in magenta, Mtu-P180A is shown 
in yellow, and Mtu-R193L is shown in white. Benzamidine is shown in orange. 
 
4.7.1 Structures Co-crystallised with PRPP and Mg2+ 
Crystals were grown and structural information obtained for Mtu-N138A, Mtu-P180A, Mtu-R193A 
and Mtu-R193L in the presence of PRPP and Mg2+. These structures are compared to the wild-type 
Mtu-AnPRT apo structure (PDB ID: 3QR9) as well as the wild-type Mtu-AnPRT structure co-
crystallised with PRPP, Mg2+ and benzamidine (PDB ID: 1ZVW).  
4.7.1.1 Mtu-N138A/PRPP/Mg2+ 
The structure of Mtu-N138A was obtained in the presence of PRPP and Mg2+ at a resolution of 1.72 
Å, with four monomers in the asymmetric unit. Chains A and C were associated as a dimer, with 
chains B and D located on either side of chain A as monomers. Chains A and B crystallised with no 
ligands present, while chains C and D both showed clear density for PRPP and Mg2+. Chains A and B 
overlaid well with chain A of both the wild-type Mtu-AnPRT apo and PRPP/Mg2+ bound structures, 
with RMSD values of 0.514 Å and 0.516 Å respectively for chain A, and 0.530 Å and 0.480 Å 
respectively for chain B. An obvious shift in position towards the active site can be observed for the 
α11’’ helix, the α11’’ - α11 loop and the α11 helix in both chains A and B of the Mtu-N138A structure 
(Figure 4.11), with a displacement of 3.7 Å and 2.0 Å respectively (as measured between G291 of the 
Mtu-N138A and the wild-type Mtu-AnPRT PRPP/Mg2+ bound structures). Finite density was not 
α8 
α9 
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observed for the β1-α5 loop for chains A or B, however, chain B showed clear density for the β2-α6 
loop folded into the anthranilate channel, a phenomenon which has been previously observed in 
Mtu-AnPRT wild-type structures (Section 3.6). The β2-α6 loop in Chain A was partially disordered, 
though enough density was present to also indicate folding into the anthranilate channel. Some 
extra coiling of the α5 helix N-terminus is also seen in both chains A and B.  
 
 
 
 
 
 
 
 
Figure 4.11 An active site comparison of Mtu-N138A and wild-type Mtu-AnPRT structures. Mtu-N138A 
(magenta), wild-type Mtu-AnPRT apo chain A (green) and wild-type Mtu-AnPRT chain A with PRPP (cyan) and 
Mg
2+
 (cyan spheres) bound. A) Chain A of Mtu-N138A. B) Chain B of Mtu-N138A. 
 
Chains C and D overlay almost perfectly with chain A of the wild-type Mtu-AnPRT PRPP/Mg2+ 
structure (with the exception of the helices displaced due to benzamidine), with RMSD values of 
0.355 Å and 0.371 Å respectively. PRPP and two Mg2+ ions are bound in each chain, in positions 
almost identical to those observed for the wild-type Mtu-AnPRT PRPP/Mg2+ structure (Figure 4.12). 
The PRPP molecules in each chain make contacts via the phosphate moiety to A141, S142, S143 and 
G110, with the ribose ring making contacts with A138 and G147. The PPi group is the most tightly 
bound of the molecule, hydrogen bonding to G107, N117, S119, T120, K135 and both Mg2+ ions. The 
two Mg2+ ions are co-ordinated to S119, D251 and E252. All of these contacts are identical to those 
made in the wild-type Mtu-AnPRT PRPP/Mg2+ structure.44 
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Figure 4.12 Stereo diagrams of PRPP binding in Mtu-N138A and wild-type Mtu-AnPRT. Mtu-N138A (magenta) 
with PRPP (green) and Mg
2+
 (green spheres) bound is overlaid with wild-type Mtu-AnPRT chain A (not shown) 
with PRPP (cyan) and Mg
2+
 (cyan spheres) bound. Polar contacts for Mtu-N138A PRPP are shown as yellow 
dashes. Water molecules are shown as red spheres. A) Chain C of Mtu-N138A. B) Chain D of Mtu-N138A. 
 
 
4.7.1.2 Mtu-P180A/PRPP/Mg2+ 
The structure of Mtu-P180A was determined at 1.80 Å in the presence of PRPP and Mg2+, with two 
non-associated monomers in the asymmetric unit. The Mtu-P180A dimers could be generated via 
crystallographic symmetry. Chain A had one PRPP molecule bound, however, no density for Mg2+ 
was observed. Interestingly, when overlaid with chain A of the wild-type Mtu-AnPRT apo structure 
(RMSD = 0.545 Å), the β2-α6 loop from Mtu-P180A chain A is shown to be in the open position 
(Figure 4.13A). When superimposed with chain A of the wild-type Mtu-AnPRT PRPP/Mg2+ bound 
structure (RMSD = 0.446 Å), however, it can be seen that the Mtu-P180A PRPP molecule is oriented 
differently, with the outermost phosphate of the PPi group overlapping with the binding site of one 
of the wild-type Mg2+ ions. In this orientation, the ribose ring is rotated approximately 180° 
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compared to wild-type PRPP, with the phosphate group pointing towards the anthranilate channel 
(Figure 4.13A and C). This PRPP orientation is also observed in the Sso-AnPRT D83G/F149S variant 
structure (PDB ID: 3GBR) (Figure 4.13B) though the PPi group is oriented differently, which is most 
likely due to the lack of extra coiling of the α5 helix N-terminus. Other structural features of chain A 
include the displacement of the α11’’ helix, α11’’-α11 loop and the α11 helix, which is similar to that 
observed for Mtu-N138A PRPP/Mg2+ bound structure. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 PRPP binding in Mtu-P180A, wild-type Mtu-AnPRT and Sso-AnPRT D83G/F149S. A) An overlay of 
Mtu-P180A chain A (yellow) with PRPP (magenta) bound, wild-type Mtu-AnPRT apo chain A (green) and wild-
type Mtu-AnPRT chain A with PRPP (cyan) and Mg
2+
 (cyan spheres) bound. B) An overlay of Mtu-P180A chain A 
(yellow) with PRPP (magenta) bound and Sso-AnPRT D83G/F149S chain A with PRPP (green) and Mn
2+
 (green 
spheres) bound. C) Stereo diagram of Mtu-P180A chain A (yellow), PRPP (magenta) and Mg
2+
 (magenta 
spheres) overlaid with wild-type Mtu-AnPRT (not shown) with PRPP (cyan) and Mg
2+
 (cyan spheres) bound and 
Sso-AnPRT D83G/F149S with PRPP (green) and Mn
2+ 
(green spheres) bound. Polar contacts for Mtu-P180A 
PRPP are shown as yellow dashes. Water molecules are shown as red spheres. 
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Chain B of Mtu-P180A shows the β2-α6 loop in the closed position, similar to chain A of the wild-
type Mtu-AnPRT PRPP/Mg2+ structure (RMSD = 0.358 Å) (Figure 4.14). This chain has PRPP bound in 
two alternate conformations with two Mg2+ ions co-ordinated. The primary conformation of PRPP 
has an occupancy of 0.8 and overlays well with the wild-type PRPP, making the same hydrogen bond 
contacts as seen in Figure 4.12 for Mtu-N138A. The secondary conformation has an occupancy of 0.2 
and is similar in position to the PRPP molecule in chain A. However, the difference in position of the 
β2-α6 loop in this chain provides different contacts for the ribose ring, with only one contact to 
G147, and the phosphate group, bound only to N138. 
 
  
 
 
 
 
Figure 4.14 Multiple PRPP binding modes in Mtu-P180A. Mtu-P180A chain B (yellow) with PRPP (magenta) and 
Mg
2+
 (magenta spheres) bound is overlaid with wild-type Mtu-AnPRT chain A with PRPP (cyan) and Mg
2+
 (cyan 
spheres) bound. Polar contacts between the phosphate and ribose ring of the Mtu-P180A PRPP (occupancy = 
0.2) are shown as yellow dashes. 
 
4.7.1.3 Mtu-R193L/PRPP/Mg2+ 
The structure of Mtu-R193L was elucidated in the presence of PRPP and Mg2+ to a resolution of 2.47 
Å. Two separate monomers are within the asymmetric unit, though dimers could be generated via 
crystallographic symmetry. Chain A of Mtu-R193L contained PRPP in the active site, but no Mg2+ 
ions. An overlay of this chain with chain A of the wild-type Mtu-AnPRT PRPP/Mg2+ structure (RMSD = 
0.464 Å) (Figure 4.15A) shows the β2-α6 loop in the closed position, with the PRPP molecules 
overlapping almost exactly, with the exception of the PPi group. In Figure 4.15A, the PPi group can be 
seen to project upwards where it overlaps with a Mg2+ ion from the wild-type Mtu-AnPRT PRPP/Mg2+ 
structure, making different contacts with G107, T115 and S119. Chain A also shows a displacement 
of the α11’’ and α11 helices of 2.5 Å from the wild-type Mtu-AnPRT PRPP/Mg2+ structure (as 
measured between G291 residues), as well as extra coiling of the α5 helix N-terminus. 
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Figure 4.15 An active site comparison of PRPP/Mg2+-bound Mtu-R193L and wild-type Mtu-AnPRT structures. 
Mtu-R193L (purple) with PRPP (green) and Mg
2+
 (green spheres) bound is overlaid with wild-type Mtu-AnPRT 
chain A (cyan) with PRPP (cyan) and Mg
2+
 (cyan spheres) bound. Polar contacts for the R193L PRPP shifted PPi 
are shown as yellow dashes. A) Chain A of Mtu-R193L. B) Chain B of Mtu-R193L. 
 
Chain B of Mtu-R193L also shows the β2-α6 loop in the closed position when overlaid with chain A of 
the wild-type Mtu-AnPRT PRPP/Mg2+ structure (RMSD = 0.412 Å). Two Mg2+ ions are present in this 
chain along with PRPP, all co-ordinated in the same manner as for the wild-type Mtu-AnPRT 
PRPP/Mg2+ structure (Figure 4.15B). Extra coiling of the α5 helix and displacement of the α11’’ and 
α11 helices are not observed in this chain. 
4.7.1.4 Mtu-R193A/PRPP/Mg2+ 
Mtu-R193A was co-crystallised with PRPP and Mg2+, with the crystal structure solved at a resolution 
of 1.93 Å. However, no ligands were observed in either of the two monomers in the asymmetric unit. 
The two monomers are non-associated in the asymmetric unit, however, dimers can be generated 
via crystallographic symmetry. Superimposing chain A of Mtu-R193A onto chain A of the wild-type 
Mtu-AnPRT PRPP/Mg2+ structure (RMSD = 0.468 Å) and chain A of the wild-type Mtu-AnPRT apo 
structure (RMSD = 0.492 Å) showed the Mtu-R193A β2-α6 loop folded into the anthranilate channel. 
Extra coiling of the α5 helix N-terminus was also observed, along with displacement of the α11’’ and 
α11 helices (Figure 4.16A). The same structural features were also present in Mtu-R193A chain B 
(Figure 4.16B), which had an RMSD value of 0.599 Å when overlaid with chain A of the wild-type 
Mtu-AnPRT PRPP/Mg2+, and 0.690 Å when overlaid with chain A of the wild-type Mtu-AnPRT apo 
structure. Chain B also showed some stabilisation of the β2-α6 loop, when compared to Mtu-R193A 
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chain A and to the wild-type Mtu-AnPRT apo and wild-type Mtu-AnPRT PRPP/Mg2+ structures (Figure 
4.16C-F). 
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Figure 4.16 A comparison of the active site and β2-α6 loop stability in PRPP/Mg2+-bound Mtu-R193A and wild-
type Mtu-AnPRT. A) Mtu-R193A chain A (orange) or B) Mtu-R193A chain B (orange) overlaid with wild-type 
Mtu-AnPRT apo chain A (green) and wild-type Mtu-AnPRT chain A (cyan) with PRPP (cyan) and Mg
2+
 (cyan 
spheres) bound. Panels C-F depict B-factor putty models for residues 101-154 of wild-type/variant Mtu-AnPRTs 
generated using PyMOL software,
53
 where larger red regions indicate residues with high B-factors, and smaller 
blue regions indicate residues with low B-factors. The average B-factors for the compared proteins range from 
23.9 – 26.0. C) Mtu-R193A chain A. D) Mtu-R193A chain B. E) Wild-type Mtu-AnPRT apo chain A. F) Wild-type 
Mtu-AnPRT chain A with PRPP (cyan) and Mg
2+
 (cyan spheres) bound. 
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4.7.1.5 Interpretation of Structures 
A comparison of all four variant structures (Mtu-N138A, Mtu-P180A, Mtu-R193L and Mtu-R193A) 
obtained in the presence of PRPP and Mg2+ raises some interesting questions about the order of 
binding of these two ligands. Chain A of the Mtu-P180A structure shows PRPP bound in a completely 
different conformation to that observed for wild-type Mtu-AnPRT with PRPP and Mg2+ bound (Figure 
4.14); a pose that could be illustrating how PRPP initially binds to the active site. Chain B of the Mtu-
P180A structure correlates with this hypothesis, as the same pose is present at an occupancy of 0.2 
together with the ‘final’ binding mode at an occupancy of 0.8. However, it is important to note that 
the rigidity present within the Mtu-AnPRT crystal structures could be influencing the mechanism by 
which PRPP binds, and as such the alternative PRPP binding observed in Mtu-P180A may not 
represent the binding events of a dynamic protein in solution.  
Further to this, it can be observed that Mg2+ is not present in chain A of the Mtu-R193L structure 
where the β2-α6 loop is in the ‘closed’ position. However, DSF experiments outlined in Section 2.4.3 
show a decided increase in Mtu-AnPRT stability when both Mg2+ and PRPP are present, which is 
likely attributable to the closure of the β2-α6 loop causing an increase to the global stability of the 
enzyme. This increase in stability was not observed when PRPP was present without Mg2+. As the 
DSF experiments are performed in solution, they are more likely to reflect the events associated 
with ligand binding. The crystal structure of Mtu-R193L, where the β2-α6 loop is ‘closed’ despite the 
absence of Mg2+, could therefore be a result of crystal packing. 
Three structural changes can be observed to contribute to the suggested order of binding of PRPP 
and Mg2+. Firstly, the β2-α6 loop curling into the anthranilate channel, which is observed in the 
unliganded chains of Mtu-N138A and Mtu-R193A. Secondly, the extra coiling of the α5 helix N-
terminus, which is present in the unliganded chains of the Mtu-N138A and Mtu-R193A structures, 
chain A of Mtu-R193L and chain A of Mtu-P180A. Thirdly, the displacement of the α11’’ helix, the 
α11’’-α11 loop and the α11 helix towards the PRPP binding site, which is also present in the 
unliganded chains of the Mtu-N138A and Mtu-R193A structures, chain A of Mtu- R193L and chain A 
of Mtu-P180A. Upon inspection of these structures, it appears that prior to PRPP binding the β2-α6 
loop is folded into the anthranilate channel. It is unclear whether movement of this loop to the 
‘open’ position (observed in the wild-type Mtu-AnPRT apo structure) appears to facilitate the initial 
stages of PRPP binding, or vice versa. As the binding of PRPP progresses, the α5 helix likely uncoils 
and becomes part of the β1-α5 loop. These PRPP binding events may somehow trigger the uncoiling 
of the α5 helix, which would also allow the binding of Mg2+ ions in the positions observed in the wild-
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type Mtu-AnPRT PRPP/Mg2+ bound structure. PRPP binding may also cause the movement of the 
α11’’ and α11 helices away from the PRPP binding site, though the mechanism for this is unclear. 
It is possible that the mutations made to Mtu-AnPRT have somehow facilitated these binding events 
and structural movements, however, similar observations were made between different variants, 
and superimposition of the structures onto wild-type proteins show little gross conformational 
changes. The folding of the β2-α6 loop into the anthranilate channel has previously been observed in 
wild-type Mtu-AnPRT structures in the presence of 4-fluoro-anthranilate (Section 3.6).  
The variant most likely to affect PRPP binding is Mtu-N138A, which binds the ribose ring of PRPP via 
the C3 hydroxyl group, and has been shown to increase the apparent KM value of PRPP (Section 
4.6.1). However, the structure obtained for Mtu-N138A has shown that PRPP is able to bind in the 
same manner as wild-type, and maintains the hydrogen bond interaction between the backbone 
oxygen of A138 and the PRPP C3 hydroxyl. The reason for the increase in the KM value is therefore 
not likely to be caused by the protein’s inability to accept a PRPP conformation similar to wild-type. 
 
4.7.2 Structures Soaked with Anthranilate 
Looped crystals of the variants Mtu-N138A, Mtu-P180A, Mtu-R193A, Mtu-R193L and Mtu-R194A, 
which were co-crystallised with PRPP and Mg2+, were soaked for various time periods with solutions 
containing 10 mM anthranilate before snap-freezing with liquid N2. Structural information was 
obtained for all five variants in the presence of different combinations of ligands, subject to the Mtu-
AnPRT-catalysed reaction of the two substrates PRPP and anthranilate. These structures are 
compared to the wild-type Mtu-AnPRT apo structure (PDB ID: 3QR9) as well as the wild-type Mtu-
AnPRT structure co-crystallised with PRPP, Mg2+ and benzamidine (PDB ID: 1ZVW).  
4.7.2.1 Mtu-N138A/PRPP/Mg2+/Anthranilate  
Structural data was obtained for Mtu-N138A, which had been soaked for 10 s with anthranilate, at a 
resolution of 2.23 Å. Two non-associated monomers were present in the asymmetric unit, though no 
evidence of bound ligands was observed in either protein chain. Both chains have unresolved density 
for the β2-α6 loop, suggesting this loop is flexible within the crystal lattice. Extra coiling of the α5 
helix is observed for both chains, however, only chain B shows some displacement of the α11’’-α11 
loop towards the PRPP binding site (Figure 4.17). 
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Figure 4.17 An active site comparison of the Mtu-N138A (10 s anth soak) and wild-type Mtu-AnPRT structures. 
Mtu-N138A (10 s Anth soak) (magenta) is overlaid with wild-type Mtu-AnPRT apo chain A (green) and wild-
type Mtu-AnPRT chain A (cyan) with PRPP (cyan) and Mg
2+
 (cyan spheres) bound. A) Chain A of Mtu-N138A (10 
s Anth soak). B) Chain B of Mtu-N138A (10 s Anth soak). 
 
4.7.2.2 Mtu-P180A/PRPP/Mg2+/Anthranilate 
Mtu-P180A was soaked in a solution containing anthranilate for 1 s before snap-freezing in liquid N2. 
A crystal structure was obtained at a resolution of 2.04 Å, containing two monomers in the 
asymmetric unit associated as a dimer. Unfortunately, no ligands were observed bound to either 
protein chain, with the exception of one Mg2+ ion bound to chain A. Chain A overlays well with chain 
A of the Mtu-AnPRT apo structure (RMSD = 0.194 Å), with the β2-α6 loop shown clearly in the open 
position (Figure 4.18A). If the previous assumption of PRPP binding preceding Mg2+ binding is 
correct, the presence of the lone Mg2+ ion in chain A may indicate the state of the enzyme post-
reaction after PPi has departed. 
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Figure 4.18 An active site comparison of the Mtu-P180A (1 s anth soak) and wild-type Mtu-AnPRT structures. 
Mtu-P180A (1 s Anth soak) (yellow) with Mg
2+
 bound (yellow spheres) is overlaid with wild-type Mtu-AnPRT 
apo chain A (green) and wild-type Mtu-AnPRT chain A (cyan) with PRPP (cyan) and Mg
2+
 (cyan spheres) bound. 
A) Chain A of Mtu-P180A (1 s Anth soak). B) Chain B of Mtu-P180A (1 s Anth soak). 
 
An overlay of chain B of Mtu-P180A with chain A of the wild-type Mtu-AnPRT apo structure also 
shows the β2-α6 loop clearly in the open position, however, the RMSD value has increased to 0.402 
Å. This is likely due to the extra coiling of the α5 helix and displacement of the α11’’ and α11 helices, 
which may also explain why there are no Mg2+ ions present in this chain (Figure 4.18B). 
4.7.2.3 Mtu-R193L/PRPP/Mg2+/Anthranilate 
The structure of Mtu-R193L was obtained at a resolution of 2.47 Å with two separate monomers in 
the asymmetric unit. Mtu-R193L was first co-crystallised in the presence of PRPP and Mg2+, and was 
soaked in a solution containing anthranilate for 5 s prior to snap-freezing with liquid N2. Chain A of 
R193L had both PRPP and two Mg2+ ions bound, and overlays well with chain A of the wild-type Mtu-
AnPRT PRPP/Mg2+ structure (RMSD = 0.380 Å). As can be seen in Figure 4.19A, the PRPP and Mg2+ 
ions are bound in a similar manner to the ligands in the wild-type Mtu-AnPRT PRPP/Mg2+ structure, 
with the β2-α6 loop in the closed position. 
Chain B of Mtu-R193L had both PPi and Mg
2+ ions bound, with these ligands shown to overlay well 
with the positions occupied by the PPi moiety and the Mg
2+ ions in chain A of the wild-type Mtu-
AnPRT PRPP/Mg2+ structure (RMSD = 0.473 Å) (Figure 4.19B). Interestingly, this chain showed the β2-
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α6 loop folded into the anthranilate channel, as was previously observed for the Mtu-R193A 
structure in Section 4.7.1.4. As with Mtu-R193A chain B, Mtu-R193L chain B also shows some 
stabilisation of the β2-α6 loop in this folded position (Figure 4.19C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19 A comparison of the active site and β2-α6 loop stability in the Mtu-R193L (5 s anth soak) and wild-
type Mtu-AnPRT structures. A) Mtu-R193L chain A (5 s Anth soak) (purple) with PRPP (magenta) and Mg
2+
 
(magenta spheres) bound or B) Mtu-R193L chain B (5 s Anth soak) (purple) with PPi and Mg
2+
 (magenta 
spheres) bound overlaid with wild-type Mtu-AnPRT apo chain A (green) and wild-type Mtu-AnPRT chain A 
(cyan) with PRPP (cyan) and Mg
2+
 (cyan spheres) bound. C) B-factor putty model of Mtu-R193L chain B with PPi 
(orange) and Mg
2+
 (magenta spheres) bound showing residues 101-154. Larger red regions indicate residues 
with high B-factors, while smaller blue regions indicate residues with low B-factors. 
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4.7.2.4 Mtu-R193A/PRPP/Mg2+/Anthranilate 
Two structures were obtained of Mtu-R193A in the presence of PRPP, Mg2+ and anthranilate. The 
first structure was obtained from a crystal that had been soaked in a solution containing anthranilate 
for 3 s before snap-freezing with liquid N2, and has a resolution of 2.20 Å. The second structure arose 
from a crystal soaked for 1 min and 10 s in anthranilate solution, and has a resolution of 2.50 Å.  
The Mtu-R193A 3 s structure has two monomers associated as a dimer in the asymmetric unit. Each 
monomer has one anthranilate bound, with both molecules bound in the same position in the outer 
site. The anthranilate molecules in each chain make the same hydrogen bond contacts to N138, 
R194 and a water molecule via the carboxylate group. The aromatic ring of anthranilate also has C-
H...π interactions to P180 via its proline ring (Figure 4.20C). Both chains also show extra coiling of the 
α5 helix, with the β2-α6 loop definitely folded into the anthranilate channel in chain B (Figure 4.20B 
and D). The β2-α6 loop in chain A is partially disordered, but has sufficient density present to suggest 
folding into the anthranilate channel (Figure 4.20A). Chain B also shows some slight displacement of 
the α11’’ and α11 helices. 
The Mtu-R193A 1 min 10 s structure has two non-associated monomers in the asymmetric unit, with 
both chains showing similar structural features to chain B of the Mtu-R193A structure soaked with 
anthranilate for 3 s (Figure 4.21A). Both monomers show one anthranilate molecule bound in the 
outer site, but with slightly different hydrogen bond contacts. Chain A shows the anthranilate 
hydrogen bonded to N138 and a water molecule via the amino group, and forming a salt bridge to 
R194 via the carboxylate group (Figure 4.21B). Chain B has the anthranilate molecule hydrogen 
bonded to N138 via the amino group, and hydrogen bonded to R194 and a water molecule via the 
carboxylate group (Figure 4.21C). The aromatic rings of the anthranilate molecules in each chain 
form C-H...π interactions to the proline ring of P180. The stability of the β2-α6 loop in each chain has 
a similar B-factor profile to that shown in Figure 4.20D. 
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Figure 4.20 A comparison of the active site and β2-α6 loop stability in the Mtu-R193A (3 s anth soak) and wild-
type Mtu-AnPRT structures. A) Mtu-R193A chain A (3 s anth soak) (orange) or B) Mtu-R193A chain B (3 s Anth 
soak) (orange) overlaid with wild-type Mtu-AnPRT apo chain A (green) and wild-type Mtu-AnPRT chain A (cyan) 
with PRPP (cyan) and Mg
2+
 (cyan spheres) bound. C) 2Fo-Fc map (blue, contoured at 1 σ) of the β2-α6 loop in 
chain A of Mtu-R193A (3s anth soak), showing likely folding into the anthranilate channel. D) Mtu-R193A chain 
B (3 s anth soak) (orange) with anthranilate (purple) bound in the outer site. Polar contacts are shown as 
yellow dashes, with water molecules shown as red spheres. E) B-factor putty model of Mtu-R193A chain B 
showing residues 101-154, where larger red regions indicate residues with high B-factors and smaller blue 
regions indicated residues with low B-factors.  
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Figure 4.21 An active site comparison of the Mtu-R193A (1 min 10 s anth soak) and wild-type Mtu-AnPRT 
structures. A) Mtu-R193A chain A (1 min 10 s anth soak) (pink) overlaid with wild-type Mtu-AnPRT apo chain A 
(green) and wild-type Mtu-AnPRT chain A (cyan) with PRPP (cyan) and Mg
2+
 (cyan spheres) bound. B) Mtu-
R193A chain A (1 min 10 s anth soak) (pink) with anthranilate (green) bound in the outer site. C) Mtu-R193A 
chain B (1 min 10 s anth soak) (pink) with anthranilate (green) bound in the outer site. Polar contacts are 
shown as yellow dashes, with water molecules shown as red spheres.  
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The structures elucidated from both Mtu-R193A soaks with anthranilate bound and the wild-type 
Mtu-AnPRT structure with 4FA (6 s soak) bound (PDB ID: 4N8Q) are overlaid in Figure 4.22. A 
comparison of these structures shows both anthranilate and 4FA bound in similar positions in the 
outer site, with the residues involved in this outer site (N138, P180 and R194) also in analogous 
orientations. The β2-α6 loop is positioned differently in the Mtu-R193A structures when compared 
to the 4FA-bound wild-type structure, which is likely due to the absence of the steric bulk of the 
R193 side-chain in the variant protein. This absence of R193 would allow further projection of the 
β2-α6 loop into the anthranilate channel. 
 
 
 
 
 
 
 
Figure 4.22 Stereo diagram of the anthranilate/4FA binding modes in Mtu-R193A (anth soaked) and wild-type 
Mtu-AnPRT structures. Mtu-R193A (3 s anth soak) (orange) with anthranilate (purple) bound is overlaid with 
Mtu-R193A (1 min 10 s anth soak) (pink) with anthranilate (green) bound and wild-type Mtu-AnPRT (6 s 4FA 
soak) (blue) with 4FA (brown) bound. Polar contacts for anthranilate from the Mtu-R193A 3 s soak and 1 min 
10 s soak are shown as yellow and black dashes respectively. 
 
4.7.2.5 Mtu-R194A/PRPP/Mg2+/Anthranilate 
The final crystal structure in this section is of Mtu-R194A, co-crystallised with PRPP and Mg2+ and 
soaked with anthranilate for 5 min at 4 °C. The structure has a resolution of 1.77 Å and has two 
monomers associated as a dimer in the asymmetric unit. Both monomers show PPi, two Mg
2+ ions 
and two anthranilate molecules bound in the anthranilate channel. Both chains overlay well with 
chain A of the wild-type Mtu-AnPRT PRPP/Mg2+ bound structure (RMSD = 0.393 Å for chain A, RMSD 
= 0.409 Å for chain B), though neither show density for the β2-α6 loop. Both chains show the PPi 
molecules and Mg2+ ions overlaid in the same positions as those observed for PPi moiety and the 
Mg2+ ions in chain A of the wild-type Mtu-AnPRT PRPP/Mg2+ bound structure (Figure 4.23A and B). 
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Although both chains of Mtu-R194A have two anthranilate molecules bound, each chain has them 
bound in different positions (Figure 4.23C and D). Chain A has one anthranilate bound in the inner 
site, making hydrogen bond contacts to G107 and T108 via the amino group, and to R193, N138, the 
amino group of the second anthranilate and three water molecules via the carboxylate group. The 
second anthranilate molecule in chain A is bound in the middle site, and is hydrogen bonded to the 
carboxylate group of the first anthranilate molecule and a water molecule via its amino group, and 
to N138 and three water molecules via its carboxylate group. Chain B also has one anthranilate 
molecule bound in the inner site, but with different hydrogen bond contacts. The amino group of the 
inner anthranilate makes contacts to a single water molecule, with the carboxylate group making 
four contacts to N138 and three water molecules. The second anthranilate molecule in chain B is 
bound in the outer site, hydrogen bonded to a single water molecule and making C-H...π interactions 
to the P180 residue. 
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Figure 4.23 An active site comparison of the Mtu-R194A (5 min anth soak) and wild-type Mtu-AnPRT 
structures. A) Mtu-R194A chain A (5 min anth soak) (purple) or B) Mtu-R194A chain B (5 min anth soak) 
(purple) is overlaid with wild-type Mtu-AnPRT apo chain A (green) and wild-type Mtu-AnPRT chain A (cyan) 
with PRPP (cyan) and Mg
2+
 (cyan spheres) bound. C) Mtu-R194A chain A (5 min anth soak) with anthranilate 
(blue) bound in both the inner site and middle site. D) Mtu-R194A chain B (5 min anth soak) with anthranilate 
(blue) bound in both the inner site and the outer site.  
 
An overlay of Mtu-R194A chain A with the wild-type Mtu-AnPRT structures containing the alternate 
substrates 4FA (6 min soak) (PDB ID: 4N5V), 4FA (6 s soak) (PDB ID: 4N8Q) and 6MA (30 min soak) 
(PDB ID: 4N93) shows the identical positioning of anthranilate, 4FA and 6MA in the inner site (Figure 
4.24A). The active site residues contributing hydrogen bonds to the inner site anthranilate are also in 
the same positions, indicating that the mutation R194A has not caused any significant changes to the 
anthranilate binding in the inner site. The Mtu-AnPRT structures containing the alternate substrates 
do not show additional anthranilate binding in the middle site, contrary to what is observed in Mtu-
R194A chain A, and instead have the second anthranilate-like substrate bound in the outer site. This 
observation suggests a possible role for R194 in the shuttling of anthranilate from the outer site to 
A. B. 
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the middle site. However, when Mtu-R194A chain A is overlaid with the Sso-AnPRT enzyme (PDB ID: 
2GVQ) (RMSD = 1.358 Å), it can be seen that the two anthranilate positions overlay almost exactly 
with the positions observed in the Sso-AnPRT protein (Figure 4.24A & C). 
When overlaid with the wild-type Mtu-AnPRT alternate substrate structures, Mtu-R194A chain B can 
be observed to have a similar anthranilate binding pattern (Figure 4.24B & D). The inner site 
anthranilate is in a slightly different position to the wild-type Mtu-AnPRTs with alternate substrates 
bound, with the amino group oriented towards R193 as opposed to G107/T108. This position also 
differs from the Sso-AnPRT structures with anthranilate bound (PDB IDs: 2GVQ and 1ZYK). The outer 
site anthranilate of Mtu-R194A aligns with the 4FA and 6MA molecules also bound in this site in 
wild-type Mtu-AnPRT, though there is a key discrepancy. The 4FA and 6MA molecules bound in the 
outer site have their amino groups oriented towards H183, while in Mtu-R194A the anthranilate 
amino group is pointing towards N138. It is likely that anthranilate binds in the outer site with its 
amino group facing towards N138, negating the necessary ring flip (discussed in Section 3.6) that 
would be required for 4FA and 6MA to adopt their inner site binding modes.  
Figure 4.24 also shows that residues from the wild-type Mtu-AnPRT 4FA 6 s soak structure are 
slightly displaced compared to Mtu-R194A and the other alternate substrate structures, which is 
likely caused by the folding of the β2-α6 loop into the anthranilate channel. 
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Figure 4.24 A comparison of anthranilate/analogue binding sites in Mtu-R194A, wild-type Mtu-AnPRT and 
wild-type Sso-AnPRT. Stereo diagram of A) Mtu-R194A chain A or B) Mtu-R194A chain B with anthranilate 
(blue) bound overlaid with wild-type Mtu-AnPRT (cyan) with 4FA (6 min soak) (green) bound, wild-type Mtu-
AnPRT (magenta) with 4FA (6 s soak) (brown) bound, wild-type Mtu-AnPRT (yellow) with 6MA (30 min soak) 
(orange) bound and Sso-AnPRT (not shown) with anthranilate (white) bound. All PRPP/PPi molecules are 
shown in pink, with Mg
2+
 colours mimicking the colour of the anthranilate-like ligand bound. Polar contacts are 
shown as yellow dashes, with water molecules shown as red spheres. (C) Surface representation of Mtu-R194A 
chain A (5 min anth soak) (purple) with anthranilate (blue) bound, overlaid with Sso-AnPRT (not shown) with 
anthranilate (green) bound. D) Surface representation of Mtu-R194A chain B (5 min anth soak) (purple) with 
anthranilate (blue) bound, overlaid with wild-type Mtu-AnPRT (not shown) with 4FA (6 min soak) (yellow) 
bound. Mg
2+
 (blue spheres) and PPi (orange) from Mtu-R194A are also shown. 
B. 
G107 
T108 R193 
R/A194 
P180 
N138 
Inner 
site 
Middle 
site 
Outer 
site 
G107 
T108 R193 
R/A194 
P180 
N138 
Inner 
site 
Middle 
site 
Outer 
site 
Inner site Inner site 
Middle site 
Outer site 
C. D. 
A. 
G107 
T108 
R193 
R/A194 
P180 
N138 
Inner 
site 
Middle 
site 
Outer 
site 
G107 
T108 
R193 
R/A194 
P180 
N138 
Inner 
site 
Middle 
site 
Outer 
site 
130 
 
4.7.2.6 Interpretation of Structures 
By comparing all of the variant Mtu-AnPRT structures that were captured in the presence of PRPP, 
Mg2+ and anthranilate, one can begin to form an understanding of the possible order of ligand 
binding events. As has been observed before in Section 4.7.1 and in the wild-type Mtu-AnPRT 
PRPP/Mg2+ bound structure, PRPP has the ability to bind to the Mtu-AnPRT apo enzyme. 
Additionally, the Mtu-R193A variant has demonstrated that anthranilate can bind to the enzyme in 
the non-productive Site 3 without PRPP or Mg2+ binding first, and corroborates with the wild-type 
Mtu-AnPRT structure with 4FA soaked in for 6 s, which has a single 4FA molecule bound in the outer 
site (Section 3.6). These observations indicate that the first substrate binding event in the ligand-free 
Mtu-AnPRT protein is either one of two options: either PRPP, or anthranilate in the non-productive 
outer site.  The β2-α6 loop would be in the ‘open’ position for PRPP binding, or folded into the 
anthranilate channel for anthranilate binding in the outer site. The flexibility of the β2-α6 loop is 
evident in all structures obtained in this study, and would be a necessary feature for random binding 
events of PRPP or anthranilate in Mtu-AnPRT. 
However, the concentration of PRPP (10 mM) used in the crystallisation conditions is very high when 
compared to the apparent KM value, and it is possible that this high concentration artificially shifts 
the equilibrium between the solvent and Mtu-AnPRT towards a PRPP-bound state. This would create 
a situation in which PRPP is already bound to Mtu-AnPRT prior to anthranilate exposure, and thus 
would not give an accurate insight into the natural order of binding events. In the presence of PRPP 
and Mg2+, Mtu-R193A showed the β2-α6 loop folded into the active site in both chains, with no 
ligands bound. However, when anthranilate is also present a single anthranilate molecule alone is 
bound in the outer site, despite the presence of PRPP and Mg2+. Given the decrease in catalytic 
turnover and anthranilate binding ability of Mtu-R193A (Section 4.6.1) coupled with the short 
anthranilate soak time of 3 s, it is reasonable to assume that the binding of anthranilate in the outer 
site is the first ligand binding event in this variant, and perhaps in Mtu-AnPRT. The positioning of the 
β2-α6 loop in the anthranilate channel likely prevents the anthranilate bound in the outer site from 
progressing further until PRPP is bound, whereupon it could simultaneously assist in moving the 
outer site anthranilate along the channel towards the catalytically relevant inner site. 
The structure of Mtu-R193L shows PPi and Mg
2+ bound in chain B, with the β2-α6 loop again folded 
into the anthranilate channel. It is possible that this variant has been captured in a post-reaction 
pose, and it could be suggested that movement of the β2-α6 loop back into this position somehow 
assists the product PRA in leaving the active site, leaving only PPi and Mg
2+ behind. This structure 
strengthens the argument for anthranilate binding prior to PRPP, as the β2-α6 loop has moved into a 
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conformation that has been seen to accommodate anthranilate binding. This leaves Mtu-AnPRT 
primed for further anthranilate binding before PPi has left the active site. 
The structure of Mtu-R194A, captured in the presence of PPi, Mg
2+ and anthranilate, is the only Mtu-
AnPRT structure to be obtained with two anthranilate molecules bound. This can be explained in 
two ways, depending on the order of ligand-binding events for Mtu-AnPRT. If the enzyme does allow 
PRPP to bind first in vivo, it is likely that the β2-α6 loop would be closed over the PRPP molecule, and 
thus be unable to fold into the anthranilate channel. Without the β2-α6 loop blocking the 
anthranilate channel, anthranilate could likely diffuse along the channel unimpeded, which would 
also allow for the presence of at least two anthranilate molecules in the channel at once. If it is 
anthranilate that binds to Mtu-AnPRT first, the β2-α6 loop is likely to be folded into the anthranilate 
channel, based on the Mtu-R193A structure with anthranilate bound and the wild-type Mtu-AnPRT 
structure with 4FA soaked in for 6 s. When positioned in the anthranilate channel, the β2-α6 loop 
could shuttle anthranilate to the active site as required. If the latter scenario is correct, the Mtu-
R194A structure could have potentially captured binding events pertaining to anthranilate inhibition, 
which is still possible for this variant (Section 4.6.2). If, as the Mtu-R193L variant suggests, the β2-α6 
loop is required to fold into the anthranilate channel for PPi release, the presence of two 
anthranilate molecules in the channel would prevent this loop movement from occurring. It is 
possible that the PPi in Mtu-R194A is stuck in the active site for this reason.  
If the binding of PRPP to Mtu-AnPRT facilitates the dissociation of PPi, it seems likely that the 
anthranilate nucleophile would be appropriately positioned in the active site prior to PRPP. If PRPP 
did bind first, it could be assumed that the β2-α6 loop would stay in the closed position until the 
reaction is complete. This loop closure leaves no obvious alternative mechanism for anthranilate 
regulation or to stop nucleophilic attack from water molecules diffusing into the anthranilate 
channel. However, if anthranilate binds first at the outer site with the β2-α6 loop folded into the 
channel, PRPP could subsequently bind and immediately react with the available anthranilate, 
reducing the risk of unproductive catalysis. 
Finally, the crystal structures discussed in this section also corroborate with the observation that 
Mtu-AnPRT utilises a sequential mechanism. The ternary mechanism equation describes substrate 
binding in their catalytically relevant sites; in this case the PRPP binding site and the catalytically 
relevant inner anthranilate site. As stated in Section 2.5.4, crystal structures of Mtu-AnPRT have 
indicated that the contacts for the catalytically relevant inner anthranilate site are only formed upon 
the binding of PRPP, where the β2-α6 loop is in the closed position.44 The proposal that anthranilate 
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binding in the outer site precedes PRPP binding in the active site still conforms to this observation, 
as the outer anthranilate site is not catalytically relevant. 
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4.8 Summary 
Point mutations to the TrpD gene were successfully carried out using PCR, with the formation of the 
Mtu mutants N138A, P180A, G107P, R193A, R193L and R194A confirmed via plasmid sequencing. 
These mutated plasmids were then successfully transformed into BL21 (DE3) pBB528/pBB541 cells. 
All six variant proteins were purified successfully, with CD spectra indicating they were all properly 
folded. Mass spectrometry was utilised to confirm that the masses of the variants were of the 
expected size, with DSF used to determine their temperatures of denaturation. Mtu-N138A, Mtu-
P180A and Mtu-R194A showed similar melting temperatures to the wild-type value of 54.1 ± 0.3 °C, 
whereas Mtu-G107P showed a decrease in protein stability with a melting temperature of 45 ± 1 °C. 
Interestingly, Mtu-R193L and Mtu-R193A showed an increase in stability, with melting temperatures 
of 66.5 ± 0.6 °C and 64.9 ± 0.6 °C respectively.  
Kinetic characterisation of all six Mtu-AnPRT variants was carried out using the UV enzyme-coupled 
assay developed in this study, with Eco-PRAI:InGPS as the coupling enzyme. Mtu-G107P was found 
to be totally inactive in this study. The apparent KM values for the natural substrate PRPP, as 
catalysed by the remaining variants, showed little variation from the wild-type value of 48 ± 2 µM, 
with the exception of Mtu-N138A which had an increased KM value of 160 ± 20 µM. The apparent KM 
values for anthranilate for Mtu-R193A and Mtu-R193L were drastically increased when compared to 
the wild-type value of 2.0 ± 0.2 µM, with values of 480 ± 24 µM and 300 ± 18 µM respectively. The 
turnover numbers of Mtu-R193A and Mtu-R193L were also affected, with kcat values of 0.075 ± 0.002 
s-1 and 0.035 ± 0.001 s-1. Anthranilate inhibition was observed for Mtu-P180A and Mtu-R194A, with 
Ki values of 440 ± 110 µM and 89 ± 11 µM respectively. Anthranilate inhibition was absent for Mtu-
N138A.  
Crystal structures were obtained for all Mtu-AnPRT variants with the exception of Mtu-G107P. Mtu-
N138A, Mtu-P180A, Mtu-R193L and Mtu-R193A were co-crystallised in the presence of PRPP and 
Mg2+. Mtu-N138A, Mtu-P180A, Mtu-R193L, Mtu-R193A and Mtu-R194A were also soaked with 
anthranilate for various time periods after co-crystallisation with PRPP and Mg2+. Mtu-R193A and 
Mtu-R194A structures were obtained with clear evidence of anthranilate bound, with other variants 
captured in differing stages of catalysis.  
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Chapter 5 
 
 
 
Inhibition of Variant Mtu-
AnPRTs 
 
 
5.1 Overview 
Chapter 5 explores the potential inhibition of the AnPRT variants Mtu-N138A, Mtu-P180A and Mtu-
R194A using the inhibitor compounds ACS172 and ACS142, previously tested on wild-type Mtu-
AnPRT in Chapter 2.  
The inhibition of these three variants by the anthranilate-like inhibitors ACS172 and ACS142 was 
successfully characterised using the enzyme-coupled assay described in Chapter 2. Mtu-N138A, Mtu-
P180A and Mtu-R194A were each co-crystallised in the presence of PRPP, Mg2+ and either ACS172 or 
ACS142, with crystal structures obtained for all three variants bound to ACS172. A crystal structure 
of Mtu-R194A bound to ACS142 was also solved. 
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5.2 Introduction 
The inhibition of wild-type Mtu-AnPRT using anthranilate-like inhibitor compounds has previously 
been investigated and discussed in Chapter 2. It was observed in structures of wild-type Mtu-AnPRT 
with inhibitors bound that many inhibitors utilised the outer site at the entrance to the anthranilate 
channel, making contacts to N138, R194 and P180. The inhibitors tested can be categorised into two 
groups: those with one aromatic ring, and those with multiple aromatic rings. Of the inhibitors that 
fall into the first category, ACS142 (Figure 5.1A) displayed the greatest inhibitory effect, with a Ki 
value of 8.5 ± 0.7 µM, and showed multiple binding modes to Mtu-AnPRT along the anthranilate 
channel. ACS172 (Figure 5.1B) had the lowest Ki value of the inhibitors defined by multiple aromatic 
rings (Ki = 5.5 ± 0.3 µM), though this inhibitor was the only compound to display pure non-
competitive inhibition. ACS172 was also observed to bind in different sites along the anthranilate 
channel, with a total of three binding modes.  
 
 
 
 
 
 
Figure 5.1 The chemical structure of A) ACS142 and B) ACS172. 
 
As has been discussed in Chapter 4, the residues N138, P180 and R194 provide contacts for 
anthranilate binding at the outer site of Mtu-AnPRT, which is likely the first recognition site for 
anthranilate upon Mtu-AnPRT binding, and thus also for any anthranilate-like inhibitor compounds. 
The inhibitor compounds ACS142 and ACS172 were chosen to be tested with the variant Mtu-
N138A, Mtu-P180A and Mtu-R194A, with the aim of investigating the effect of these outer site 
residues on inhibitor potency. 
 
 
 
A. B. 
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5.3 Kinetic Characterisation 
The compounds ACS142 and ACS172 were tested for inhibition against the Mtu-AnPRT variants Mtu-
N138A, Mtu-P180A and Mtu-R194A using the enzyme-coupled assay (Section 7.1.24/7.5.1), with Ki 
values listed in Table 5.1. Results were fitted to each of four inhibition equations (competitive, pure 
non-competitive, uncompetitive and mixed inhibition) and the χ2 values compared to determine 
which fit best described the data. 
 
Mtu-AnPRT variant Inhibitor compound Ki value (µM) Type of inhibition 
Wild-Type 
ACS172 5.5 ± 0.3 Pure non-competitive 
ACS142 8.5 ± 0.7 Competitive 
N138A 
ACS172 16 ± 1 Pure non-competitive 
ACS142 563 ± 58 Uncompetitive 
P180A 
ACS172 45 ± 3 Pure non-competitive 
ACS142 1100 ± 60 Pure non-competitive 
R194A 
ACS172 35 ± 2 Pure non-competitive 
ACS142 348 ± 48 Competitive 
 
Table 5.1 Ki values for ACS142 and ACS72 against wild-type/variant Mtu-AnPRTs.  
 
The anthranilate channel present in Mtu-AnPRT complicates the understanding of the kinetically 
determined inhibition profiles. Crystal structures of wild-type Mtu-AnPRT have shown that ACS172 
and ACS142 have the potential to bind in multiple sites along the channel, however, it is likely that 
these inhibitors first bind at the outer site prior to diffusion further along the channel. The diffusion 
of these inhibitors along the channel would then leave the same outer binding site available for 
subsequent inhibitor/anthranilate molecules to bind.  
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Traditionally, pure non-competitive inhibition occurs when an inhibitor compound can bind 
reversibly either to the free enzyme or to the enzyme-substrate complex, with identical dissociation 
constants (Figure 5.2).  Usually, this would indicate that the inhibitor and substrate bind at different 
sites on the enzyme, and that this binding site has the same affinity for the inhibitor whether or not 
anthranilate was bound. However, the unique anthranilate channel present in Mtu-AnPRTs likely 
allows anthranilate or the inhibitors to bind in the outer site and then progress towards the inner 
site, leaving the outer site again open for anthranilate/inhibitor binding. The wild-type Mtu-AnPRT 
enzyme displays this type of inhibition behaviour with ACS172, which is postulated to occur due to 
the simultaneous presence of ACS172 and anthranilate within the anthranilate channel (discussed in 
Section 2.6.1). Mtu-N138A, Mtu-P180A and Mtu-R194A had no effect on the mode of inhibition of 
ACS172, demonstrating pure non-competitive inhibition for all three variants. This observation 
indicates that removing any one of the residues N138, P180 or R194 does not detract from the 
enzyme’s ability to accommodate both ACS172 and anthranilate within the anthranilate channel. 
 
 
 
 
 
 
 
 
 
Figure 5.2 Reaction schemes describing uninhibited enzyme turnover as well as competitive, pure non-
competitive and uncompetitive inhibition. Abbreviations are as follows: E = enzyme, S = substrate, I = inhibitor, 
k = rate constant, KI = dissociation constant. 
 
A decrease in inhibitor potency for ACS172 was observed for all three variants. The P180A mutation 
had the greatest effect on ACS172 potency, with an 8-fold increase in Ki value. Mtu-P180A showed a 
2-fold increase in the KM value of anthranilate, and had no effect on the maximum rate of catalysis. 
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Taken in this context, the decrease in ACS172 potency against Mtu-P180A is not largely significant. 
Mtu-R194A also demonstrated a decrease in ACS173 potency, though to a lesser extent than Mtu-
P180A. Mtu-N138A had a negligible effect on ACS172 potency with a 3-fold increase in the Ki value, 
and showed a similar 4-fold increase in the KM value of anthranilate. The absence of any significant 
differences between ACS172 potency against wild-type Mtu-AnPRT and Mtu-N138A is a surprising 
result, given that of the three residues P180, R194 and N138, the latter is the only one conserved.  
The inhibition behaviour for ACS142 differed greatly between the three variants, with only Mtu-
R194A still able to maintain the competitive inhibition demonstrated for wild-type Mtu-AnPRT. Mtu-
R194A also showed the smallest change in the Ki value for this inhibitor, with a 40-fold increase. This 
40-fold increase for Mtu-R194A is significant when compared to its relatively small 3-fold decrease in 
the binding affinity of anthranilate, as compared to wild-type Mtu-AnPRT.   
Interestingly, the substitution of residue N138 changed the type of inhibition behaviour observed for 
ACS142 to uncompetitive, which indicates that an inhibitor can only bind to an enzyme-substrate 
complex, thus rendering the complex incapable of product formation (Figure 5.2). If it is assumed 
that ACS142 binds in the outer site of Mtu-N138A after anthranilate is already bound, a complex 
would be formed in which Mtu-N138A has anthranilate bound in the inner site and ACS142 bound in 
the outer site. The traditional definition of uncompetitive inhibition states that product formation 
does not occur, however, the unusual nature of the anthranilate channel in Mtu-AnPRT may allow 
anthranilate and PRPP to react, though product release could be prevented (Figure 5.3). 
 Mtu-N138A displays a 3-fold decrease in the binding affinity of PRPP, and therefore an alternative 
explanation for the uncompetitive inhibition observed for ACS142 could be that ACS142 binding in 
the outer site of Mtu-N138A instigates a further reduction in the binding affinity for PRPP. Thus, 
PRPP may not bind to Mtu-N138A at all in this scenario. Binding events outlined in Figure 5.3 also 
imply that prior to anthranilate binding, Mtu-N138A is in a conformation that cannot support 
ACS142 binding, perhaps caused by a higher intolerance of the additional methyl groups. Mtu-
N138A also causes a decrease in ACS142 potency, with a 66-fold increase in Ki value.  
 
 
 
 
 
139 
 
 
 
 
 
Figure 5.3 A possible inhibition scheme for Mtu-N138A in the presence of anthranilate (Anth), PRPP and 
ACS142. IS and OS denote inner site and outer site binding respectively. * indicates the diffusion of 
anthranilate from the outer site to the inner site. ? indicates that it is unclear whether this reaction occurs. 
Binding of anthranilate/ACS142 in the middle site is excluded for clarity. 
 
The largest Ki value for ACS142 was observed with Mtu-P180A, which displayed a 130-fold increase 
compared to wild-type Mtu-AnPRT. This implies that the P180 residue is critical for the binding of 
this inhibitor. The substitution of the P180 residue for A180 has also changed the type of inhibition 
from competitive to pure non-competitive, which indicates that ACS142 can bind to Mtu-P180A 
either with or without anthranilate already bound (Figure 5.4), and that the preferred binding site of 
this inhibitor in this enzyme variant is not the catalytic site (inner site) for anthranilate. 
 
 
 
 
 
Figure 5.4 A possible inhibition scheme for Mtu-P180A in the presence of anthranilate (Anth), PRPP and 
ACS142. IS and OS denote inner site and outer site binding respectively. * indicates the diffusion of 
anthranilate from the outer site to the inner site. # indicates the diffusion of ACS142 from the outer site to the 
inner site. ? indicates that it is unclear whether this reaction occurs. Binding of anthranilate/ACS142 in the 
middle site is excluded for clarity. 
 
Overall, Mtu-N138A, Mtu-P180A and Mtu-R194A have a more pronounced effect for the smaller 
inhibitor molecule ACS142 than for ACS172. This is likely due to the difference in size of the two 
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compounds, with the extra aromatic ring and carboxylate group on ACS172 able to make more 
contacts to Mtu-AnPRT, which would hold it more firmly in place when one contact is removed. The 
wild-type Mtu-AnPRT structure with ACS142 bound (PDB ID: 3UU1) shows that the ACS142 molecule 
makes a total of two hydrogen bonds to the surrounding protein when bound in the outer site. 
These hydrogen bonds are to R194 and N138, with a third C-H...π interaction between the ACS142 
aromatic ring and the P180 proline ring. Removing any one of these residues would eliminate one 
third of the potential binding interactions for ACS142. In comparison, the wild-type Mtu-AnPRT 
structure with ACS172 bound (PDB ID: 3QQS) demonstrates ACS172 forming an additional salt bridge 
to R193 via its inner carboxylate group, when bound in Mode 1.  
Of the three residues tested, P180 is the most crucial for the potency of these two inhibitors, as 
evidenced by the Ki values, highlighting the importance of the C-H
...π interactions between the 
inhibitor aromatic rings and the proline ring. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Inhibition graphs for determination of Ki values for ACS142 and ACS172 in the presence of variant 
Mtu-AnPRTs as calculated by the graphing software Grafit 5.
67
 A) Mtu-N138A. B) Mtu-P180A. C) Mtu-R194A. 
Solutions contained PRPP held at a concentration of 0.6 mM, at a temperature of 25 °C, pH 8.0.    
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5.4 Structural Characterisation 
The variants Mtu-N138A, Mtu-P180A and Mtu-R194A were co-crystallised with 10 mM PRPP, 10 mM 
MgCl2 and either 10 mM ACS172 or 10 mM ACS142. The inhibitor concentrations used in this study 
differs to the 1-5 mM used for obtaining wild-type Mtu-AnPRT inhibitor bound structures (Section 
2.7). Equimolar concentrations of PRPP, Mg2+ and inhibitor were used in an attempt to remove the 
potential for an artificial Mtu-AnPRT PRPP-bound state driven by high concentrations of PRPP. All 
crystals grew with the same diamond morphology observed for wild-type Mtu-AnPRT crystals (Figure 
5.6), and had formed within 24 hours. The data processing and refinement statistics for the crystals 
described in this section can be found in Appendix 3, with ligand omit maps located in Appendix 4.  
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Crystals of Mtu-R194A co-crystallised with 10 mM PRPP, 10 mM MgCl2 and 10 mM ACS172 in the 
presence of 0.2 M imidazole malate (pH 8.5) and 13% PEG-4000 (w/v). 
 
5.4.1 Structures Containing ACS172 
Crystal structures of the variants Mtu-N138A, Mtu-P180A and Mtu-R194A were successfully 
obtained in the presence of ACS172. PRPP and Mg2+ were also present in the crystal conditions, but 
none of the structures showed positive density for these ligands bound anywhere in the asymmetric 
unit. Inspection of the asymmetric units of these structures showed the presence of two separate 
Mtu-AnPRT monomers, however, dimers could be generated via crystallographic symmetry. These 
structures are compared to the wild-type Mtu-AnPRT structure with PRPP, Mg2+ and ACS172 bound 
(PDB ID: 3QQS). 
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5.4.1.1 Mtu-N138A/PRPP/Mg2+/ACS172 
The structure of Mtu-N138A was elucidated in the presence of ACS172 to a resolution of 2.4 Å. Chain 
A of Mtu-N138A shows ACS172 bound in the anthranilate outer site, in a mode similar to that of 
‘Mode 3’ as described for wild-type Mtu-AnPRT (Section 2.7). An overlay of chain A with chain C 
from the wild-type structure (RMSD = 0.392 Å) shows the Mode 3 ligands bound in a slightly 
different conformation, with the two carboxylate groups of the Mtu-N138A ACS172 molecule 
making hydrogen bonds to R194 as well as C-H...π interactions to P180 (Figure 5.7A). The wild-type 
ACS172 molecule also makes these contacts, though the carboxylate group of the inner aromatic 
ring makes an extra hydrogen bond with N138. Another significant difference between the two 
structures is the presence of an additional ACS172 molecule further into the anthranilate channel in 
the wild-type structure. The absence of this second molecule in Mtu-N138A could point to the 
importance of residue N138 for ACS172 movement up the anthranilate channel, and thus also for 
anthranilate movement. The position of the R193 side-chain in Mtu-N138A chain A could not be 
determined with confidence due to a lack of electron density, and has been modelled in as an 
alanine. 
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Figure 5.7 Stereo diagrams of ACS172 binding in Mtu-N138A and wild-type Mtu-AnPRT. Wild-type Mtu-AnPRT 
(green) with PRPP (cyan), Mg
2+
 (red spheres) and ACS172 (orange) bound is overlaid with Mtu-N138A 
(magenta) with ACS172 (purple) bound. Polar contacts for wild-type Mtu-AnPRT bound ACS172 and Mtu-
N138A bound ACS172 are shown as black and yellow dashes respectively. The binding modes of wild-type 
Mtu-AnPRT bound ACS172 are indicated by orange text. Residue numbers for Mtu-N138A are indicated by 
black text. A) Mtu-N138A chain A overlaid with wild-type chain C. B) Mtu-N138A chain B overlaid with wild-
type chain A. 
 
Chain B of Mtu-N138A shows ACS172 (occupancy = 0.8) bound in a position almost identical to 
‘Mode 1’ of ACS172 bound to wild-type, however, differing hydrogen bond contacts are made 
between the two molecules (Figure 5.7B). The Mtu-N138A structure has the carboxylate group of 
the inner aromatic ring hydrogen bonded to Y186, with a salt bridge formed with R193. No contacts 
are made by the carboxylate group of the outer aromatic ring. The ACS172 molecule bound in chain 
A of the wild-type structure is hydrogen bonded to R194 and N138 via the carboxylate group of the 
outer aromatic ring, and forms a salt bridge with R193 via the carboxylate group of the inner 
aromatic ring. 
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5.4.1.2 Mtu-P180A/PRPP/Mg2+/ACS172 
The crystal structure of Mtu-P180A was obtained with one ACS172 molecule bound in each of the 
two monomers present, at a resolution of 1.95 Å. An overlay of Mtu-P180A chain A with wild-type 
chain A (RMSD = 0.269 Å) shows the positions of the two ACS172 molecules (in Mode 1) to be almost 
identical (Figure 5.8A). Both ACS172 molecules make hydrogen bond contacts with R194 and N138 
via their outer aromatic ring carboxylate groups; two residues which appear to hold the outer 
aromatic ring in place despite the lack of C-H...π interactions caused by the absence of P180. The 
Mtu-P180A-bound ACS172 carboxylate group on the inner aromatic ring is hydrogen bonded to 
N138, with a salt bridge formed with R193.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Stereo diagrams of ACS172 binding in Mtu-P180A and wild-type Mtu-AnPRT. Wild-type Mtu-AnPRT 
(green) with PRPP (cyan) Mg
2+
 (red spheres) and ACS172 (orange) bound is overlaid with Mtu-P180A (yellow) 
with ACS172 (purple) bound. Polar contacts for wild-type Mtu-AnPRT bound ACS172 and Mtu-P180A bound 
ACS172 are shown as black and yellow dashes respectively. The binding modes of wild-type Mtu-AnPRT bound 
ACS172 are indicated by orange text. Residue numbers for Mtu-P180A are indicated by black text. A) Mtu-
P180A chain A overlaid with wild-type chain A. B) Mtu-P180A chain B overlaid with wild-type chain C. 
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An overlay of Mtu-P180A chain B with wild-type chain C (RMSD = 0.274 Å) shows ACS172 bound in 
Mode 3 (Figure 5.8B). The carboxylate group on the outer aromatic ring makes hydrogen bond 
contacts to R194 and a water molecule, while the carboxylate group on the inner aromatic ring 
hydrogen bonds to R194 and N138. The ACS172 molecule bound to the wild-type structure shows 
the inner aromatic ring in an almost identical position to the ACS172 molecule from Mtu-P180A, 
with similar hydrogen bonds made. This indicates that the replacement of P180 with A180 has little 
effect on the orientation of the inner aromatic ring of Mode 3, and that hydrogen bonds to R194 and 
N138 are sufficient to hold this ring in the position displayed in wild-type Mtu-AnPRT. The outer 
aromatic ring of the ACS172 molecule bound to Mtu-P180A is slightly displaced relative to the 
position observed in the wild-type Mtu-AnPRT ACS172, which is likely due to the lack of potential 
hydrogen bonds available for this ring, rendering it more mobile. 
5.4.1.3 Mtu-R194A/PRPP/Mg2+/ACS172 
The structure of Mtu-R194A with ACS172 bound was solved at a resolution of 2.06 Å, with one 
ACS172 molecule bound in each monomer. Both chain A and chain B of Mtu-R194A show ACS172 
bound in Mode 1 (Figure 5.9), making it the only variant structure to have both ACS172 molecules in 
the same binding mode, though the ACS172 in chain B is at an occupancy of 0.8. An overlay of Mtu-
R194A chain A with wild-type Mtu-AnPRT chain A (RMSD = 0.298 Å) shows a similarity in the position 
of both ACS172 and the surrounding residues, with the inner carboxylate group hydrogen bonded to 
R193, Y186 and a water molecule, with the outer carboxylate group hydrogen bonded to N138 only. 
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Figure 5.9 Stereo diagrams of ACS172 binding in Mtu-R194A and wild-type Mtu-AnPRT. Wild-type Mtu-AnPRT 
(green) with PRPP (cyan) Mg
2+
 (red spheres) and ACS172 (orange) bound is overlaid with Mtu-R194A (blue) 
with ACS172 (purple) bound. Polar contacts for wild-type Mtu-AnPRT bound ACS172 and Mtu-R194A bound 
ACS172 are shown as black and yellow dashes respectively. The binding modes of wild-type Mtu-AnPRT bound 
ACS172 are indicated by orange text. Residue numbers for Mtu-R194A are indicated by black text. A) Mtu-
R194A chain A overlaid with wild-type chain A. B) Mtu-R194A chain B overlaid with wild-type chain A. 
 
An overlay of Mtu-R194A chain B with wild-type Mtu-AnPRT (RMSD = 0.629 Å) shows an apparent 
difference in the positions of N138 and P180, which could be due to the disordered nature of the 
Mtu-R194A β2-α6 loop. Despite this residue displacement, the hydrogen bond contacts formed 
between ACS172 and Mtu-R194A are still similar to those made between ACS172 and wild-type, with 
the former hydrogen bonded to N138 and R193. Interestingly, a salt bridge between R193 and the 
inner carboxylate group of the ACS172 molecule bound to Mtu-R194A is not observed in either chain 
of this structure. This observation could indicate the importance of the hydrogen bond between 
R194 and the outer carboxylate group of ACS172 in positioning the ACS172 molecule correctly for 
effectual channel shuttling. 
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5.4.1.4 Interpretation of Structures 
In all three of the variant structures obtained with ACS172 bound, it is interesting to notice that 
none of them have either PRPP or Mg2+ bound, despite their presence in the crystallisation 
conditions in an equimolar ratio with ACS172. Extra coiling at the N-terminus of the α5 helix and 
displacement of the α11’’-α11 loop is present in every variant protein chain with ACS172 bound, 
with the exception of Mtu-R194A chain A. These structural features are present in several crystal 
structures discussed in Chapter 4, where PRPP is absent or atypically bound. As discussed in Section 
4.7.1.5, it is possible that the β2-α6 loop movement from the anthranilate channel to the open 
position could facilitate the initial stages of PRPP binding, which could simultaneously cause the 
uncoiling of the α5 helix. If this hypothesis is correct, it is possible that these variant structures with 
ACS172 bound have captured events preceding PRPP and Mg2+ binding. There do not seem to be any 
structural features preventing PRPP or Mg2+ from binding to Mtu-R194A chain A, however, as the β2-
α6 loop is in the open conformation (Figure 5.10). Density for the β2-α6 loop is undefined in all other 
chains of the variant structures. 
If Mtu-AnPRT requires anthranilate binding in the outer site to precede PRPP binding, it could be 
assumed that the anthranilate-like inhibitor ACS172 would also precede PRPP binding. Despite the 
presence of PRPP and Mg2+ in the crystallisation conditions, only one ACS172 molecule is bound per 
monomer in either Mode 1 or Mode 3 (where one aromatic ring is bound in the outer site), 
indicating that ACS172 binding is likely the first binding event. Adding weight to this suggestion are 
the observations that the variants Mtu-N138A, Mtu-P180A and Mtu-R194A all have the ability to 
bind PRPP as was observed in the crystal structures described in Section 4.7, but in these 
experimental conditions they do not.  
The structures outlined in Section 5.4.1 were obtained in the presence of equimolar concentrations 
of PRPP, Mg2+ and ACS172 (10 mM), yet only the presence of ACS172 was observed in a bound state. 
Previous structures of wild-type Mtu-AnPRT with ACS172 bound were obtained by co-crystallisation 
with 10 mM PRPP, 10 mM MgCl2 and 1-5 mM ACS172, and occupancy for all three ligands was 
observed.41a Assuming that PRPP, Mg2+ and ACS172 have similar binding affinities for wild-type Mtu-
AnPRT, the excess concentrations of PRPP and Mg2+ in the crystal drop may have driven the Mtu-
AnPRT protein towards a PRPP/Mg2+ bound state, according to Le Chatelier’s principle.76 If this 
assumption is correct, it could explain the differences in ligand binding observed between the wild-
type and variant Mtu-AnPRT structures in the presence of PRPP, Mg2+ and ACS172.   
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Figure 5.10 An active site comparison of wild-type/variant Mtu-AnPRT structures with ACS172 bound. A) An 
overlay of chain A wild-type Mtu-AnPRT (green) with PRPP (cyan), Mg
2+
 (red spheres) and ACS172 bound with 
Mtu-N138A chain A (magenta), Mtu-P180A chain B (yellow), and Mtu-R194A chain A (blue). B) An overlay of 
chain C wild-type Mtu-AnPRT (green) with PRPP (cyan), Mg
2+
 (red spheres) and ACS172 bound with Mtu-N138A 
chain B (magenta) and Mtu-P180A chain A (yellow). 
 
5.4.2 Structures Containing ACS142 
Crystals were grown of Mtu-N138A, Mtu-P180A and Mtu-R194A co-crystallised with PRPP, Mg2+ and 
ACS142. Unfortunately, Mtu-N138A and Mtu-P180A did not yield diffraction-quality crystals, and 
thus only the structure of Mtu-R194A with ACS142 bound was obtained during this study. This 
structure showed Mtu-R194A bound to ACS142 alone, with no positive density to signify PRPP or 
Mg2+ bound anywhere in the asymmetric unit. This structure is compared to the wild-type Mtu-
AnPRT structure with PRPP, Mg2+ and ACS142 bound (PDB ID: 3UU1).  
5.4.2.1 Mtu-R194A/PRPP/Mg2+/ACS142 
The crystal structure of Mtu-R194A with ACS142 bound was solved at a resolution of 2.23 Å, and 
contained two separate monomers in the asymmetric unit, with dimers generated via 
crystallographic symmetry. Chain A of Mtu-R194A has two ACS142 molecules bound within the 
anthranilate channel: one in the outer site, and one in the inner site at 0.8 occupancy. When 
overlaid with chain B of the wild-type Mtu-AnPRT structure with ACS142 bound (RMSD=0.364 Å) it 
can be observed that both ACS142 molecules in the outer site are almost identical in their positions 
(Figure 5.11A). The Mtu-R194A ACS142 molecule in the outer site is hydrogen bonded to N138 via its 
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carboxylate group, and is oriented parallel to P180. The wild-type ACS142 molecule in the outer site 
makes additional hydrogen bonds to R194 and three water molecules. The Mtu-R194A ACS142 
inhibitor bound in the outer site is hydrogen bonded to R193 alone via its carboxylate group, 
whereas the wild-type ACS142 is hydrogen bonded via its carboxylate group to R193 and a water 
molecule, and is hydrogen bonded to two water molecules via its amino group. The ACS142 
molecules bound in the inner site are significantly different in their positions, with the amino group 
of the Mtu-R194A ACS142 molecule pointing away from the PRPP binding site instead of towards it, 
as can be seen for the wild-type ACS142 molecule. However, the wild-type Mtu-AnPRT structure 
shows the outer site ACS142 molecule with its amino group pointing away from N138, in a different 
orientation to the inner site ACS142 molecule. This could indicate that ACS142 has the ability to 
diffuse through the channel in either orientation, which is perhaps warranted by the symmetry of 
the ACS142 methyl groups relative to the carboxylate group. 
It is possible that the Mtu-R194A ACS142 molecule present in the inner site cannot be modelled in at 
full occupancy due to movement of this molecule from the middle site to the inner site. The Fo-Fc 
map for chain A of Mtu-R194A shows large areas of density at 3.0 σ, which are not present in the 
2Fo-Fc map, indicating a possible transition of ACS142 from the middle site towards the inner site 
(Figure 5.11B). 
Chain B of the Mtu-R194A structure has only one ACS142 molecule bound within the anthranilate 
channel, located in the outer site (Figure 5.11C). By superimposing Mtu-R194A chain B onto wild-
type chain A, it can be seen that the position of Mtu-R194A ACS142 is positioned closer to H183, 
presumably caused by the removal of the potential hydrogen bond between the ACS142 carboxylate 
group and the absent R194 side-chain. The positions of the Mtu-R194A residues N138 and P180 have 
also shifted, possibly to accommodate this different ACS142 binding position. In this outer site 
binding mode, the Mtu-R194A ACS142 molecule makes hydrogen bond contacts to N138 via its 
carboxylate group, and to a single water molecule via its amino group. In comparison, the wild-type 
ACS142 molecule makes hydrogen bonds to R193, R194 and N138 via its carboxylate group.  
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Figure 5.11 A comparison of ACS142 binding in Mtu-R194A and wild-type Mtu-AnPRT. A) Mtu-R194A chain A 
(blue) with ACS142 (yellow) bound overlaid with wild-type chain B (green) with PRPP (cyan), Mg
2+
 (red 
spheres) and ACS142 (pink) bound. Polar contacts for wild-type Mtu-AnPRT bound ACS142 and Mtu-R194A 
bound ACS142 are shown as black and yellow dashes respectively. Residue numbers for Mtu-R194A are 
indicated by black text. B) Mtu-R194A chain A overlaid with wild-type chain B. The 2Fo-Fc map for Mtu-R194A is 
shown as blue mesh, contoured at 1.0 σ. The Fo-Fc map for Mtu-R194A is shown as green mesh, contoured at 
3.0 σ. C) Mtu-R194A chain B overlaid with wild-type chain A. 
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5.4.2.2 Interpretation of Structure 
It can again be noticed in the Mtu-R194A structure that neither PRPP nor Mg2+ are bound, despite 
their presence in the crystallisation conditions. Extra coiling of the α5 helix can be observed in both 
chains which would likely preclude these ligands from binding, as well as the displacement of the 
α11’’-α11 loop present in chain B (Figure 5.12). As was discussed in Section 5.4.1.4, it is possible that 
the β2-α6 loop movement from the anthranilate channel to the open position could facilitate the 
initial stages of PRPP binding, which could simultaneously cause the uncoiling of the α5 helix. The 
Mtu-R194A structure with ACS142 bound is therefore likely to have captured events preceding PRPP 
and Mg2+ binding, underlining the enzyme’s preference for binding the anthranilate-like ACS142 
molecule prior to the PRPP/Mg2+ ligands. 
The presence of two ACS142 molecules within the anthranilate channel without PRPP or Mg2+ bound 
indicates that the closing of the β2-α6 loop upon PRPP binding is not required for this inhibitor to 
move from the outer site to the inner site in the Mtu-R194A variant. The role of residue R194 could 
be to assist in holding anthranilate-like compounds in the outer site until PRPP is bound which, if 
correct, could also explain the presence of two anthranilate molecules within the anthranilate 
channel in the Mtu-R194A structure discussed in Chapter 4. 
 
 
 
 
 
 
 
Figure 5.12 An active site comparison of Mtu-R194A and wild-type Mtu-AnPRT structures with ACS142 bound. 
A) An overlay of wild-type Mtu-AnPRT chain B (green) with PRPP (cyan), Mg
2+
 (red spheres) and ACS142 (not 
shown) bound with Mtu-R194A chain A (blue) with ACS142 bound (not shown). B) An overlay of wild-type Mtu-
AnPRT chain A (green) with PRPP (cyan), Mg
2+
 (red spheres) and ACS142 (not shown) bound with Mtu-R194A 
chain B (blue) with ACS142 (not shown) bound.  
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The Mtu-R194A structure with ACS142 bound also suggests that R194 plays a key role in orientating 
the inhibitor for efficient shuttling further through the anthranilate channel, as evidenced by the 
differences in ACS142 binding poses between the wild-type and Mtu-R194A structures. As ACS142 
has a similar structure to anthranilate, it can be assumed that this would apply to wild-type Mtu-
AnPRT also. The binding of ACS142 to Mtu-R194A was disrupted to a greater extent than the larger 
ACS172 inhibitor, which again suggests an important hydrogen bonding role for the non-conserved 
R194 residue. 
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5.5 Summary 
The inhibitors ACS172 and ACS142 were tested against the Mtu-N138A, Mtu-P180A and Mtu-R194A 
variants using the enzyme-coupled assay. None of the variants changed the mode of inhibition of 
ACS172, with all displaying pure non-competitive behaviour. The absence of residue P180 had the 
greatest effect on the inhibitor potency of ACS172, with Mtu-P180A showing an 8-fold increase in 
the Ki value. Mtu-N138A and Mtu-P180A both changed the mode of inhibition of ACS142 from 
competitive to uncompetitive and pure non-competitive respectively. Mtu-P180A had the greatest 
effect on inhibitor potency for ACS142 also, with a 130-fold increase in the Ki value. 
Crystal structures were obtained for Mtu-N138A, Mtu-P180A and Mtu-R194A in the presence of 
PRPP, Mg2+ and ACS172, with the inhibitor found to bind in the anthranilate outer site either in 
Mode 1 or Mode 3. A crystal structure was also solved for Mtu-R194A in the presence of PRPP, Mg2+ 
and ACS142, with two inhibitor molecules bound to chain A of the structure, and one inhibitor 
molecule bound to chain B. Interestingly, neither PRPP nor Mg2+ were observed to bind to any of the 
structures obtained in this chapter. 
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Chapter 6 
 
 
Discussion 
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6.1 Key Findings of This Thesis 
The aim of this research was to provide further insight into the active site machinery of Mtu-AnPRT, 
in order to aid future tuberculosis drug development. To achieve this goal, the wild-type Mtu-AnPRT 
enzyme was successfully purified and physically characterised using a range of techniques including 
DSF and CD. The kinetic characterisation of Mtu-AnPRT was accomplished using a novel enzyme-
coupled UV-based assay, incorporating Mtu-AnPRT and Eco-PRAI:InGPS, which monitored the 
formation of InGP. Subjecting Mtu-AnPRT to high concentrations of anthranilate revealed a 
substantial decrease in enzyme activity, indicative of anthranilate inhibition. The successful 
characterisation of several inhibitor compounds was achieved using this assay, which revealed a ‘bi-
anthranilate’-like inhibitor (ACS172) as the most potent against Mtu-AnPRT. Crystal structures of 
Mtu-AnPRT with these compounds bound identified several common inhibitor binding residues 
(N138, P180, R193 and R194) as well as a third potential binding site for anthranilate located at the 
entrance to the anthranilate channel. A new apo structure of Mtu-AnPRT was also elucidated in the 
absence of the crystal additive benzamidine, which highlights the rearrangement of several Mtu-
AnPRT helices to accommodate this compound in previous Mtu-AnPRT structures. 
The substrate specificity of Mtu-AnPRT was probed using a range of fluoro-, methyl- and methoxy-
substituted anthranilate analogues. The ability of Mtu-AnPRT to utilise these analogues as substrates 
was tested using a commercially available PPi assay. All fluoro-analogues were turned over by Mtu-
AnPRT at a catalytic rate comparable to the natural substrate anthranilate, with analogue inhibition 
of Mtu-AnPRT displayed at high concentrations. Methyl-substituted analogues were also accepted as 
substrates for Mtu-AnPRT, though with heavily decreased binding affinities and at relatively slow 
catalytic rates. The methoxy-substituted compounds were not viable substrates. Mtu-AnPRT is 
therefore able to tolerate small additional functional groups on the aromatic ring of anthranilate. 
The products formed by the reaction of Mtu-AnPRT with anthranilate and the substrate analogues 
were characterised using 1H NMR spectroscopy, which confirmed that Mtu-AnPRT catalysed 
production of PRA-substituted compounds and also revealed the presence of PRA anomers. These α 
and β anomers were found to interconvert via an imine intermediate using mass spectrometry 
experiments. The PRA-substituted products, formed via the Mtu-AnPRT catalysis of PRPP and 
anthranilate analogues, were also confirmed as viable substrates for Eco-PRAI:InGPS, with the 
exception of 3M-PRA.  
Six variant Mtu-AnPRT proteins were generated in order to examine the necessity of several active 
site residues identified as contributing to substrate binding. The variant proteins Mtu-G107P, Mtu-
N183A, Mtu-P180A, Mtu-R193A, Mtu-R193L and Mtu-R194A were all successfully expressed and 
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purified, and displayed similar physical attributes to the wild-type Mtu-AnPRT enzyme. Kinetic 
characterisation of these variants showed that Mtu-G107P was the only variant that did not display 
catalytic activity. Wild-type Mtu-AnPRT, Mtu-N138A, Mtu-P180A and Mtu-R194A had similar binding 
affinities for both natural substrates, with comparable catalytic rates. Mtu-R193A and Mtu-R193L, 
on the other hand, demonstrated a substantial decrease both in the binding affinity of anthranilate 
and the catalytic rate when compared to wild-type Mtu-AnPRT, indicating a vital role for R193 in 
these events. Crystal structures of the variants in the presence of PRPP and Mg2+ showed an intact 
active site which retained the ability to bind these ligands, with the exceptions of Mtu-R193A, which 
remained ligand-free, and Mtu-G107P, which could not be crystallised. The crystal structures of Mtu-
P180A and Mtu-R193L also revealed alternate binding modes for PRPP. Anthranilate soaking of these 
variants yielded structures in varying stages of catalysis, with only Mtu-R193A and Mtu-R194A 
showing positive density for anthranilate. These are the first structures of a Mtu-AnPRT variant with 
anthranilate bound, and show anthranilate bound in the outer site. Mtu-R194A also shows 
anthranilate bound in the middle site and inner site, and confirms the existence of three 
anthranilate binding sites.  
Mtu-N138A, Mtu-P180A and Mtu-R194A were kinetically characterised in the presence of either 
ACS142, an anthranilate-like inhibitor with two additional methyl groups on the C3 and C5 positions, 
or ACS172, a ‘bi-anthranilate’-like inhibitor. These variants were found not to have a significant 
effect on the potency of ACS172, with increases in Ki values similar to increases in the apparent KM 
values for anthranilate, caused by the introduction of the N138A, P180A or R194A mutations. 
Consequently, no major differences were observed between the ACS172 binding modes of the 
variant and wild-type Mtu-AnPRT structures with ACS172 bound. Mtu-N138A, Mtu-P180A and Mtu-
R194A did have a significant effect on the potency of ACS142, causing a minimum 40-fold increase in 
the Ki values. The structure of Mtu-R194A with ACS142 bound showed some inconsistencies in the 
binding modes of ACS142 in both the inner and outer sites, which could explain the reduction in 
potency of this inhibitor. The structures of Mtu-N138A and Mtu-P180A were not obtained in the 
presence of ACS142. PRPP and Mg2+ were not observed to bind to the variant structures with either 
ACS172 or ACS142 bound. 
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6.2 Reaction Mechanism 
Both the structures of Mtu-AnPRT with alternate anthranilate-like substrates bound and the variant 
Mtu-AnPRT structures with anthranilate bound have confirmed the presence of three binding sites 
(inner, middle and outer) for anthranilate within the anthranilate channel of Mtu-AnPRT (Figure 6.1). 
The inner and middle anthranilate sites in these Mtu-AnPRT structures also confirm a 
correspondence in anthranilate binding sites to those of the Sso-AnPRT enzyme, that was suspected 
prior to this research. The Mtu-AnPRT structure with PRPP, Mg2+ and 4FA bound (6 min soak) (PDB 
ID: 4N5V) has 4FA bound in the inner site, in a pose that indicates the nucleophilic attack of 4FA at 
the C1 carbon of PRPP from the β-position. The distance from the 4FA amino group nitrogen to the 
C1 carbon of PRPP in the 4N5V structure is approximately 4.2 Å.  
 
 
 
 
 
 
 
Figure 6.1 The three anthranilate binding sites within Mtu-AnPRT. Wild-type Mtu-AnPRT (green) with PRPP 
(magenta), Mg
2+
 (blue spheres) and 4FA (cyan) bound (PDB ID: 4N5V) is overlaid with the anthranilate 
molecules (yellow) from Mtu-R194A (5 min anth soak). 
 
It is unclear whether the nucleophilic attack of anthranilate on PRPP takes place via an SN1 or SN2 
mechanism, as the inversion of stereochemistry from the α-PRPP to the β-PRA product is dictated by 
the chiral active site of Mtu-AnPRT, and is characteristic of both reaction mechanisms. As yet, a 
detailed characterisation of the reaction mechanism of AnPRTs has not been carried out, however, 
the proposal that AnPRTs may have evolved from PyNPs due to structural similarities43, 45 could 
suggest a similarity in the reaction mechanisms between these two enzymes. It has been proposed 
that some purine and pyrimidine NPs undergo an SN1 mechanism, via ribosyl-oxocarbenium ion 
Inner site 
Middle site 
Outer site 
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migration between the phosphate and the purine/pyrimidine base. The structure of purine NP with 
the transition state mimic immucillin-H bound (PDB ID: 1B8O) supports this hypothesis (Figure 6.2).71 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 The bovine purine NP active site with the inhibitor immucillin-H bound. A) Stereo diagram of purine 
NP (green) (PDB ID: 1B8O) shown bound to the inhibitor immunocillin-H (purple) and a phosphate ion 
(orange). Polar contacts are shown as yellow dashes, with bond distances indicated in Å.  The path of migration 
between the C1’ carbon of immucillin-H and the phosphate oxygen, which would occur with the natural 
substrates, is outlined. B) The purine NP transition state,
77
 which is mimicked by C) immucillin-H. 
 
The purine/pyrimidine NPs catalyse the reversible phosphorolysis of purine/pyrimidine nucleosides 
to the free purines/pyrimidines and the corresponding ribose 1-phosphates, similar to the reaction 
catalysed by AnPRTs (Figure 6.3). The ribosyl-oxocarbenium ion migration mechanism is thought to 
be facilitated by the anchoring of the phosphate moiety by protein interactions and Mg2+ ion co-
ordination, and the anchoring of the purine/pyrimidine moiety via protein interactions. In 
comparison, the ribose sugar of the purine/pyrimidine nucleoside creates few protein interactions.  
Upon formation of the ribosyl-oxocarbenium ion intermediate, the phosphate and the 
purine/pyrimidine moieties remain in place, while the relatively ‘free’ ribose sugar group migrates 
to/from the phosphate molecule, forming the free purine/pyrimidine and α-D-ribose 1-phosphate.71  
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Figure 6.3 A comparison of the reactions catalysed by A) purine NP, B) pyrimidine NP, C) hypoxanthine-guanine 
PRT (HGPRT) and D) Mtu-AnPRT.  
 
Type I PRTs have shown a propensity for SN1 mechanisms, as evidenced by kinetic isotope effect 
experiments on orotate and hypoxanthine-guanine PRTs.31b, 71 It has been suggested that the type I 
AnPRTs also utilise ribosyl-oxocarbenium ion migration in their SN1 mechanisms. For example, in 
hypoxanthine-guanine PRTs the ribose ring of PRPP could migrate from the PPi moiety to 
hypoxanthine-guanine, forming a bond between the C1’ carbon of the ribose ring and the N9 
nitrogen of the hypoxanthine-guanine (Figure 6.3).31b, 78 It is entirely possible that the type III Mtu-
AnPRT also uses this mechanism, based on the crystal structures of this enzyme (Figure 6.4). It is 
reasonable to assume that the PPi moiety of PRPP, when bound to Mtu-AnPRT, would be held firmly 
in place during the Mtu-AnPRT-catalysed reaction. This thesis has described numerous Mtu-AnPRT 
crystal structures that have displayed virtually identical PRPP binding modes, in which the PPi moiety 
is anchored by several hydrogen bonds to the surrounding protein residues, as well as by co-
ordination to two Mg2+ ions. The phosphate group on the C5 position of PRPP is also stabilised by 
A. 
B. 
C. 
D. 
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several hydrogen bonds to the flexible β2-α6 loop and the β1-α5 loop. The ribose ring of PRPP 
hydrogen bonds to the backbone carbonyls of N138 and R139 via the C2 hydroxyl, and to the 
backbone nitrogen of G147 via the C3 hydroxyl, which are all located on the flexible β2-α6 loop. The 
ribose ring is therefore the least protein-interactive element of PRPP.  
 
 
 
 
 
 
 
Figure 6.4 Stereo diagram of PRPP, Mg
2+ 
and 4FA bound to Mtu-AnPRT with the potential ribosyl-
oxocarbenium ion path of migration outlined. Mtu-AnPRT (PDB ID: 4N5V) residues are shown in cyan, with 
PRPP in yellow, Mg
2+
 as green spheres and 4FA in magenta. Polar contacts are shown as yellow dashes, with 
bond distances indicated in Å. 
 
The crystal structure of Mtu-R193L co-crystallised with PRPP and Mg2+ and soaked for 5 s with 
anthranilate shows PPi and Mg
2+ bound, indicating that a reaction between PRPP and anthranilate 
has taken place. When overlaid with the wild-type Mtu-AnPRT structure with PRPP and Mg2+ ions 
bound, the Mtu-R193L-bound PPi molecule can be seen to overlay well with the PPi moiety of the 
PRPP molecule bound to the wild-type structure, indicating that it does not move during catalysis. 
The structure of Sso-AnPRT with PPi and Mg
2+ bound has been solved (PDB ID: 1GXB), and shows 
these ligands bound in identical positions to those found in the Sso-AnPRT structure with PRPP and 
Mg2+ bound (PDB ID: 1ZXY). The 1GXB structure arose from the soaking of Sso-AnPRT with 10 mM 
PRPP, 10 mM MgCl2 and 5 mM aniline-2-arsenic acid for 15 mins. The presence of PPi in the active 
site of Sso-AnPRT was attributed to the hydrolysis of PRPP, however, aniline-2-arsenic acid was not 
tested as a substrate or inhibitor of Sso-AnPRT.45a The ability of Mtu-AnPRT to utilise orthanilate as a 
substrate could indicate that Sso-AnPRT has the ability to utilise aniline-2-arsenic acid as a substrate, 
given the similarity of their chemical structures (Figure 6.5). If correct, the presence of PPi in the 
active site of Sso-AnPRT could be the result of the catalytic turnover of PRPP and aniline-2-arsenic 
4.2 4.2 
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acid by Sso-AnPRT, which would provide further evidence that PPi is the final product to leave the 
AnPRT active site post-reaction.   
 
 
 
Figure 6.5 The chemical structures of A) orthanilate and B) aniline-2-arsenic acid. 
 
The structure of Mtu-AnPRT with PRPP, Mg2+ and 4FA (6 min soak) bound (PDB ID: 4N5V) has 4FA 
bound in the inner site, with hydrogen bonds to R193 via the 4FA carboxylate group in each active 
site of the dimer. Kinetic analysis of the Mtu-R193A and Mtu-R193L variants has established the 
necessity of the R193 residue in both the binding of anthranilate and for catalytic turnover. The role 
of the R193 residue could be to assist in anchoring the inner site anthranilate during catalysis while 
the ribosyl-oxocarbenium ion migrates towards it. This hypothesis for the role of R193 would explain 
both the decrease in anthranilate binding affinity and catalytic turnover rate observed for Mtu-
R193A and Mtu-R193L. The structures of wild-type Mtu-AnPRT with PRPP, Mg2+ and 6MA (30 min 
soak) bound (PDB ID: 4N93) and of Mtu-R194A with PPi, Mg
2+ and anthranilate bound also show the 
side-chain of R193 hydrogen bonded to the inner site anthranilate/6MA molecule.  
The structures of Mtu-AnPRT with PRPP, Mg2+ and 4FA (6 min soak)/6MA (30 min soak) bound and 
Mtu-R194A with PPi, Mg
2+ and anthranilate bound highlight the involvement of the G107 residue in 
binding the anthranilate/4FA/6MA molecule bound in the inner site. A hydrogen bond between the 
anthranilate/4FA/6MA amino group and the backbone carbonyl of G107 is observed in all three 
structures. The G107 residue is also observed to hydrogen bond to the PPi moiety in PRPP and in PPi. 
The G107 residue likely anchors both the inner site anthranilate molecule and the PPi moiety of PRPP 
during catalysis, which would provide some explanation towards the total inactivity observed for 
Mtu-G107P. The introduction of a proline mutation at position 107 (Figure 6.6) highlights several 
unfavourable interactions between the proline ring and Mg1, the Mg-binding residue D251, and the 
PPi moiety of PRPP, which could conceivably disrupt the binding of PRPP and Mg
2+. 
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Figure 6.6 Stereo diagram of the possible effects of a G107P mutation in Mtu-AnPRT. Mtu-AnPRT (green) with 
PRPP (magenta), Mg
2+
 (blue spheres) and 4FA (cyan) bound (PDB ID: 4N5V) is shown with a proline residue 
(white) at position 107. Potentially unfavourable interactions between the proline residue and surrounding 
ligands/residues are indicated by yellow dashes, with bond lengths shown in Å. 
 
The presence of both α and β anomers of PRA in solution post-reaction can be detected by NMR 
spectroscopy, and this anomerisation is also reported for similar compounds such as phosphoribosyl 
amine.75a  By trapping the reduced PRA product through selective reduction with CNBH3, it is clear 
that anomerisation occurs via an imine intermediate. It seems improbable that Mtu-AnPRT catalyses 
the formation of both anomers, as the direction from which anthranilate approaches PRPP through 
the anthranilate channel clearly promotes the inversion of stereochemistry. The product of the Mtu-
AnPRT reaction is most likely β-PRA, which then rapidly interconverts in solution between α and  
anomers without enzyme facilitation.  
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6.3 Substrate Specificity 
Fluoro-analogues of anthranilate are more readily accepted as Mtu-AnPRT substrates than methyl-
analogues. The trend shown by the apparent KM values of the fluoro-analogues indicates that 4FA 
and 6FA have a higher, anthranilate-like affinity for Mtu-AnPRT than 3FA and 5FA. This difference in 
tolerance to the position of the fluorine substitution is likely caused by the electrostatic interactions 
made within the anthranilate channel. It is also of interest to note that 4FA and 6FA are the only two 
fluorinated analogues so far that can be observed to bind in the inner site of Mtu-AnPRT. The Mtu-
AnPRT structure with 4FA bound in the inner site shows this compound bound in almost identical 
positions to the anthranilate molecules bound in the inner site in the Sso-AnPRT (PDB IDs: 1ZYK & 
2GVQ) and Mtu-R194A enzymes, and is a strong indication that these fluoro-analogues are turned 
over via the equivalent mechanism that Mtu-AnPRT utilises for anthranilate.  
Structures of 3FA and 5FA obtained by Dr Alina Castell are yet to be completely refined, and will 
hopefully provide further insight towards the reason for the reduced binding affinity of Mtu-AnPRT 
for these analogues. However, if we compare the Mtu-R194A and Mtu-R193A structures with 
anthranilate bound in the outer site, it can be seen that any substituent in the C3 position of 
anthranilate would project towards the β2-α6 loop when it is folded into the channel (Figure 6.7). If 
it is assumed that the β2-α6 loop is required to fold into the channel for efficient anthranilate 
binding in the outer site, it is entirely possible that an anthranilate analogue containing a fluoro- or 
methyl-group moiety at C3 would encounter steric hindrances when binding at the outer site. Any 
substitutions to the C5 position of anthranilate would project towards the backbone carbonyl of 
H183, potentially creating unfavourable steric and/or electrostatic interactions with Mtu-AnPRT.  
On the other hand, if we use the Mtu-AnPRT structure with 4FA bound (6 s soak) as a template, the 
amino group of 4FA points towards the backbone carbonyl of H183. If the 3FA and 5FA molecules 
bind in this orientation, the C3 fluorine would project towards the side-chain of H183, with the C5 
fluorine projecting towards the β2-α6 loop when folded into the anthranilate channel. Regardless of 
whether these analogues bind with the amino group oriented towards N138 or H183, there are 
potentially unfavourable interactions that could explain this decrease in their binding affinity for 
Mtu-AnPRT. 
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Figure 6.7 The outer binding site for anthranilate in Mtu-AnPRT. A) Mtu-R194A (purple) with anthranilate 
(yellow) bound overlaid with Mtu-R193A (1 min 10 s soak) (green) with anthranilate (magenta) bound.  
Potential steric clashes for C3 and C5 substitutions are shown as yellow and black dashes for Mtu-R194A and 
Mtu-R193A (1 min 10 s soak) respectively. B) Mtu-AnPRT (6 s soak) (cyan) with 4FA (green) bound. Potential 
steric clashes for C3 and C5 substitutions are shown as yellow dashes. Bond distances are indicated in Å. 
 
Methy-substituted anthranilate analogues are not favourably tolerated by Mtu-AnPRT, as indicated 
by the dramatic increases in the KM values and decreases in the kcat values recorded for these 
compounds. The overall reduction in the ability of Mtu-AnPRT to accept any of the methyl-analogues 
as substrates points to unfavourable steric interactions within the anthranilate channel, rather than 
electronic interactions, as the root cause. Orthanilate, which has a sulfonyl group in place of the 
anthranilate carboxylate group, is also accepted as a poor Mtu-AnPRT substrate, which indicates the 
allowance for extra steric bulk at this position. The sulfonate functional group present in orthanilate 
is larger than the carboxylate group of anthranilate in two ways: firstly, there are three oxygens 
present on the sulfonate group, and only two on the carboxylate group, and secondly, sulfur has a 
larger atomic radius of 100 pm compared to the 70 pm atomic radius of carbon.79  
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6.4 Substrate Inhibition 
The anthranilate inhibition observed in wild-type Mtu-AnPRT is perhaps a means of regulating the 
production of PRA, and subsequently the formation of the pathway end-product tryptophan. 
Inhibition of an AnPRT due to anthranilate alone has not been reported for any other AnPRT 
enzymes to the author’s knowledge. At anthranilate concentrations above 15 µM the activity of 
Mtu-AnPRT steadily decreases, with the specific activity of the enzyme dropping to approximately 
50% of its maximum at 100 µM. It has been reported that anthranilate is a metabolic intermediate 
not normally accumulated within the cell,80 although as the exact cellular concentration of this 
compound is not currently known, it is difficult to confidently assert the relevance of the 
anthranilate inhibition observed in this study. 
Substitutions to the key residues thought to be involved with binding anthranilate in the outer site of 
Mtu-AnPRT identified the absolute importance of the interaction between N138 and anthranilate for 
intact anthranilate inhibition. Mtu-N138A showed a complete lack of anthranilate inhibition up to 
220 µM, and could indicate why 3FA and 4FA showed a significant decrease in their ability to cause 
substrate inhibition. Structures of Mtu-AnPRT with 4FA bound (both the 6 min and 6 s soaks) 
showed the 4FA compounds bound in the outer site with their amino groups oriented towards H183 
rather than N138, which effectively removes any hydrogen bonding interactions with N138, and thus 
the ability to effectively inhibit Mtu-AnPRT. It is possible that 3FA also binds with its amino group 
oriented towards H183, which would both cause steric clashes with H183 (Section 6.3) and remove 
any hydrogen bonding with N138. If correct, the extra steric hindrance caused by 3FA would explain 
the increase in the Ki value compared to 4FA.  
Mtu-P180A and Mtu-R194A also showed decreases in their ability to facilitate anthranilate 
inhibition, and several structures described in this research have demonstrated the involvement of 
P180 and R194 in binding anthranilate or its analogues in the outer site. These kinetic and structural 
observations further indicate the binding of anthranilate in the outer site as a key event in the 
inhibition of Mtu-AnPRT by anthranilate.  
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6.5 Effect of Mutations to Mtu-AnPRT 
The thermal stabilities of the Mtu-AnPRT variants Mtu-N138A, Mtu-P180A and Mtu-R194A were not 
significantly different to that of the wild-type enzyme. However, Mtu-R193A and Mtu-R193L both 
showed a dramatic increase in thermal stability of approximately 10 °C. Crystal structures of the 
Mtu-R193A enzyme all displayed a common structural feature whereby the β2-α6 loop was folded 
into the anthranilate channel, indicating a possible preference for this loop conformation in this 
variant. Structures of Mtu-R193L showed more variety in the position of the β2-α6 loop, which could 
be observed both in the ‘closed’ position or folded into the anthranilate channel depending on the 
ligands present in the crystal condition.  
A comparison of the Mtu-R193A and Mtu-R193L structures with the wild-type Mtu-AnPRT structure 
with 4FA (6 s soak) bound (which also shows the β2-α6 loop folded into the anthranilate channel) 
shows a slight difference in the β2-α6 loop position (Figure 6.8). This discrepancy is possibly due to 
the removal of the full R193 side-chain in Mtu-R193A and Mtu-R193L. The alternate β2-α6 loop 
positions observed in the Mtu-R193A and Mtu-R193L structures allow for a hydrogen bond between 
S143 and Y186, which is not present in the wild-type structure with 4FA bound. This extra hydrogen 
bond between S143 and Y186 may tether the β2-α6 loop in a thermodynamically favourable 
position, which could possibly result in an overall increase in the variants’ stability.  
 
 
 
 
 
 
Figure 6.8 Stereo diagram of β2-α6 loop folding into the anthranilate channel in wild-type Mtu-AnPRT, Mtu-
R193A and Mtu-R193L. Wild-type Mtu-AnPRT (cyan) with 4FA (6 s soak) (green) bound is overlaid with Mtu-
R193A (pink) with anthranilate (1 min 10 s soak) (magenta) bound and Mtu-R193L (purple) with PPi (orange) 
and Mg
2+
 (red spheres) bound (5 s anth soak). Polar contacts are shown as yellow dashes. 
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Mtu-G107P shows a decrease in thermal stability of 9 °C when compared to the wild-type Mtu-
AnPRT enzyme. The G107 residue is the first residue of the β1-α5 loop, located adjacent to the C-
terminus of the β1 strand. The introduction of a proline residue at this position near to the β1 
strand, which is approximately central to the seven-stranded β-sheet of Mtu-AnPRT (Figure 6.9), 
could create unfavourable electrostatic/steric interactions at the centre of the β-sheet that 
propagate outwards. If correct, the G107P mutation would cause a slight shift in the Mtu-AnPRT 
secondary structure, which could also explain the decrease in thermal stability of the Mtu-G107P 
variant.  
 
 
 
 
 
 
Figure 6.9 The position of residue 107 within Mtu-AnPRT. Mtu-AnPRT (green) with PRPP, Mg
2+
 and 4FA (not 
shown) bound (PDB ID: 4N5V) is shown with a proline residue (magenta) at position 107.  
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6.6 Drug Design and Future Work 
The structures of several variant and wild-type Mtu-AnPRTs have indicated that anthranilate binding 
precedes PRPP/Mg2+ binding (Section 4.7.2). If anthranilate is used as a template for drug design, 
there are several different approaches that could be used to block the biosynthesis of tryptophan 
using Mtu-AnPRT. Such tactics involve the design of drugs that will effectively bind to and 
subsequently block the active site/anthranilate channel of Mtu-AnPRT, as well as the catalysis of 
anthranilate-like compounds by Mtu-AnPRT to form prodrugs. Other avenues of drug design include 
transition state mimicry and allosteric inhibition. 
Crystal structures of wild-type and variant Mtu-AnPRTs with anthranilate-like inhibitors bound 
(Section 2.7/Section 5.3) have elucidated several key residues involved with inhibitor binding in the 
anthranilate channel: N138, P180, R193 and R194. Kinetic analysis of these inhibitors with the 
enzyme-coupled UV-based assay elucidated the ‘bi-anthranilate’-like inhibitor ACS172 as the most 
potent inhibitor, followed by ACS142. Further substitutions/additions of chemical groups to these 
inhibitors to enhance their potency would be a worthwhile investment, and is currently being 
investigated for ACS172 at the University of Auckland. A ‘tri-anthranilate’-like inhibitor is also under 
investigation, which could potentially bind to all three anthranilate binding sites within the 
anthranilate channel. 
The discovery of alternate anthranilate-like substrates for Mtu-AnPRT illuminates the possibility of a 
prodrug that could travel through the tryptophan biosynthetic pathway, creating tryptophan 
analogues that might conceivably be incorporated into protein synthesis within Mtu. With the 
exception of 3MA and orthanilate, this study has shown that Eco-PRAI:InGPS does have the ability to 
completely turn over both the fluoro- and methyl-substituted PRA products of the Mtu-AnPRT 
reaction. 4FA is the best example in this study of a potential prodrug, with KM and kcat values similar 
to that of the natural substrate anthranilate, a significantly higher Ki value, and the ability of its Mtu-
AnPRT product 4F-PRA to be turned over relatively quickly by Eco-PRAI:InGPS. Further investigation 
into alternate substitutions at this C4 position may yield even better candidates, which could then be 
tested in vivo against Mycobacterium smegmatis, for example, as a next step in prodrug 
development. Mycobacterium smegmatis is a relatively easy strain of mycobacteria to work with, as 
it grows faster than other strains, is non-pathogenic and has similar characteristics to Mtu.81 
Compounds that mimic the transition states of reacting substrates have also been shown to be 
potent inhibitors of enzymes.71, 82 Compounds mimicking the transition state of Mtu-AnPRT are likely 
to have a greater potency than those that imitate just one substrate, as they may resemble a species 
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that has a high affinity for the enzyme.77 Additionally, a greater number of contacts would be made 
to the enzyme both in the PRPP and inner site anthranilate binding sites. Regardless of the catalytic 
mechanism that Mtu-AnPRT utilises, it can be asserted that anthranilate approaches PRPP from the 
β position, which has been observed in several structures of wild-type and variant Mtu-AnPRT 
structures described in this thesis. A transition state mimic compound could therefore be based on 
the basic template outlined in Figure 6.10.  Kinetic isotope effect studies of the Mtu-AnPRT reaction 
could lead to a more accurate prediction of the transition state of this enzyme, and thus to the 
design of more potent drug compounds. However, measurements of the kinetic isotope effects may 
be difficult to obtain due to the instabilities of the PRPP and PRA molecules. 
 
 
 
 
Figure 6.10 A potential transition state analogue of Mtu-AnPRT, which would act as a template for further drug 
design. Dashed lines indicate linker regions. 
 
Allosteric inhibition of Mtu-AnPRT by tryptophan has not been examined, however, there is some 
evidence within the literature that this occurs with other AnPRT orthologues.66b, 68, 83 The AnPRT 
enzyme in Salmonella typhimurium is covalently linked to the preceding AS enzyme in the 
tryptophan pathway, due to gene fusion. Experiments to disrupt this covalent linkage were 
successful, and the AS-linked and separate AnPRT enzymes were tested for tryptophan inhibition 
and compared. Both forms of AnPRT showed inhibition by tryptophan, though the AS-linked form 
was more significantly inhibited than the separate form.83a It is possible that the mode of tryptophan 
inhibition is allosteric, as structures of Mtu-AnPRT have been shown to bind benzamidine in a 
location removed from the active site near the hinge region of the protein. Tryptophan could 
conceivably bind in this hinge region and disrupt the Mtu-AnPRT dynamics, which may also hinder 
the enzyme catalysis. Further studies would need to be conducted in this area to confirm tryptophan 
inhibition of Mtu-AnPRT. If Mtu-AnPRT is allosterically inhibited by tryptophan, compounds similar in 
structure to this aromatic amino acid could be used as allosteric site drug compounds.  
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6.7 Concluding Remarks 
Discovering novel drugs that will successfully target Mycobacterium tuberculosis is becoming ever 
more crucial as drug-resistant strains emerge, with the constant concern of a completely drug-
resistant ‘superbug’ looming on the horizon. Knowledge of the active site mechanisms of enzymes 
proved necessary to Mtu virulence is a key ingredient in further drug-discovery for tuberculosis, as 
essential protein-substrate interactions can be identified and replicated in the synthesis of potential 
inhibitor compounds. This thesis has provided considerable insight into the active site mechanism of 
Mtu-AnPRT, and highlights significant features of the enzyme that have assisted in the conception of 
several potential drug design strategies. 
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Chapter 7 
 
 
Methods and Materials 
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7.1 General Methods 
7.1.1 Water 
All water used in these experiments was from a Millipore Milli-Q system. This water is referred to as 
Milli-Q water. All water used for PCRs and crystal formation was autoclaved prior to use. 
7.1.2 pH Measurements 
pH solutions were measured using a Denver Instruments UB-10 Ultra-Basic pH meter, with a 
standard probe. Solutions were made more acidic by addition of 1 M or 10 M HCl and basic by 
addition of either 1 M or 10 M NaOH. 
7.1.3 Plasmids 
M. tuberculosis genomic DNA containing the ORF that encodes the TrpD gene (Rv2192c) was 
previously amplified by PCR, and subsequently cloned into the pET-23a(+) vector. E. coli genomic 
DNA containing the ORF that encodes the TrpFC gene was also previously amplified by PCR, and 
cloned into both pProEX-HTb and pET-42a(+)rTEV vectors.56 The pET-23a (+) vector is a 3666 bp 
cloning vector containing a T7/lac promoter for E. coli expression under high lactose conditions, and 
introduces a non-cleavable C-terminal His-tag. pProEX-HTb is a 4779 bp cloning vector containing a 
T7/lac promoter, a cleavable N-terminal His-tag, and an rTEV site which can be recognised by TEV 
protease for selective His-tag cleavage. The pET-42a(+)rTEV 5930 bp cloning vector contains a T7/lac 
promoter, an rTEV site, and introduces an N-terminal GST-tag, two N-terminal His-tags and an S-tag. 
All three plasmids have an ampicillin resistance gene included to allow for selective growth of cells 
containing these plasmids when ampicillin is present. 
7.1.4 Antibiotics 
Ampicillin was added to all growth media to a final concentration of 0.1 mg/mL. Stock solutions of 
ampicillin at 100 mg/mL dissolved in Milli-Q were created, filter sterilised and stored at -80 °C, and 
freeze-thawed a maximum of two times. The chaperone 3 cell line used contains resistance to 
chloramphenicol and spectinomycin. When this cell line was used, these antibiotics were added to 
all growth media in addition to ampicillin, to a final concentration of 25 µg/mL for chloramphenicol 
and 0.1 mg/mL for spectinomycin. Stock solutions of chloramphenicol at 25 mg/mL dissolved in 
ethanol and spectinomycin at 10 mg/mL dissolved in Milli-Q were created, filter sterilised and stored 
at -80 °C, and freeze-thawed a maximum of two times. 
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7.1.5 Cell Lines 
The cell lines used for plasmid propagation were either E. coli XL1-Blue or TOP10 (Invitrogen). For 
protein expression E.coli BL21 (DE3) cells or E. coli BL21 (DE3) cells containing the plasmids pBB528 
and pBB541for co-expression of the chaperonins GroEL and GroES were used. 
7.1.6 Preparation of Chemically Competent Cells 
Chemically competent cells were prepared using the method of Hanahan84. An overnight culture of 
the cells to be made competent was grown in the presence of the appropriate antibiotic(s). The 
following day lysogeny broth (LB) medium with the appropriate antibiotic was inoculated with one 
hundredth the volume of the overnight culture. Cells were grown at 37 °C until reaching an OD600 of 
0.3 AU to 0.6 AU. The culture medium was then incubated on ice for 10 - 15 min, before being 
harvested by centrifugation for 15 min at 4 000 rpm and 4 °C, in a pre-chilled centrifuge and rotor. 
The pellet was then resuspended in 18 mL of RF1 solution and incubated on ice for 30 min. The cells 
were then harvested again by the same centrifugation method, and resuspended in 4 mL of RF2 
solution. Suspended cells were then split into 50 µL to 100 µL aliquots, flash-frozen in liquid nitrogen 
and stored at -80 °C. 
RF1 solution: 100 mM RbCl2, 50 mM MnCl2, 30 mM KOAc, 10 mM CaCl2, pH 5.8 (adjusted using 
concentrated acetic acid). 
RF2 solution: 10 mM RbCl2, 10 mM MOPS, 75 mM CaCl2 · 6H2O, 15% (v/v) glycerol, pH 5.8 (adjusted 
using NaOH). 
The RF1 and RF2 solutions were filter-sterilised (0.2 µm) rather than autoclaved to avoid formation 
of a Rb precipitate, and stored at 4 °C. 
7.1.7 Transformation 
Chemically competent cells (100 µL to 200 µL aliquots) were thawed on ice before addition of 2 μL of 
either PCR product or purified plasmid. The mixture was left on ice for 30 min then placed in a 42 °C 
water bath for 30 s to 45 s before being placed on ice again for 2 min. Cells were then outgrown for 
1 hr at 37 °C while shaking after addition of  250 µL super optimal broth (SOC) or LB medium. A 
portion (50 µL to 200 µL) of the transformed cells was spread directly onto an LB-agar plate 
containing the appropriate antibiotic(s) and left to grow on the inverted medium overnight at 37 °C. 
SOC medium: 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgSO4, 
20 mM glucose. Filter sterilised in aliquots. 
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7.1.8 Glycerol Stocks 
In order to keep cells viable, all strains of E. coli cells containing plasmids were flash frozen and 
stored at -80 °C as glycerol stocks. Glycerol stocks were created by adding 400 µL of 50% (v/v) 
glycerol with 800 µL of an overnight culture in either a 1.6 mL eppendorf or screw-top tube. 
7.1.9 Culture Media 
LB-agar was prepared by dissolving LB (Lennox L) (20 g L−1) and agar (15 g L−1) base in Milli-Q water 
and sterilised by autoclaving. The LB-agar solution was then heated in a microwave oven until 
boiling, and left to cool in a 60 °C oven. The LB-agar solution was then further cooled to 50 °C before 
antibiotic(s) were added immediately prior to pouring into round petri dishes. 
LB media for plasmid extraction and pre-cultures were prepared by dissolving 20 g L−1 LB (Lennox L) 
base in Milli-Q water and sterilised by autoclaving. Antibiotic(s) were added immediately prior to 
use. 
7.1.10 Plasmid Extraction and Purification 
Plasmids were extracted using a High Pure Plasmid Isolation Kit (Roche). Small cultures (5 mL) of 
plasmid-containing cells were grown overnight with the appropriate antibiotic(s). The cultures were 
harvested the following morning and plasmids extracted and purified as per the kit instructions. The 
concentration of purified plasmid was measured by absorption at 260 nm using an appropriately 
blanked Nanodrop ND-1000 spectrophotometer. 
7.1.11 Protein Expression Cultures 
Autoinduction of protein expression was used for larger cultures, based on the methods of Studier.85 
For 1 L of culture, 10 g tryptone and 5 g yeast extract in 960 mL of water was autoclaved in a 2 L to 3 
L baffled conical flask. Added to this was 20 mL of a 50 x 5052 stock solution, 20 mL of a 50 x M stock 
solution, 1 mL of 1 M MgSO4, 0.2 mL of a trace metal solution, and the appropriate antibiotic(s). The 
complete medium was then inoculated with 10 mL of an overnight pre-culture and placed in a 
shaking incubator (170 rpm to 180 rpm) for 4 hrs at 37 °C before being transferred to 20 °C for 20 - 
36 hrs. The amounts and volumes were appropriately scaled depending on the culture volume. 
50 x 5052 stock: 25% (w/v) glycerol, 2.5% (w/v) glucose, and 10% (w/v) lactose. Filter sterilised (0.2 
μm). 
50 x M stock: 500 mL, 1.25 M Na2HPO4, 1.25 M KH2PO4, 2.5 M NH4Cl, 0.25 M Na2SO4. Autoclaved. 
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Trace metal solution: 50 mM FeCl3, 20 mM CaCl2, 10 mM MnCl2/ZnSO4, 2 mM CoCl2, CuCl2, NiCl2, 
NaMoO4, Na2SeO3 and H3Bo3 in 60 mM HCl. 
7.1.12 Cell Harvesting 
The method used to harvest cells from cultures used for protein expression varied depending on 
rotor and centrifuge availability. Typically, large cultures were harvested in 0.8 L or 1 L bottles at 14 
000 g for 30 min at 4 °C. The supernatant liquid was removed and pellets were then transferred to 
50 mL centrifuge tubes and stored at -80 °C. Alternatively, cultures were sometimes progressively 
harvested in 50 mL centrifuge tubes at 12 000 g for 10 min at 4 °C, or in 0.4 L buckets at 4 618 g for 
40 min at 4 °C before being transferred to 50 mL centrifuge tubes and stored at -80 °C. Small volume 
cultures (5 mL) were progressively harvested in 1.6 mL micro-centrifuge tubes at 17 000 g for 3 min. 
7.1.13 Cell Lysis 
Cells were lysed by one of two methods. The first method using sonication was performed with an 
Omni-Ruptor 4000 Ultrasonic Homogenizer (Omni International). Cell pellets were resuspended in 
chilled lysis buffer (typically 50 mL to 100 mL) on ice, and sonicated in a beaker surrounded by 
packed ice by one of two sonication protocols. Cells were sonicated at 70 – 80% power either for 6 - 
8 multiples of 10 s with 1 min pauses between bursts, or by 30 ms pulses for 25 - 35 min with 70 – 
80% pulsation.   
The second method utilised a Microfluidics Lab Homogeniser M-110P, and was performed by 
resuspending the cell pellet as mentioned above and passing cells through the homogeniser twice to 
ensure complete lysis. The lysis buffer for Mtu-AnPRT and Eco-PRAI:InGPS was either  50 mM 
Tris.HCl pH 8.0, 200 mM NaCl and 25 mM imidazole, or 20 mM Na2SO4, pH 8.0 for CD analysis. 
Cellular debris were removed by centrifugation either at 12 000 g or 19 500 g for 30 min at 4 °C 
depending on rotor and centrifuge availability. 
7.1.14 Protein Purification 
All proteins were purified by a two- or three- step procedure composed of IMAC chromatography 
followed by desalting, with an additional SEC chromatography step depending on protein purity. The 
chromatography was performed on Bio-Rad Biologic DuoFlow and GE Healthcare ÄKTApurifier™ 10 
machines. 
Before use, all buffers were filtered (0.2 μm) under vacuum. Samples were all likewise filtered 
before being loaded on either a 50 mL or 200 mL Superloop™ (GE Healthcare). The eluate was 
fractionated in 2 mL fractions collected in 96-well plates. On ÄKTApurifier™ 10 machines, the eluate 
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from injection of the sample onto the column (flow-through) was collected in 50 mL centrifuge 
tubes. Elution from the columns was monitored principally at 280 nm, and depending on the 
machine being used, also at 260nm and 214 nm. When the fractions corresponding to Mtu-
AnPRT/Eco-PRAI:InGPS could not be deduced from the chromatogram, suspected 
AnPRT/PRAI:InGPS-containing fractions were analysed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and/or for AnPRT/PRAI:InGPS activity. Fractions containing 
AnPRT/PRAI:InGPS were then pooled and prepared for the next chromatographic step. 
7.1.15 Immobilized Metal Affinity Chromatography (IMAC) 
IMAC was performed using a precharged Ni Sepharose™ High Performance resin packed in a 
HisTrap™ HP column (GE Healthcare), normally at 4 °C. The supernatant liquid (resulting from 
removal of the cellular debris by centrifugation after cell lysis) was passed onto the column in lysis 
buffer, and elution from the column was performed using a gradient of increasing imidazole 
concentration (linear) from 25mM to 200 mM over 50 mL at a flow rate of 2 - 3 mL min−1. 
7.1.16 Desalting  
Fractions of interest containing high concentrations of imidazole were desalted prior to storage. 
Desalting was performed using a HiPrep 26/10 Desalting column prepacked with Sephadex G-25 Fine 
(GE Healthcare), usually at 4 °C in either low imidazole buffer or crystal buffer (50 mM Tris.HCl, 150 
mM NaCl, 5% glycerol) depending on the future use of the protein. The elution flow rate was 2 - 5 
mL min−1. 
7.1.17 Size Exclusion Chromatography (SEC) 
Fractions containing Mtu-AnPRT/Eco-PRAI:InGPS from either IMAC or desalting were pooled and 
loaded into a loop. SEC was performed using a HiLoad™ 26/60 Superdex™ 200 prep grade column 
(GE Healthcare), usually at 4 °C in either low imidazole buffer or crystal buffer depending on the 
future use of the protein. The elution flow rate was 0.5 - 1 mL min−1. 
7.1.18 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE was performed using pre-cast gels using NuPAGE® 10% Bis-Tris Gel 1.0mm × 12-well pre-
cast gels (Invitrogen) in NuPAGE® MOPS SDS Running Buffer (Invitrogen). Electrophoresis was 
performed using a XCell SureLock™ Electrophoresis Cell (Invitrogen), at 200 V for 50 min. Samples 
were mixed with NuPAGE® LDS Sample Buffer (4×) and DTT, and  boiled before loading.  
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7.1.19 Visualisation 
All SDS-PAGE gels were stained in square petri dishes by coomassie brilliant blue R-250, for at least 1 
hour before being destained to remove excess dye.  
Stain: 0.1% (w/v) coomassie brilliant blue R-250, 10% (v/v) acetic acid and 40% (v/v) methanol 
Destain: 10% (v/v) acetic acid and 40% (v/v) methanol 
Molecular weight standards (Novex® Sharp Pre-Stained Protein Standards (Invitrogen)) were run as 
the sample in one lane of each gel. Photographs of gels were taken on a white light transilluminator 
in a Molecular Imager® Gel Doc™ XR (Bio-Rad). 
7.1.20 Concentrating and Buffer Exchanging of Protein Solutions 
Protein solutions were concentrated using 10 000 Da molecular weight cut-off (MWCO) devices 
(Vivaspin 2 (GE Healthcare), Vivaspin 500 and Vivaspin 20 (Sartorius Stedim Biotech) and Amicon® 
Ultra-4 (Millipore)). All filtration units were rinsed before use with Milli-Q water. Protein solutions 
were buffer exchanged by repeatedly concentrating in a MWCO device and diluting with desired 
buffer. 
7.1.21 Enzyme Storage 
Purified protein was divided into aliquots in either 0.6 mL or 1.2 mL micro-centrifuge tubes in 0.2 mL 
to 1.2 mL aliquots, flash-frozen in liquid nitrogen, and stored at -80 °C. All protein samples were 
rapidly thawed immediately before use and kept on ice. Protein solutions were stored at 0.5 mg mL−1 
to 10 mg mL−1. 
7.1.22 Protein Concentration Determination 
Protein concentrations were measured by their absorbance at 280nm by an appropriately blanked 
Nanodrop ND-1000 spectrophotometer, using 2 μL samples of purified protein solution. The 
concentration was calculated from the absorption using molar extinction coefficient values of 34 615 
M−1 cm−1 and 40 715 M−1 cm−1 for Mtu-AnPRT and Eco-PRAI:InGPS respectively. The coefficient 
values, calculated from protein sequences using the ProtParam tool on the ExPASy Proteomics 
Server,62 were the same for both wild-type and mutant proteins. 
7.1.23 Agarose Gel Electrophoresis 
Separation of DNA was performed by agarose gel electrophoresis, using either 1% (w/v) agarose gels 
or pre-cast E-Gel® 1.2% (w/v) agarose gels (Invitrogen). DNA was stained for both self-poured and 
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pre-cast gels by inclusion of SYBR® Safe DNA stain. Agarose gels were created by dissolving 1% (w/v) 
agarose in 40 mL of Tris-acetate-EDTA (TAE) buffer and heating in a microwave oven until the 
agarose was dissolved. The hot agarose solution was left to cool in a 60 °C oven. Immediately before 
pouring, 4 µL SYBR® Safe DNA stain was added. Samples were mixed with a (6×) sample loading dye. 
Electrophoresis was performed for 45 min at 85 V in TAE buffer using a Mini-Sub® Cell GT (Bio-Rad). 
TAE buffer: 50 mM Tris, 1 mM EDTA, 20 mM acetic acid 
Sample loading dye (6×): 60 mM Tris-HCl, 60 mM EDTA, 0.2% (w/v) orange G, 0.05% (w/v) xylene 
cyanol ff, 60% (v/v) glycerol 
The E-Gel® agarose gels were used according to the manufacturer’s instructions. Samples were 
loaded without a sample loading dye directly into the wells, and separation could be monitored in 
real-time during electrophoresis using the E-Gel® iBase™ Safe Imager™ systems at 480 nm. 
Typically 20 μL from 50 μL PCR reactions were loaded onto the agarose gels for visualisation of 
amplification products. To one well of each agarose gel, 2 μL of DNA ladder (1 kb Plus DNA Ladder 
(Invitrogen)) was used to estimate DNA size. Stained DNA was visualised and photographed under 
UV (302 nm) using a Molecular Imager® Gel Doc™ XR (Bio-Rad). 
7.1.24 Enzyme-Coupled Activity Assay 
All kinetic measurements were made using a Varian Cary 100 UV-visible spectrophotometer, 
stoppered 1 cm pathlength quartz cuvettes and a total assay volume of 1 mL. All assay solutions 
were equilibrated to 25 °C and baseline absorbance before initialisation with either Mtu-AnPRT or 
anthranilate. Standard reaction mixtures contained 50 mM Tris.HCl pH 8.0, 200 mM NaCl, 1 mM 
MgCl2 (except when testing the effect of Mg
2+ concentration), and a variable concentration of 
anthranilate, PRPP, Mtu-AnPRT, Eco-PRAI:InGPS and inhibitors (when tested). Assay buffers were 
treated with Chelex® 100 resin (Bio-Rad) prior to use to remove metal ions, and Chelex-treated 
buffer solution was used to create concentrated stock solutions of PRPP and anthranilate. MgCl2 
solutions were created using either Chelex-treated buffer or Milli-Q water.  
Initial rates of reaction were measured as a least-squares fit of the initial rate data using Cary WinUV 
Kinetics Application (version 3.00, Varian). A unit of enzyme activity was defined as the formation of 
1 μmol min−1 of InGP at 25 °C, and could be calculated from the measured gain of absorbance (at 
270 nm) using Beer’s Law (ε is 7500 L mol−1 cm−1). The values of the kinetic parameters were 
determined by fitting data to the Michaelis-Menten equation  using the software GraFit 
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567 (Erithacus Software Limited). For determination of the Mtu-AnPRT mechanism, data were fitted 
to the ternary mechanism equation: . Substrate inhibition data were 
fitted to the substrate inhibition equation: . For determination of Ki values, data 
were fitted to four inhibition equations: competitive: , pure non-competitive: 
, uncompetitive:  and mixed: . A statistical 
F-test was performed on data fitted to each inhibition equation using Grafit 567 and the χ2 values 
compared for selection of the best fit equation. 
7.1.25 Determination of Substrate Concentrations 
The concentrations of natural substrate solutions (PRPP and anthranilate) were determined using 
the enzyme-coupled assay system. The concentration of the substrate not being measured was used 
in excess and the substrate for which the concentration was being measured was used at a limiting 
concentration. That the correct substrate was limiting was checked by addition of more of it after 
the reaction had reached completion. The change in absorbance, between that before initiation of 
the reaction and that at completion, was measured as ΔA1. A control reaction, absent in one of the 
substrates, was used to measure the change in absorbance due to the addition of enzyme to the 
cuvette at initiation of the reaction (ΔA2). The total change in absorbance (ΔA1 + ΔA2), was converted 
using Beer’s Law to a concentration of the limiting substrate in the cuvette, and the stock substrate 
concentration calculated. 
7.1.26 Pyrophosphate Activity Assay 
All kinetic measurements were made using a Varian Cary 100 UV-visible spectrophotometer, 
stoppered 1 cm pathlength quartz cuvettes and a total assay volume of 1 mL. All assay solutions 
were equilibrated to 22 °C and baseline absorbance before initialisation with anthranilate. Standard 
reaction mixtures contained MESG (200 µM), PNP (1 U), inorganic pyrophosphatase (0.03 U) 50 µL of 
20X reaction buffer (1 M Tris.HCl, 20 mM MgCl2, pH 7.5, containing 2 mM sodium azide) from the 
commercially available EnzChek® Pyrophosphate Assay Kit E-6645 (Invitrogen™) as well as PRPP (120 
µM), MgCl2 (1 mM) and varying concentrations of anthranilate or anthranilate analogues, Mtu-
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AnPRT and Eco-PRAI:InGPS. Solutions were made up to 1 mL total volume with autoclaved Milli-Q 
water.  
Initial rates of reaction were measured as a least-squares fit of the initial rate data using the Cary 
WinUV Kinetics Application (version 3.00, Varian). A unit of enzyme activity was defined as the 
formation of 1 μmol min−1 of 2-amino-6-mercapto-7-methylpurine at 22 °C, and could be calculated 
from the measured gain of absorbance (at 360 nm) using Beer’s Law (ε is 26 200 L mol−1 cm−1). The 
values of the kinetic parameters were determined by fitting data to the Michaelis-Menten equation 
 using the software GraFit 567 (Erithacus Software Limited). Substrate inhibition data 
were fitted to the substrate inhibition equation . 
7.1.27 Mass Spectrometry for Determination of Protein Mass 
The masses of purified proteins were measured by Bruker maXis 3G UHF-TOF tandem mass 
spectrometer. Proteins were either buffer exchanged into 5 mM ammonium bicarbonate, or were 
diluted from stored concentrations to 1 mg mL−1 with water. 
7.1.28 Differential Scanning Fluorimetry (DSF) 
Melt temperatures of the proteins were determined both with and without the presence of different 
additives by DSF, using an iCycler iQ5 Multicolour Real-Time PCR Detection System (Bio-Rad). The 
method used was based on that of Ericsson et al.64 Triplicate protein samples were added with 
mixing to buffer (potentially containing additives) and SYPRO orange dye (Invitrogen) in a 96-well 
microplate (vide infra), which was then sealed. The melt proceeded in 0.2 °C increments from 20 - 95 
°C, with a 20 s dwell time after each temperature rise. Measurements of the fluorescence were 
made at the end of each dwell time. 
For each sample (three replicates and blank) 100 μL of buffer (50 mM Tris.HCl pH 8.0, 200 mM NaCl) 
including any additive(s) was prepared, to which 5 μL of 250x SYPRO orange dye was added 
(condition solution). In the blank well for the sample, 21 μL of the condition solution was added to 4 
μL of water. Then, 16 μL of protein (at 1 mg mL−1) was added to the remaining condition solution 
before 25 μL was dispensed into three replicate wells. Additives used in experiments were as 
follows: PRPP (0.6 mM) Mg2+ (1 mM) or anthranilate (15 μM, 100 μM, 1 mM or 5 mM). 
 For analysis an Excel spreadsheet with custom VBA-scripted macro was created by Dr Timothy 
Allison to toggle and dynamically display melt and derivative curves for each sample. The melt 
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temperatures were calculated as the temperature of maximum inflection of the melting curve after 
subtracting the reading of a blank well containing buffer and dye but lacking protein. 
7.1.29 Circular Dichroism (CD) 
CD experiments were performed using a JASCO J-815 Spectropolarimeter. All CD spectra were 
recorded from 260 nm to 195 nm using a 0.5 nm data pitch, 1 s response, 1 nm bandwidth at 25 °C. 
A 3 mL protein solution at a concentration of 0.03 mg mL−1 in a 3 mL quartz cuvette with 1 cm path 
length was used for each measurement. The buffer for all experiments was 20 mM sodium 
phosphate pH 8.0. Blank spectra were recorded of buffer alone for each experiment before addition 
of protein. Data were smoothed using the Savitzky-Golay algorithm of the Jasco Spectra Manager™ 
(version 1.5) with a convolution width of 15. 
7.1.30 Crystallisation of Variant Mtu-AnPRT 
Crystals of variant Mtu-AnPRTs were grown by hanging-drop vapour diffusion in 24-well VDX plates 
(Hampton Research). Protein solutions (3 mg mL−1 to 7 mg mL−1), in 50 mM Tris.HCl (pH 8.0), 150 
mM NaCL and 5% glycerol (v/v)) were mixed 1:1 (v/v) with a reservoir solution containing 200 mM 
sodium imidazole malate (pH 6.5 – 8.0), 5% - 15% PEG-4000, and Milli-Q. The additives (PRPP, MgCl2, 
anthranilate, ACS172 and ACS142) were all present at a concentration of 10 mM unless otherwise 
stated. All additives were co-crystallised with Mtu-AnPRT with the exception of anthranilate, which 
was soaked into the crystal in the presence of 26% glycerol and the crystal’s mother liquor. Droplets 
were seeded with wild-type Mtu-AnPRT crystals using a cat whisker. Droplet sizes were 2 μL, and the 
reservoir solution volume 500 μL. Unless otherwise stated, the crystallisation trays were left at 20 °C 
until immediately before data collection, with crystals being transferred briefly into a cryoprotectant 
composed of 26% glycerol in the respective reservoir solution. Crystals typically began to form after 
4 h and were fully formed in 24 h. 
7.1.31 X-Ray Data Collection and Data Processing 
X-Ray diffraction data were collected at the Australian Synchrotron. Protein was transported frozen 
to Melbourne the day before collection.  Crystals were mounted on loops, flash-frozen in liquid 
nitrogen and placed in a sample storage cassette (Crystal Positioning Systems), which was stored in a 
dry shipper (Taylor-Wharton CX100) and transported as checked-in luggage. Data collection at the 
Australian Synchrotron used either the Macromolecular Crystallography (MX1) or Micro 
Crystallography (MX2) beamlines86 and were processed using XDS,87 iMosflm,88 Scala or Aimless 
(CCP4 suite89). Resolution cutoffs were determined based on a CC½ value of > 0.5.90 
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7.1.32 Structure Determination and Refinement 
Structures of Mtu-AnPRT variant proteins were solved by molecular replacement using PhaserMR 
(CCP4 suite), using chain A of the structure of wild-type Mtu-AnPRT (PDB ID: 3QR9) as a starting 
model (with all non-protein molecules removed) and performing ten rounds of rigid-body 
refinement using Refmac5.91 Each structure had the same set of reflections for calculation of Rfree as 
the starting model 3QR9, and these were carried through the refinement process for each structure. 
Further refinements were conducted with Refmac5,91 and electron-density maps were analysed with 
Coot.92 The validation tools of Coot and MolProbity93 were used to check for, and correct, 
conformation infelicities. 
In the refinement of ligand-bound structures, the model of the protein in the absence of any ligands 
was refined and rebuilt until the model was in close agreement with the electron density map. At 
this stage, waters and ligands other than the ligands of interest (eg. glycerol) were added to the 
model, except for the regions of the structure where the electron density suggested the presence of 
the ligands of interest. Waters were added into appropriate electron density if the water would have 
at least one hydrogen bond to the protein. Waters in secondary and higher shells were only added if 
the position of the water molecule allowed the establishment of an uninterrupted chain of 
interactions to a protein atom. Solvent ligands (eg. glycerol) were modelled into appropriate density 
and their occupancy refined by inspection of electron density maps after refinement.  
 
After the model and electron density was judged in good agreement in all regions apart from the 
ligand binding site(s) of interest, the electron density in the ligand binding site(s) was examined. If 
appropriate electron density was present, the ligand(s) of interest and water molecules were added 
to the model and the final rounds of refinement carried out. Ligand restraints were generated by 
using the PRODRG server.94 The occupancies of ligands of interest were refined by inspection of the 
electron density maps after refinement. The 2Fo−Fc omit maps shown in figures were generated 
using the program FFT (CCP4 suite) before addition of the ligands to the model. 
7.2 Methods in Chapter 2 
7.2.1 Kinetics 
The assays for determining the kinetic parameters kept the concentration of one substrate constant 
while varying that of the other and vice versa. The concentration of Mtu-AnPRT used in each assay 
ranged from 0.1 – 0.3 µM in the cuvette depending on the experiment. Eco-PRAI:InGPS was always 
held at a concentration with a minimum 10-fold excess compared to Mtu-AnPRT, and ranged from 3 
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– 6 µM in the cuvette. To determine the kinetic parameters for wild-type Mtu-AnPRT, the following 
concentrations of substrates and metal were used in the enzyme-coupled assay: MgCl2 (1 mM), PRPP 
(either held at 0.6 mM for determination of anthranilate parameters, or varied from 0 – 320 µM) 
and anthranilate (either held at 15 µM for determination of PRPP parameters, or varied from 0 – 11 
µM). 
For determination of Mg2+ inhibition, all other components were held at the concentrations 
mentioned in the above paragraph, with a range of 0 – 12 mM for MgCl2. For determination of 
anthranilate inhibition, all other components were held at the concentrations mentioned in the 
above paragraph, with a range of 0 – 100 µM for anthranilate. For determination of the Mtu-AnPRT 
mechanism, all components were held at the concentrations mentioned in the above paragraph, 
except for anthranilate and PRPP which varied from 0 – 20 µM and 0 – 62.5 µM respectively. 
Ki values of inhibitors thought to compete with anthranilate were determined using the enzyme-
coupled assay, with PRPP held at a saturating concentration of 0.6 mM, MgCl2 at 1 mM, Mtu-AnPRT  
ranging from 0.1 – 0.3 µM, and Eco-PRAI:InGPS ranging from 3 – 6 µM. The inhibitor ACS172 was 
tested from 0 – 8 µM, with an anthranilate range of 0 – 12 µM. The inhibitor ACS142 was tested 
from 0 – 20 µM, with an anthranilate range of 0 – 12 µM. The inhibitor ACS145 was tested from 0 – 
90 µM, with an anthranilate range of 0 – 6 µM. The inhibitor ACS174 was tested from 0 – 13 µM, 
with an anthranilate range of 0 – 7.5 µM. The inhibitor ACS10 was tested from 0 – 60 µM, with an 
anthranilate range of 0 – 5.5 µM. The inhibitor ACS126 was tested from 0 – 104 µM, with an 
anthranilate range of 0 – 5.5 µM. The inhibitor ACS165 was tested from 0 – 43.8 µM, with an 
anthranilate range of 0 – 5.5 µM. The inhibitor ACS179 was tested from 0 – 14.4 µM, with an 
anthranilate range of 0 – 7.5 µM.  
Ki values of inhibitors thought to compete with PRPP were determined using the enzyme-coupled 
assay, with anthranilate held at a saturating concentration of 15 µM, MgCl2 at 1 mM, Mtu-AnPRT  
ranging from 0.1 – 0.3 µM, and Eco-PRAI:InGPS ranging from 3 – 6 µM. The inhibitor R5P was tested 
from 0 – 240 µM, with a PRPP range of 0 – 25 mM.  
7.3 Methods in Chapter 3 
7.3.1 Kinetics – PPi Assay 
The final concentrations of the following components were included in the PPi assay and held at 
these concentrations: PRPP (120 µM), MgCl2 (1 mM), Mtu-AnPRT (0.1 – 0.3 µM), Eco-PRAI-InGPS (3 - 
6 µM), MESG (200 µM), PNP (1 U), inorganic pyrophosphatase (0.03 U), 50 µL of 20X reaction buffer 
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(1 M Tris-HCl, 20 mM MgCl2, pH 7.5, containing 2 mM sodium azide) and sterile Milli Q water to 1 
mL. Anthranilate was tested from 0 – 16 µM. 3FA was tested from 0 – 400 µM. 4FA was tested from 
0 – 16 µM. 5FA was tested from 0 – 20 µM. 6FA was tested from 0 – 10 µM. 3MA was tested from 0 
– 500 µM. 4MA was tested from 0 – 660 µM. 5MA was tested from 0 – 840 µM. 6MA was tested 
from 0 – 700 µM. ACS130 was tested from 0 – 250 µM.  
Ki values of anthranilate analogues were obtained using the PPi assay and contained the same 
components at the same concentrations as mentioned in the above paragraph. Anthranilate was 
tested from 0 – 100 µM. 3FA was tested from 0 – 700 µM. 4FA was tested from 0 – 100 µM. 5FA was 
tested from 0 – 100 µM. 6FA was tested from 0 – 60 µM.  
7.3.2 Mass Spectrometry - Anomerisation 
Solutions for determination of the mode of anomerization of PRA via mass spectroscopy contained 2 
mM PRPP, 2 mM anthranilate, 1 mM MgCl2, and 20 mM NaCNBH3 made up to 2 mL with Tris.HCl 
buffer (50 mM Tris.HCl, 150 mM NaCl; pH 8.0). Solutions were mixed by inversion and 0.2 µM Mtu-
AnPRT added. After 5 mins reaction time, solutions were spun through Vivaspin 10 000 MWCO 
concentrators to remove the enzyme present, flash frozen with liquid nitrogen, and left to freeze dry 
(FreeZone 2.5, Labconco) for 4 - 5 days. Dried products were then resuspended in Milli Q and 
analysed via Ultra High Resolution Time Of Flight (UHR-TOF) tandem mass spectrometry (Bruker 
maXis 3G). 
7.3.3 Kinetics – Enzyme Coupled Assay 
To detect turnover of anthranilate analogues by both Mtu-AnPRT and Eco-PRAI:InGPS, the enzyme-
coupled assay was utilised. The following compounds were included in the assay: MgCl2 (1 mM), 
PRPP (0.6 mM), Mtu-AnPRT (0.1 µM), anthranilate/analogue (200 µM) and Eco-PRAI:InGPS (4 – 8 
µM). 
Solutions for wavelength scan analysis of fluoro-/anthranilate contained 1 mM MgCl2, 0.1 µM Mtu-
AnPRT, 1.7 µM Eco-PRAI:InGPS, 0.6 mM PRPP and 100 µM fluoro-/anthranilate. Solutions for 
wavelength scan analysis of methyl-anthranilate contained 1 mM MgCl2, 30 µM Mtu-AnPRT, 150 µM 
Eco-PRAI:InGPS, 0.6 mM PRPP and 0.5 mM methyl-anthranilate. Reactions were scanned from 360 - 
220 nm with a cycle length time of 2.5 mins. Solutions were thermally equilibrated for 5 min prior to 
initiation with alternate substrate and either allowed to go to completion or to a maximum of 50 
cycles. 
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7.3.4 Mass Spectrometry – Eco-PRAI:InGPS Turnover 
Solutions for analysis of Mtu-AnPRT/Eco-PRAI:InGPS reaction products contained 1.2 mM PRPP, 400 
µM fluoro-/anthranilate or 2 mM methyl-anthranilate, 2 mM MgCl2, 0.6 µM Mtu-AnPRT, 6 µM Eco-
PRAI:InGPS made up to 500 µL with H2O for fluoro-/anthranilate or 5 mM NH4HCO3 for methyl-
anthranilate. Reactions for fluoro-/anthranilate were initiated with Mtu-AnPRT immediately prior to 
analysis via mass spectrometry, whereas reactions for methyl-anthranilate were incubated with all 
substituents present for 1 hr prior to analysis. 
7.4 Methods in Chapter 4 
7.4.1 Primer Design 
Primers for the mutations described in Section 4.3 were designed using the web-based QuikChange 
Primer Design tool by Agilent Technologies95 and were ordered from Invitrogen™.  
R193A Forward Primer  5’ CACGCGGCCGCGGTAGCCCGCGAGATC 3’ 
R193A Reverse Primer  5’ GATCTCGCGGGCTACCGCGGCCGCGTG 3’ 
N138A Forward Primer  5’ GGTCAAGCACGGCGCCCGAGCGGCGTCC 3’ 
N138A Reverse Primer  5’ GGACGCCGCTCGGGCGCCGTGCTTGACC 3’ 
G107P Forward Primer  5’ CGTCGACGTCGTCCCCACCGGTGGCGAC 3’ 
G107P Reverse Primer  5’ GTCGCCACCGGTGGGGACGACGTCGACG 3’ 
P180A Forward Primer  5’ GTTCTGCTTCGCGGCGCGGTTCCATCC 3’ 
P180A Reverse Primer  5’ GGATGGAACCGCGCCGCGAAGCAGAAC 3’ 
R194A Forward Primer  5’ GGCCGCGGTACGCGCCGAGATCGGTGTG 3’ 
R194A Reverse Primer  5’ CACACCGATCTCGGCGCGTACCGCGGCC 3’ 
R193L Forward Primer  5’ GGCCGCGGTACTCCGCGAGATCG 3’ 
R193L Reverse Primer  5’ CGATCTCGCGGAGTACCGCGGCC 3’ 
7.4.2 Site-Directed Mutagenesis 
Mutagenesis was performed using either a Quikchange® Lightning Mutagenesis Kit (Stratagene) or 
Phusion® High-Fidelity DNA Polymerase (Thermo Fisher Scientific) with dNTPs from Invitrogen. PCRs 
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were performed in a Veriti® 96-well Thermal Cycler (Applied Biosystems) or an iCycler (Bio-Rad). 
Primers for mutagenesis were synthesised by Invitrogen and resuspended in sterilised Milli-Q water 
to a concentration of 100 μM. Each PCR reaction solution was 50 μL and typicially 85 ng of plasmid 
template and 200 ng of each primer was used. Initially, the cycling protocols used were those 
recommended by each kit or polymerase. If the use of these protocols did not yield the desired 
product, touchdown PCR was utilised with components from the Quikchange® Lightning 
Mutagenesis Kit (Stratagene) (see below). Template DNA (which is methylated) was digested by 
treatment with the restriction enzyme Dpn1 according to the protocols of the kit. 
Touchdown PCR Protocol 
1 x denaturation 95 °C 2 min 
21 x    denaturation 95 °C 30 s 
annealing 72 °C* 30 s 
            extension 72 °C 6 min 
14 x    denaturation 95 °C 30 s 
annealing 40 °C 30 s 
extension 72 °C 6 min 
1 x final extension 72 °C 10 min 
Hold   4 °C ∞ 
*This temperature drops 1.5 °C every cycle. 
7.4.3 DNA Sequencing 
All DNA sequencing was performed at Canterbury Sequencing and Genotyping using an Applied 
Biosystems 3130xl Genetic Analyzer with BigDye Terminator 189 v3.1 (Applied Biosystems) 
sequencing chemistry. Typically 300 ng to 700 ng of purified double-stranded plasmid and 3.2 μM of 
primer were supplied for each sample. As all AnPRT genes were in the pET-23a(+) vector containing a 
T7 promoter, TOPO forward and reverse primers from Invitrogen or Geneworks were used for all 
sequencing. 
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Forward: 5’ TAA TAC GAC TCA CTA TAG GG 
Reverse: 5’ TAG TTA TTG CTC AGC GGT GG 
7.4.4 Kinetics 
The enzyme-coupled assay for determining the kinetic parameters of Mtu-AnPRT variants kept the 
concentration of one substrate constant while varying that of the other and vice versa. The following 
components were used in the assay: MgCl2 (1 mM), Eco-PRAI:InGPS (3 – 10 µM - held at a minimum 
10-fold excess), PRPP (either held at 0.6 mM for determination of anthranilate parameters, or 
varied), anthranilate (either held at saturating concentration for determination of PRPP parameters, 
or varied) and Mtu-AnPRT variant. PRPP, anthranilate and Mtu-AnPRT variant concentrations are as 
described below: 
N138A (0.46 µM) Anthranilate range: 0 – 220 µM 
PRPP range: 0 – 560 µM (anthranilate held at 200 µM) 
R194A (0.1 µM)  Anthranilate range: 0 – 20 µM 
   PRPP range: 0 – 130 µM (anthranilate held at 25 µM) 
R193A (0.6 µM)  Anthranilate range: 0 – 1 mM  
   PRPP range: 0 – 170 µM (anthranilate held at 200 µM) 
R193L (1 µM)  Anthranilate range: 0 – 500 µM 
   PRPP range: 0 – 400 µM (anthranilate held at 200 µM) 
P180A (0.1 µM)  Anthranilate range: 0 – 12 µM 
   PRPP range: 0 – 420 µM (anthranilate held at 25 µM) 
The concentration of the inactive variant G107P was increased from 0.5 – 1.2 µM during 
experiments and was tested in the presence of up to 1 mM PRPP and up to 1 mM anthranilate.  
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7.4.5 Crystallisation and Data Collection  
N138A/PRPP/Mg 
The X-ray diffraction data for Mtu-AnPRT N138A was collected at the Australian Synchrotron on the 
Macromolecular Crystallography (MX1) beamline. Data were collected for crystals grown in 0.2 M 
imidazole malate (pH 6.5) with 7% PEG-4000. N138A crystallised in the monoclinic space group 
P1211 and diffracted to 1.72 Å, with unit cell dimensions of a = 94.7 Å, b = 78.0 Å and c = 101.3 Å.  
P180A/PRPP/Mg 
The X-ray diffraction data for Mtu-AnPRT P180A was collected at the Australian Synchrotron on the 
Macromolecular Crystallography (MX1) beamline. Data were collected for crystals grown in 0.2 M 
imidazole malate (pH 7.0) with 11% PEG-4000. P180A crystallised in the monoclinic space group 
C121 and diffracted to 1.80 Å, with unit cell dimensions of a = 95.2 Å, b = 78.3 Å and c = 102.2 Å.  
R193L/PRPP/Mg 
The X-ray diffraction data for Mtu-AnPRT R193L was collected at the Australian Synchrotron on the 
Macromolecular Crystallography (MX1) beamline. Data were collected for crystals grown in 0.2 M 
imidazole malate (pH 6.5) with 7% PEG-4000. R193L crystallised in the monoclinic space group C121 
and diffracted to 2.47 Å, with unit cell dimensions of a = 94.4 Å, b = 78.1 Å and c = 100.4 Å.  
R193A/PRPP/Mg 
The X-ray diffraction data for Mtu-AnPRT R193A was collected at the Australian Synchrotron on the 
Macromolecular Crystallography (MX1) beamline. Data were collected for crystals grown in 0.2 M 
imidazole malate (pH 8.0) with 7% PEG-4000. R193A crystallised in the orthorhombic space group 
P212121 and diffracted to 2.04 Å, with unit cell dimensions of a = 79.6 Å, b = 92.5 Å and c = 120.3 Å.  
N138A/PRPP/Mg/anth soaked for 10 s 
The X-ray diffraction data for Mtu-AnPRT N138A was collected at the Australian Synchrotron on the 
Macromolecular Crystallography (MX1) beamline. Data were collected for crystals grown in 0.2 M 
imidazole malate (pH 7.5) with 9% PEG-4000. N138A crystallised in the orthorhombic space group 
P212121 and diffracted to 2.23 Å, with unit cell dimensions of a = 79.7 Å, b = 91.7 Å and c = 119.4 Å.  
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P180A/PRPP/Mg/anth soaked for 1 s 
The X-ray diffraction data for Mtu-AnPRT P180A was collected at the Australian Synchrotron on the 
Micro Crystallography (MX2) beamline. Data were collected for crystals grown in 0.2 M imidazole 
malate (pH 8.0) with 7% PEG-4000. P180A crystallised in the orthorhombic space group P212121 and 
diffracted to 2.04 Å, with unit cell dimensions of a = 79.6 Å, b = 92.5 Å and c = 120.3 Å.  
R193L/PRPP/Mg/anth soaked for 5 s  
The X-ray diffraction data for Mtu-AnPRT R193L was collected at the Australian Synchrotron on the 
Macromolecular Crystallography (MX1) beamline. Data were collected for crystals grown in 0.2 M 
imidazole malate (pH 6.5) with 9% PEG-4000. R193L crystallised in the monoclinic space group C121 
and diffracted to 2.33 Å, with unit cell dimensions of a = 94.5 Å, b = 78.1 Å and c = 100.6 Å.  
R193A/PRPP/Mg/anth soaked for 3 s 
The X-ray diffraction data for Mtu-AnPRT R193A was collected at the Australian Synchrotron on the 
Macromolecular Crystallography (MX1) beamline. Data were collected for crystals grown in 0.2 M 
imidazole malate (pH 6.5) with 9% PEG-4000. R193A crystallised in the orthorhombic space group 
P212121 and diffracted to 2.20 Å, with unit cell dimensions of a = 80.0 Å, b = 91.7 Å and c = 120.8 Å.  
R193A/PRPP/Mg/anth soaked for 1 min 10 s 
The X-ray diffraction data for Mtu-AnPRT R193A was collected at the Australian Synchrotron on the 
Macromolecular Crystallography (MX1) beamline. Data were collected for crystals grown in 0.2 M 
imidazole malate (pH 6.5) with 7% PEG-4000. R193A crystallised in the orthorhombic space group 
P212121 and diffracted to 2.50 Å, with unit cell dimensions of a = 79.7 Å, b = 91.4 Å and c = 119.1 Å.  
R194A/PRPP/Mg/anth soaked for 5 min 
The X-ray diffraction data for Mtu-AnPRT R194A was collected at the Australian Synchrotron on the 
Macromolecular Crystallography (MX1) beamline. Data were collected for crystals grown in 0.2 M 
imidazole malate (pH 7.0) with 11% PEG-4000. R194A crystallised in the monoclinic space group 
C121 and diffracted to 1.77 Å, with unit cell dimensions of a = 94.9 Å, b = 78.6 Å and c = 101.3 Å.  
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7.5 Methods in Chapter 5 
7.5.1 Kinetics 
Ki values of the inhibitors ACS172 and ACS142 for the Mtu-AnPRT variants N138A, P180A and R194A 
were determined using the enzyme-coupled assay, with PRPP held at a saturating concentration of 
0.6 mM, MgCl2 at 1 mM, and Eco-PRAI:InGPS ranging from 3 – 6 µM.  
N138A (0.46 µM) ACS172 was tested from 0 - 110 µM, with an anthranilate range of 0 – 27 µM 
 ACS142 was tested from 0 – 630 µM with an anthranilate range of 0 – 24 µM 
P180A (0.1 µM) ACS172 was tested from 0 - 110 µM, with an anthranilate range of 0 – 19 µM 
  ACS142 was tested from 0 – 690 µM with an anthranilate range of 0 – 18 µM 
R194A (0.1 µM)  ACS172 was tested from 0 - 60 µM, with an anthranilate range of 0 – 9 µM 
  ACS142 was tested from 0 – 690 µM with an anthranilate range of 0 – 18 µM 
7.5.2 Crystallisation and Data Collection 
N138A/PRPP/Mg/ACS172 
The X-ray diffraction data for Mtu-AnPRT N138A was collected at the Australian Synchrotron on the 
Macromolecular Crystallography (MX1) beamline. Data were collected for crystals grown in 0.2 M 
imidazole malate (pH 6.5) with 7% PEG-4000. N138A crystallised in the monoclinic space group C121 
and diffracted to 2.40 Å, with unit cell dimensions of a = 94.7 Å, b = 78.1 Å and c = 102.5 Å. 
P180A/PRPP/Mg/ACS172 
The X-ray diffraction data for Mtu-AnPRT P180A was collected at the Australian Synchrotron on the 
Macromolecular Crystallography (MX1) beamline. Data were collected for crystals grown in 0.2 M 
imidazole malate (pH 6.5) with 5% PEG-4000. P180A crystallised in the monoclinic space group C121 
and diffracted to 1.95 Å, with unit cell dimensions of a = 95.5 Å, b = 78.1 Å and c = 101.9 Å.  
R194A/PRPP/Mg/ACS172 
The X-ray diffraction data for Mtu-AnPRT R194A was collected at the Australian Synchrotron on the 
Macromolecular Crystallography (MX1) beamline. Data were collected for crystals grown in 0.2 M 
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imidazole malate (pH 7.0) with 7% PEG-4000. R194A crystallised in the monoclinic space group C121 
and diffracted to 2.06 Å, with unit cell dimensions of a = 95.1 Å, b = 78.1 Å and c = 102.8 Å.  
R194A/PRPP/Mg/ACS142 
The X-ray diffraction data for Mtu-AnPRT R194A was collected at the Australian Synchrotron on the 
Macromolecular Crystallography (MX1) beamline. Data were collected for crystals grown in 0.2 M 
imidazole malate (pH 6.5) with 9% PEG-4000. R194A crystallised in the monoclinic space group C121 
and diffracted to 2.23 Å, with unit cell dimensions of a = 95.0 Å, b = 78.5 Å and c = 102.5 Å.  
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Appendix 1 
Differential Scanning Fluorimetry Raw Data 
This appendix contains raw DSF data for Eco-PRAI:InGPS, Mtu-AnPRT with and without ligands 
present, and for variant Mtu-AnPRT proteins. The differentiated relative fluorescence units (RFU) are 
plotted against temperature in °C. The denaturation temperature is derived from the local minimum 
for each data set. 
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Appendix 2 
1H NMR Spectra for Mtu-AnPRT Catalysis of Anthranilate Analogues 
This appendix contains the 1H NMR spectra obtained by Dr Esther Bulloch at the University of 
Auckland, and shows the successful conversion of each alternate substrate into the respective PRA 
substituted product with the exception of 3MA. 
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Appendix 3 
Crystal Structure Data Tables 
This appendix contains the final statistics for each crystal structure solved in this thesis, obtained 
from structure processing and refinement using CCP4 software.89 
Complex N138A/PRPP/Mg P180A/PRPP/Mg R193L/PRPP/Mg 
Data Collection 
Space group P1211 C121 C121 
Cell dimensions    
a, b, c (Å) 94.7, 78.0, 101.3 95.2, 78.3, 102.2 94.4, 78.1, 100.4 
α, β, γ (°) 90.0, 111.3, 90.0 90.0, 111.7, 90.0 90.0, 110.5, 90.0 
No. of unique 
reflections 
145346 64672 24299 
Resolution range
a
 (Å) 94.38-1.72 (1.75-1.72) 58.65-1.80 (1.85-1.80) 39.95-2.47 (2.59-2.47) 
CC½ 0.998 (0.583) 0.999 (0.583) 0.988 (0.569) 
Rmerge
a,b
 0.214 (2.82) 0.239 (3.79) 0.186 (1.08) 
 I/σ(I)
a
 8.2 (0.9) 20.0 (1.7) 7.5 (1.9) 
Completeness
a
 (%) 99.7 (98.5) 100 (100) 98.8 (98.9) 
Redundancy
a
 14.3 (12.3) 28.7 (23.6) 5.0 (5.1) 
Refinement 
No. of atoms, B factor
c
    
Protein 9910, 17.9 4930, 21.3 4936, 20.7 
Solvent 660, 26.9 236, 31.7 46, 34.4 
PRPP 44, 22.9 66, 26.6 44, 53.2 
Mg
2+
 4, 23.7 2, 23.0 2, 43.9 
Rwork
a,d
 (%), Rfree
a,e
 (%) 26.9, 30.2 (48.8,  51.4) 19.1, 22.0 (28.4, 31.3) 21.1, 26.1 (31.7 , 35.6) 
Ramachandran 
outliers
f
 (%) 
0.29 0.15 0.15 
RMSD
g
    
Bond lengths (Å) 0.009 0.010 0.007 
Bond angles (°) 1.465 1.484 1.377 
 
a
 – Data for the outer resolution shell are shown in parentheses. 
b
 – Rmerge  = ∑hkl I(hkl) - <I(hkl)> / ∑hkl I(hkl), where <I(hkl)> is the mean of the symmetry-equivalent reflections of 
I(hkl).  
c
 –Å
2
 The average atomic temperature factor.  
d
 – Rwork = (|Fobs| - |Fcalc|) / |Fobs|. 
e – Rfree = ∑T (|Fobs| - |Fcalc|) / ∑T |Fobs|, where T is a test data set of 5% of the total reflections randomly chosen 
and set aside before refinement. 
f
 – Ramachandran outliers calculated using Molprobity.
93
 
g
 - Ideal values from Engh and Huber (1991).
96
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Complex 
Anth Soak Time 
R193A/PRPP/Mg N138A/PRPP/Mg/Anth 
(10 s) 
P180A/PRPP/Mg/Anth 
(1 s) 
Data Collection 
Space group C121 P212121 P212121 
Cell dimensions    
a, b, c (Å) 94.5, 77.8, 101.9 79.7, 91.7, 119.4 79.6, 92.5, 120.3 
α, β, γ (°) 90.0, 111.8, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
No. of unique 
reflections 
50966 43292 56304 
Resolution range
a
 (Å) 47.31-1.93 (1.98-1.93) 119.4-2.23 (2.30-2.23) 120.3-2.04 (2.10-2.04) 
CC½ 0.996 (0.560) 0.995 (0.581) 0.998 (0.576) 
Rmerge
a,b
 0.129 (1.66) 0.267 (2.17) 0.183 (1.59) 
 I/σ(I)
a
 8.2 (0.9) 12.4 (1.1) 14.5 (1.0) 
Completeness
a
 (%) 99.0 (98.3) 99.7 (97.3) 98.6 (82.2) 
Redundancy
a
 4.7 (4.7) 13.9 (8.0) 13.6 (4.2) 
Refinement 
No. of atoms, B factor
c
    
Protein 4962, 25.8 4985, 26.2 5008, 32.2 
Solvent 148, 33.7 154, 38.5 224, 36.9 
PRPP N/A N/A N/A 
Mg
2+
 N/A N/A 1, 49.6 
Anthranilate N/A N/A N/A 
Rwork
a,d
 (%), Rfree
a,e
 (%) 24.1, 28.3 (38.4, 40.6) 21.4, 25.5 (39.5, 44.9) 20.8, 24.3 (42.5, 47.5) 
Ramachandran 
outliers
f
 (%) 
0.29 0.29 0.43 
RMSD
g
    
Bond lengths (Å) 0.011 0.010 0.010 
Bond angles (°) 1.432 1.460 1.424 
 
a
 – Data for the outer resolution shell are shown in parentheses. 
b
 – Rmerge  = ∑hkl I(hkl) - <I(hkl)> / ∑hkl I(hkl), where <I(hkl)> is the mean of the symmetry-equivalent reflections of 
I(hkl).  
c
 –Å
2
 The average atomic temperature factor.  
d
 – Rwork = (|Fobs| - |Fcalc|) / |Fobs|. 
e – Rfree = ∑T (|Fobs| - |Fcalc|) / ∑T |Fobs|, where T is a test data set of 5% of the total reflections randomly chosen 
and set aside before refinement. 
f
 – Ramachandran outliers calculated using Molprobity.
93
 
g
 - Ideal values from Engh and Huber (1991).
96
 
 
 
 
 
 
 
 
 
200 
 
 
a
 – Data for the outer resolution shell are shown in parentheses. 
b
 – Rmerge  = ∑hkl I(hkl) - <I(hkl)> / ∑hkl I(hkl), where <I(hkl)> is the mean of the symmetry-equivalent reflections of 
I(hkl).  
c
 –Å
2
 The average atomic temperature factor.  
d
 – Rwork = (|Fobs| - |Fcalc|) / |Fobs|. 
e – Rfree = ∑T (|Fobs| - |Fcalc|) / ∑T |Fobs|, where T is a test data set of 5% of the total reflections randomly chosen 
and set aside before refinement. 
f
 – Ramachandran outliers calculated using Molprobity.
93
 
g
 - Ideal values from Engh and Huber (1991).
96
 
 
 
 
 
 
 
 
 
Complex 
Anth Soak Time 
R193L/PRPP/Mg/Anth 
(5 s) 
R193A/PRPP/Mg/Anth 
(3 s) 
R193A/PRPP/Mg/Anth 
(1 min 10 s) 
Data Collection 
Space group C121 P212121 P212121 
Cell dimensions    
a, b, c (Å) 94.5, 78.1, 100.6 80.0, 91.7, 120.8 79.7, 91.4, 119.1 
α, β, γ (°) 90.0, 110.6, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
No. of unique 
reflections 
29405 44908 30694 
Resolution range
a
 (Å) 94.12-2.33 (2.41-2.33) 120.8-2.20 (2.27-2.20) 119.1-2.50 (2.60-2.50) 
CC½ 0.996 (0.576) 0.999 (0.938) 0.995 (0.689) 
Rmerge
a,b
 0.182 (1.72) 0.068 (0.254) 0.255 (1.40) 
 I/σ(I)
a
 10.2 (1.2) 37.9 (7.0) 13.2 (1.9) 
Completeness
a
 (%) 100 (99.9) 98.1 (81.2) 99.5 (95.5) 
Redundancy
a
 7.4 (7.5) 13.8 (5.6) 14.1 (11.2) 
Refinement 
No. of atoms, B factor
c
    
Protein 4938, 32.5 4976, 27.8 4987, 28.1 
Solvent 60, 40.6 235, 35.2 102, 33.6 
PRPP 22, 52.4 N/A N/A 
Mg
2+
 4, 53.1 N/A N/A 
Anthranilate N/A 20, 63.1 20, 57.0 
Pyrophosphate 9, 75.7 N/A N/A 
Rwork
a,d
 (%), Rfree
a,e
 (%) 20.1, 25.7 (31.5, 36.1) 20.4, 23.5 (49.5, 47.4) 20.1, 26.1 (26.7, 33.8) 
Ramachandran 
outliers
f
 (%) 
0.00 0.44 0.29 
RMSD
g
    
Bond lengths (Å) 0.010 0.011 0.010 
Bond angles (°) 1.442 1.435 1.455 
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Complex 
 Anth Soak Time 
R194A/PRPP/Mg/Anth 
(5 min) 
 N138A/PRPP/Mg/172 P180A/PRPP/Mg/172 
Data Collection 
Space group C121 C121 C121 
Cell dimensions    
a, b, c (Å) 94.9, 78.6, 101.3 94.7, 78.1, 102.5 95.5, 78.1, 101.9 
α, β, γ (°) 90.0, 110.2, 90.0 90.0, 111.9, 90.0 90.0, 111.5, 90.0 
No. of unique 
reflections 
68018 27281 50366 
Resolution range
a
 (Å) 95.1-1.77 (1.87-1.77) 47.6-2.40 (2.49-2.40) 47.4-1.95 (2.00-1.95) 
CC½ 0.998 (0.502) 0.998 (0.829) 0.991 (0.532) 
Rmerge
a,b
 0.136 (2.28) 0.117 (0.692) 0.139 (1.75) 
 I/σ(I)
a
 12.0 (1.2) 16.4 (3.3) 15.3 (1.3) 
Completeness
a
 (%) 99.8 (99.4) 100 (100) 100 (99.9) 
Redundancy
a
 12.2 (9.1) 7.5 (7.6) 7.6 (7.6) 
Refinement 
No. of atoms, B factor
c
    
Protein 5027, 26.8 4857, 26.3 4849, 25.8 
Solvent 520, 39.8 67, 28.6 150, 34.3 
Mg
2+
 4, 35.4 N/A N/A 
Anthranilate 40, 39.1 N/A N/A 
Pyrophosphate 18, 26.3 N/A N/A 
172 N/A 38, 46.4 38, 48.1 
Rwork
a,d
 (%), Rfree
a,e
 (%) 18.7/22.1(39.4/42.2) 21.9, 26.8 (28.2, 38.3) 25.4, 29.9 (34.9 , 36.3) 
Ramachandran 
outliers
f
 (%) 
0.15 0.30 0.30 
RMSD
g
    
Bond lengths (Å) 0.010 0.009 0.010 
Bond angles (°) 1.455 1.373 1.409 
 
a
 – Data for the outer resolution shell are shown in parentheses. 
b
 – Rmerge  = ∑hkl I(hkl) - <I(hkl)> / ∑hkl I(hkl), where <I(hkl)> is the mean of the symmetry-equivalent reflections of 
I(hkl).  
c
 –Å
2
 The average atomic temperature factor.  
d
 – Rwork = (|Fobs| - |Fcalc|) / |Fobs|. 
e – Rfree = ∑T (|Fobs| - |Fcalc|) / ∑T |Fobs|, where T is a test data set of 5% of the total reflections randomly chosen 
and set aside before refinement. 
f
 – Ramachandran outliers calculated using Molprobity.
93
 
g
 - Ideal values from Engh and Huber (1991).
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Complex R194A/PRPP/Mg/172 R194A/PRPP/Mg/142 
Data Collection 
Space group C121 C121 
Cell dimensions   
a, b, c (Å) 95.1, 78.1, 102.8 95.0, 78.5, 102.5 
α, β, γ (°) 90.0, 111.8, 90.0 90.0, 111.8, 90.0 
No. of unique 
reflections 
43298 34186 
Resolution range
a
 (Å) 47.7-2.06 (2.12-2.06) 47.6-2.23 (2.30-2.23) 
CC½ 0.998 (0.542) 0.998 (0.665) 
Rmerge
a,b
 0.151 (1.43) 0.146 (1.39) 
 I/σ(I)
a
 13.8 (1.5) 12.2 (1.7) 
Completeness
a
 (%) 100 (100) 100 (99.9) 
Redundancy
a
 7.6 (7.6) 7.5 (7.5) 
Refinement 
No. of atoms, B factor
c
   
Protein 4934, 24.6 4828, 30.1 
Solvent 158, 31.8 58, 38.9 
172 38, 52.5 N/A 
142 N/A 36, 64.2 
Rwork
a,d
 (%), Rfree
a,e
 (%) 18.6, 22.3 (27.9, 28.6) 20.0, 23.3 (34.0, 37.8) 
Ramachandran 
outliers
f
 (%) 
0.29 0.30 
RMSD
g
   
Bond lengths (Å) 0.010 0.010 
Bond angles (°) 1.411 1.436 
 
a
 – Data for the outer resolution shell are shown in parentheses. 
b
 – Rmerge  = ∑hkl I(hkl) - <I(hkl)> / ∑hkl I(hkl), where <I(hkl)> is the mean of the symmetry-equivalent reflections of 
I(hkl).  
c
 –Å
2
 The average atomic temperature factor.  
d
 – Rwork = (|Fobs| - |Fcalc|) / |Fobs|. 
e – Rfree = ∑T (|Fobs| - |Fcalc|) / ∑T |Fobs|, where T is a test data set of 5% of the total reflections randomly chosen 
and set aside before refinement. 
f
 – Ramachandran outliers calculated using Molprobity.
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g
 - Ideal values from Engh and Huber (1991).
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Appendix 4 
Crystal Structure Omit Maps 
This appendix contains the difference and post-refinement maps for all ligands bound to variant 
Mtu-AnPRTs. The left-hand side panels depict the difference maps prior to the addition of ligands to 
the structures, with the Fo-Fc maps contoured at 3.0 σ, and coloured green for positive density and 
red for negative density. The right-hand side panels depict the post-refinement maps for the ligands, 
with the 2Fo-Fc maps contoured at 1.0 σ and coloured blue, and the Fo-Fc maps contoured at 3.0 σ 
and coloured green for positive density and red for negative density. Water molecules are not 
included. 
N138A/PRPP/Mg 
Chain C – PRPP (green), Mg (green spheres)   Chain D – PRPP (green), Mg (green spheres) 
 
 
 
 
P180A/PRPP/Mg 
Chain A – PRPP (magenta), Mg (magenta spheres) Chain B – PRPP (magenta), Mg (magenta 
spheres)  
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R193L/PRPP/Mg 
Chain A – PRPP (green), Mg (green spheres)   Chain B – PRPP (green), Mg (green spheres) 
 
 
 
 
R193L/PRPP/Mg/Anth (5 s soak) 
Chain A – PRPP (magenta), Mg (magenta spheres) Chain B – PRPP (magenta), Mg (magenta 
spheres)  
 
 
 
 
R193A/PRPP/Mg/Anth (3 s soak) 
Chain A – Anth (purple)     Chain B – Anth (purple) 
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R193A/PRPP/Mg/Anth (1 min 10 s soak) 
Chain A – Anth (green)     Chain B – Anth (green) 
  
 
 
 
 
R194A/PRPP/Mg/Anth (5 min soak) 
Chain A – Anth (blue), PPi (orange),    Chain B – Anth (blue), PPi (orange), 
Mg (blue spheres)      Mg (blue spheres) 
 
 
 
 
 
N138A/PRPP/Mg/ACS172 
Chain A – ACS172 (purple)     Chain B – ACS172 (purple)   
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P180A/PRPP/Mg/ACS172 
Chain A – ACS172 (purple)     Chain B – ACS172 (purple) 
 
 
 
 
 
R194A/PRPP/Mg/ACS172 
Chain A – ACS172 (purple)     Chain B – ACS172 (purple) 
 
 
 
 
 
R194A/PRPP/Mg/ACS142 
Chain A – ACS142 (yellow)     Chain B – ACS142 (yellow) 
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